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1General introduction
Worldwide impact of coronary artery disease: how serious is it?  
For decades coronary artery disease (CAD) has been the most common manifestation of 
cardiovascular disease and leading cause of death worldwide [1, 2]. According to the 2017 
Global Burden of Disease Study, CAD affected 126.5 million people [1] in that year and 
resulted in 8.9 million deaths [2], which is 15.9% of all deaths. Although temporal analyses 
from population-based epidemiological data have shown favorable trends with declining 
CAD mortality rates in economically developed (Western) areas of Europe [3] and the United 
States [4] over the past decennia, developing (non-Western) regions nowadays encounter a 
substantial rise in CAD burden [5, 6]. All in all, CAD has remained and continues to be an 
enormous disease burden worldwide.           
Coronary artery disease: a manifestation of atherosclerosis 
Coronary atherosclerosis is the underlying multifactorial pathophysiological process that 
eventually leads to CAD. The pathogenesis of atherosclerosis involves multiple molecular 
mediators, influenced by both environmental (risk) factors and genetic predisposition. These 
determinants subsequently promote a sequence of events leading to atherosclerotic plaque 
progression, ultimately resulting in a clinical event.       
Determinants of atherosclerosis 
In a healthy coronary artery, the lumen along the inner side of a vessel wall is covered with a 
monolayer of endothelial cells. The endothelium possesses several functions and is involved 
in many biological processes regulating vascular homeostasis, including blood coagulation, 
vessel tone regulation and controlling the passage of components out of the bloodstream [7]. 
Endothelial dysfunction occurs at prone areas where the endothelial cell layer is injured by 
(external) stimuli, such as for example toxic substances in cigarette smoke, endotoxins or 
blood flow disturbances. A leaky, activated and dysfunctional endothelium leads to a series 
of lipid-driven immunoinflammatory and fibroproliferative responses and is an important 
initial step in the manifestation of atherosclerosis [7]. By expressing adhesion molecules 
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on the surfaces of injured endothelial cells, leukocytes (most importantly monocytes and 
T-lymphocytes) are recruited and captured [7, 8]. Also, changes in endothelial permeability 
promote plasma molecules and lipoprotein particles to pass from the lumen through a defective 
endothelium into the subendothelial space. Specifically, low-density lipoprotein (LDL) 
particles get entrapped and modified (i.e. oxidized) [9]. 
Oxidized LDL is one of the most important atherogenic 
chemoattractants, meaning that chemokines are attracted 
to stimulate transendothelial migration of the attached 
leucocytes on the endothelium. Once differentiated into 
macrophages, monocytes produce pro-inflammatory 
cytokines (e.g. TNF-α) [10] and facilitate phagocytosis of 
oxidized LDL, leading to the development of lipid-laden 
macrophages becoming ‘foam cells’ [8]. Consequently, 
these foam cells undergo apoptosis and necrosis with a 
release of even more lipids, cytokines and prothrombotic 
molecules that locally accumulate, leading to the 
formation of a necrotic lipid core within the intima [11]. 
In response to this biochemical outburst reaction, smooth muscle cells from the vascular 
wall are activated as well to proliferate and synthesize extracellular matrix proteins [11]. In 
conclusion, endothelial dysfunction initiates a series of biochemical reactions, creating a 
local pro-atherogenic environment.      
  Risk factors act as irritative stimuli at several points in this pathogenic pathway, 
aggravating the underlying processes. Cigarette smoking impacts all phases of atherosclerosis 
and is one the most important risk factors for CAD worldwide [12]. For example, the toxic 
components of cigarette smoke contribute to atherosclerosis by mediating endothelial 
dysfunction, enhancing oxidative modification of LDL, stimulating pro-inflammatory 
cytokines leading to increased leukocyte recruitment and inducing a prothrombotic state in 
the coronary arteries [13]. Lipid abnormalities (dyslipidemia), in particular elevated levels of 
LDL, form another important CAD risk factor [12]. A direct excessive supply of circulating 
amounts of lipoproteins, that are retained, accumulated and subsequently modified in the 
atherosclerotic plaque, mainly triggers a local inflammatory response [14]. A state of chronic 
hyperglycemia in diabetes mellitus (type 2) is related to dyslipidemia, partly explaining the 
strong association between diabetes and CAD [12]. Besides the impact of hyperglycemia on 
Formation of ‘foam cells’. 
Image adapted from Hansson et al. N Engl J Med 
2005; 352: 1685-1695.
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dyslipidemia, it causes oxidative stress and thereby plenty of other pro-atherogenic responses 
including enhancement of endothelium dysfunction, inflammation and thrombogenicity [15]. 
Lastly, hypertension might also lead to atherosclerosis and is considered to be a major risk 
factor as well for the risk of CAD [12]. Since hypertension causes increased arterial wall 
thickness, it is hypothesized that a larger diffusion distance from the lumen for oxygen is 
created, probably leading to increased concentrations of free radicals (oxidative stress) [16]. 
Consequently, endothelial injury is induced that promotes leukocyte recruitment and smooth 
muscle cell proliferation. Against this background of external influences on the initiation and 
development of atherosclerosis, underlying synergistic interactions with genetic determinants 
steer all processes into a certain direction. In all biological pathways of atherogenesis, many 
regulatory genes are identified to be involved and thus largely determine an individual’s 
susceptibility to CAD [17].  
  Altogether it can be concluded that the underlying pathophysiological processes, 
its interplay with environmental risk factors and involvement of many genes, make 
atherosclerosis a very complex disease.   
Coronary atherosclerotic plaque progression: from initiation to disease   
The previously mentioned cell types contribute to coronary atherosclerotic plaque 
progression. Under the driving influence of risk factors, an atherosclerotic plaque progresses 
through multiple stages: from early ‘fatty streaks’ to ‘thin-cap fibroatheromas’, giving rise to 
various clinical expressions of CAD (Figure 1).  
  The earliest coronary lesion histologically is the ‘fatty streak’, which starts as focal 
thickening of the vascular wall intima layer with accumulation of primarily macrophage 
foam cells, along with smooth muscle cells [18]. As these lesions expand (‘pathological intimal 
thickening’), extracellular lipid pools are formed underneath layers of smooth muscle cells 
in a proteoglycan-rich matrix with affinity for plasma lipoprotein particles [18, 19]. Typically, 
these lesions contain a deeply located soft lipid core and an absent necrotic core. As this 
stage further progresses, ‘fibrous cap atheromas’ are formed, which are all identified by 
fibrous cap development [20]. A fibrous cap is a distinct layer of connective tissue covering 
a necrotic, fatty mass and is usually crucial for maintaining plaque integrity and stability. 
Depending in which direction the plaque has progressed and what the prevailing compound 
of the plaque is, distinct types of fibrous cap atheromas can be discerned. The ‘classic’ 
fibroatheroma plaque is defined as a lesion with a necrotic, fatty core and a thick cellular 
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fibrous cap. When the lesion contains a remarkable amount of collagen-rich fibrous tissue 
and little lipid, the lesion is classified as a ‘fibrotic’ lesion. If the fibrous cap encapsulates 
mainly calcified tissue, the lesion is referred to as a ‘fibrocalcific’ lesion. The final and most 
critical stage of atherosclerotic plaque progression is the ‘thin-cap fibroatheroma’ (TCFA), 
which is characterized by a relatively large eccentric necrotic core and an overlying thin 
fibrous cap (< 65μm), infiltrated by macrophages [20]. This specific lesion type is vulnerable 
for disruption of the fibrous cap. Once the fibrous cap ruptures, the thrombogenic material is 
exposed to the circulating blood and a coagulation cascade is activated, leading to formation 
of luminal thrombosis.
  
intimal 
thickening
soft lipid core
thin fibrous 
cap
Thin-cap fibroatheroma.      Pathological intimal thickening.
Image adapted from Bentzon et al.     Image adapted from
Circ Res 2014; 114:1852-1866.    © 2019 UpToDate, Inc.
A couple of mechanisms are believed to be responsible for the dynamic progression of 
atherosclerotic plaque growth and destabilization. First, human autopsy studies have identified 
intraplaque hemorrhage as a common repetitive feature in advanced coronary atherosclerotic 
lesions [21]. This treat results from neovascularization, leading to fragile, disrupted, leaky 
microvessels with extravasation from red blood cells within the atherosclerotic plaque. 
Another common source of intraplaque hemorrhage is direct entrance of blood into the plaque 
from the lumen through a plaque fissure. Not only it causes episodic plaque growth, but also 
triggers a cellular response involving plaque infiltration by cholesterol and inflammatory cells, 
which in turn leads to plaque instability [21, 22]. A major protective mechanism against direct 
toxic effects of haemoglobin, released from the red blood cells within the atherosclerotic 
plaque, is the presence of circulating haptoglobin, whose major function is to bind excess 
haemoglobin [23]. A second mechanism through which atherosclerotic plaques progress is 
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through subclinical episodes of healed plaque disruption or erosion. It has been demonstrated 
that an ongoing process of repeated arterial wound healing in human coronary arteries leads 
to a significant increase in plaque burden, progressing towards severe stenosis [24].
  Progression of atherosclerotic plaque slowly leads to luminal narrowing and is generally 
asymptomatic until the plaque stenosis exceeds a certain percentage of the luminal diameter. 
These stenotic lesions could give rise to symptoms of clinically chronic stable CAD. All 
previously mentioned intact ‘fibrous cap atheromas’, isolating the thrombogenic fatty, 
necrotic core with a thick fibrous cap from the circulating blood, can lead to symptoms of 
stable CAD. Conversely, TCFA plaques are assumed to be more rupture-prone, frequently 
causing plaque ruptures and thereby leading to acute onsets of luminal superimposed 
thrombosis, resulting in the clinical manifestation of acute coronary syndrome (ACS) [20, 25, 
26]. Plaque rupture is the most frequent underlying cause of coronary thrombus formation, 
followed by plaque erosion, typically characterized by an absent endothelium, minimal 
inflammation and abundant smooth muscle cells [25, 27]. Vulnerable plaques of the erosion-type 
are heterogenous and not clearly defined yet according to distinguishable plaque features [28]. 
In unstable angina pectoris or non-ST-segment elevation myocardial infarction, recurrent 
transient episodes of incomplete thrombotic vessel occlusion occur at either the site of plaque 
disruption or erosion. In acute ST-segment elevation myocardial infarction, an abrupt and 
persistent occluding thrombus in the infarct-related coronary artery is causing local cessation 
of myocardial perfusion, leading to myocardial necrosis.  
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Figure 1: Simplified scheme of coronary atherosclerotic plaque progression
1. Fatty streak
2. Pathological Intimal Thickening
3b. Fibrocalcific lesions
4. Thin-cap fibroatheroma 
Acute coronary syndrome
Intraplaque 
hemorrhage
Healed plaque 
ruptures / 
erosions
Lesion type
Luminal thrombosis
ErosionRupture Calcified nodule
3c. Fibroatheroma lesions 
3a. Fibrotic / fibrous lesions
Fibrous cap 
atheromas
Figure 1. Simplified scheme of coronary atherosclerotic plaque progression.
Blood biomarkers & genetic polymorphisms: better understanding of human 
atherosclerosis, enhanced risk stratification and improved treatment benefit in 
established CAD 
Discoveries in basic experimental research from laboratory and animal studies have been 
crucial in the development of understanding the underlying mechanisms in atherosclerosis. 
Despite considerable advances in learning the complex pathophysiology of atherosclerosis 
from these studies, significant results obtained in experiments may not be directly applied to 
humans [29]. For instance, this can be illustrated by the fact that large randomized controlled 
clinical trials were not able to demonstrate benefit of anti-oxidant supplements on CAD 
outcome [30]. Thus, we still lack definitive evidence to show that certain biological processes 
such as lipoprotein oxidation have a crucial causal role in human atherosclerosis [31]. Many 
questions in human CAD research have arisen and still remain unanswered. Furthermore, 
despite augmented knowledge, advanced diagnostic technologies and improved treatment 
strategies, atherosclerosis and its clinical sequelae continue to be an enormous disease burden 
globally. Hence, further clinical research within the field of underlying mechanisms in CAD 
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is indispensable.       
  In the meantime, in order to further improve cardiovascular outcome in CAD patients, 
risk stratification tools for purposes of secondary prevention should be further evaluated. 
Prognostication by identifying individuals at high risk of recurrent cardiovascular events 
remains a challenge. Nowadays, in clinical practice routinely used risk assessment tools for 
CAD consist mainly of determining conventional risk factors (e.g. Framingham risk score), 
integrated with clinical parameters from invasive (e.g. SYNTAX score) and non-invasive 
diagnostic tools (e.g. left ventricular function assessed by imaging) and well-established 
cardiovascular blood biomarkers (e.g. NT-proBNP, cardiac troponins). Advances have been 
made with several novel blood biomarkers, that independently of clinical factors carry 
prognostic information and improve risk stratification in established CAD [32]. By studying 
(novel) blood biomarkers in detail, not only valuable knowledge on atherosclerosis could be 
obtained in a non-invasive manner, but also the dynamic and versatile nature of atherosclerotic 
disease might be more accurately reflected.              
  In line with the usefulness of biomarkers, genetic information might be valuable as 
well in risk prediction. Common variants of genes involved in atherosclerosis, captured 
by genetic markers in the form of single-nucleotide polymorphisms (SNPs), might serve 
as risk predictors of CAD. After all, a  positive family history significantly determines 
the risk of CAD, independently of traditional cardiovascular risk factors [33]. For example, 
carriers of a common genetic variant of haptoglobin (Hp2-2 genotype) were found out to 
have a 1.5-fold elevated risk for major cardiovascular events [23]. This suggests that genetic 
factors could potentially refine current CAD risk stratification [34]. Additionally, genetic 
variants involved in pharmacodynamic pathways could also be applied in predicting therapy 
response [35]. Thereby, treatment could be more targeted towards those who are most likely 
to benefit in order to enhance their likelihood of successful response. Thus, investigating and 
including genetic information has the potential to reach a more personalized and accurate risk 
stratification approach.  
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Outline of this thesis
Against the previously described pathophysiological background and remaining challenges 
within the field of atherosclerosis and CAD, the purpose of this thesis was three-fold: 
studying blood biomarkers for a better understanding of human atherosclerosis (1), enhanced 
risk stratification (2) and improved treatment benefit (3) in patients with established CAD. 
Therefore, different tools - which may reflect the patient’s underlying coronary atherosclerotic 
disease - such as intracoronary imaging, (repeated) blood biomarker measurements and 
determination of certain genetic polymorphisms, have been investigated. 
  
1. Better understanding of human atherosclerosis by linking blood biomarkers to 
intracoronary imaging. 
In the first part of this thesis, circulating blood biomarkers are studied in relation 
to coronary atherosclerosis by means of intracoronary imaging (virtual-histology 
intravascular ultrasound and near-infrared spectroscopy) in CAD patients. Investigating 
biological processes that might be linked to atherosclerosis increases our knowledge of 
the CAD pathogenesis and consequently may be useful for improving cardiovascular risk 
stratification or secondary prevention treatment strategies. Furthermore, the relationship 
between these biomarkers and 1-year cardiovascular outcome has been investigated as 
well to explore their potential additional value in cardiovascular risk prediction.  
2. Enhanced risk stratification in established CAD by studying blood biomarker 
patterns in detail. 
In the second part, the behavioral temporal pattern after an acute coronary syndrome of 
novel and established biomarkers is described during 1-year follow-up. This has been 
performed by frequently repeated blood sample measurements, which gives us an unique 
insight in the value of these biomarkers for purposes of secondary cardiovascular risk 
prediction.     
3. Enhanced risk stratification and improved treatment benefit in established CAD by 
genetic polymorphisms.
In the third part, the relationship between some specific genetic polymorphisms and 
various cardiovascular outcome parameters has been studied in order to investigate its 
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usefulness in cardiovascular risk stratification. Furthermore, the value of some genetic 
variants for targeting therapy in patients who would benefit most from ACE-inhibitors 
has been assessed as well.   
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PART I
Coronary plaque characteristics 
and cardiovascular outcome 

2
Smoking in relation to coronary 
atherosclerotic plaque burden, 
volume and composition on 
intravascular ultrasound.
Abstract
Rationale: This study aimed to evaluate the relationship between cigarette smoking and 
coronary atherosclerotic burden, volume and composition as determined in-vivo by grayscale 
and virtual histology (VH) intravascular ultrasound (IVUS). 
Methods & Results: Between 2008 and 2011, (VH-)IVUS of a non-culprit coronary artery 
was performed in 581 patients undergoing coronary angiography. To account for differences 
in baseline characteristics, current smokers were matched to never smokers by age, gender 
and indication for catheterization, resulting in 280 patients available for further analysis. 
Coronary atherosclerotic plaque volume, burden, composition (fibrous, fibro-fatty, dense 
calcium and necrotic core) and high-risk lesions (VH-IVUS derived thin-cap fibroatheroma 
(TCFA), plaque burden ≥70%, minimal luminal area ≤4.0 mm2) were assessed. Cigarette 
smoking showed a tendency towards higher coronary plaque burden (mean±SD, 38.6±12.5% 
in current versus 36.4±11.0% in never smokers, p=0.080; and odds ratio (OR) of current 
smoking for plaque burden above versus below the median 1.69 (1.04 - 2.75), p=0.033). This 
effect was driven by an association in patients presenting with an acute coronary syndrome 
(ACS) (current smokers, plaque burden 38.3±12.8% versus never smokers, plaque burden 
Buljubasic N, Akkerhuis KM, de Boer SP, Cheng JM, Garcia-Garcia HM, Lenzen 
MJ, Oemrawsingh RM, Battes LC, Rijndertse M, Regar E, Serruys PW, van Geuns 
RJ, Boersma E, Kardys I.
PLoS One. 2015; 10(10): e0141093. doi: 10.1371/journal.pone.0141093.
Smoking in relation to coronary 
atherosclerotic plaque burden, 
volume and composition on 
intravascular ultrasound.
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35.0±11.2%, p=0.049; OR 1.88 (1.02 - 3.44), p=0.042). Fibrous tissue tended to be lower in 
current smokers (mean±SD, 57.7±10.5% versus 60.4±12.6%, p=0.050) and fibro-fatty tissue 
was higher in current smokers (median [IQR], 9.6 [6.0 - 13.7]% versus 8.6 [5.8 - 12.2]%, 
p=0.039). However, differences in percentage necrotic core and dense calcium could not be 
demonstrated. Also, no differences were found with regard to high-risk lesions.
Conclusions: An association between smoking and degree of coronary atherosclerosis was 
present in patients undergoing coronary angiography who presented with ACS. Although 
smoking was associated with higher fibro-fatty percentage, no associations could be 
demonstrated with percentage necrotic core, nor with VH-IVUS derived TCFA lesions. 
Since the magnitude of the differences in both degree and composition of atherosclerosis was 
modest, clinical relevance of the findings may be questioned.
Introduction
Cigarette smoking is a well-known risk factor for developing coronary artery disease (CAD). 
Previous epidemiologic studies have demonstrated that cigarette smoking is associated with 
severity of atherosclerosis on both coronary angiography and coronary CT angiography [1,2], 
increased risk of myocardial infarction [3] and cardiovascular death [4,5]. 
  In line with the above, several pathophysiologic effects of cigarette smoke exposure 
on cardiovascular function have been described. Both active and passive cigarette smoke 
exposure have been shown to promote endothelial dysfunction, stimulate inflammatory 
processes at the vessel wall and enhance vascular prothrombotic effects [6,7]. Thus, ample 
fundamental research evidence is available demonstrating that smoking directly impacts 
multiple aspects of atherosclerosis. However, less is currently known about the associations 
of smoking with in-vivo, macroscopic plaque composition and plaque vulnerability. Although 
coronary angiography enables evaluation of the unobstructed part of the lumen, it does 
not provide information on the structure of the arterial wall itself. Grayscale intravascular 
ultrasound (IVUS) also provides limited information on plaque characteristics. 
  Virtual histology (VH)-IVUS of the coronary arteries allows spectral analysis of 
backscattered radiofrequency ultrasound signal and herewith enables in-vivo analysis of 
the composition of atherosclerotic plaque as well as identification of thin-cap fibroatheroma 
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(TCFA) lesions [8]. Until now, the association between smoking and in-vivo coronary plaque 
composition has only been examined in two studies. The first [9,10] applied VH-IVUS and 
examined several plaque components, but did not assess VH-IVUS derived TCFA. The 
second [11] used integrated backscatter IVUS, which is based on the same principle as VH-
IVUS, but examined 30 patients only. 
  The main objective of the current study is to evaluate the relationship between cigarette 
smoking and coronary atherosclerotic plaque burden, volume and composition as assessed 
by (VH-)IVUS, including VH-IVUS derived TCFA lesions, in patients undergoing coronary 
catheterization for stable coronary artery disease (CAD) or acute coronary syndrome (ACS). 
With this investigation we aim to improve our understanding of the complex pathophysiologic 
relation between cigarette smoke exposure and cardiovascular disease.
Methods
Study population and baseline characteristics
This study was performed within the framework of the European collaborative Project on 
Inflammation and Vascular Wall Remodeling in Atherosclerosis—Intravascular Ultrasound 
(ATHEROREMO-IVUS) study. The design of the ATHEROREMO-IVUS study has been 
described in detail elsewhere [12]. In brief, 581 patients who underwent diagnostic coronary 
angiography or percutaneous coronary intervention (PCI) for ACS or stable CAD have been 
included in this study between 2008 and 2011 at Erasmus MC, Rotterdam, the Netherlands. 
The ATHEROREMO-IVUS study has been approved by the human research ethics committee 
of the Erasmus MC. Written informed consent was obtained from all participants. The study 
is registered in ClinicalTrials.gov, number NCT01789411.
  Baseline characteristics of the patients, including smoking status, were prospectively 
entered into a dedicated database. Smoking status was determined by self-report. Patients 
were categorized into those who currently smoke cigarettes (including those that had quit less 
than 1 year ago), those who had never smoked, and those who had smoked in the past (and had 
quit more than 1 year ago). For the current sub-study, patients from the full ATHEROREMO-
IVUS study cohort were eligible when they were current or never smokers. Patients who 
had quit smoking more than 1 year ago (n=104), or for whom information on smoking was 
lacking (n=1), were excluded, leaving 476 patients eligible for analysis.
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Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS imaging of a non-
culprit coronary artery was performed. The predefined order of preference for selection of 
the non-culprit vessel was: 1. left anterior descending (LAD) artery; 2. right coronary artery 
(RCA); 3. left circumflex (LCX) artery. All IVUS data were acquired with the Volcano™ s5/
s5i Imaging System (Volcano Corp., San Diego, CA, USA), using a Volcano™ Eagle Eye™ 
Gold IVUS catheter (20 MHz). An automatic pullback system was used with a standard pull 
back speed of 0.5 mm per second. IVUS images were analyzed offline by an independent 
core laboratory (Cardialysis BV, Rotterdam, the Netherlands) that had no knowledge of 
clinical data. IVUS grayscale and virtual histology analyses were performed using pcVH 2.1 
and qVH (Volcano Corp., San Diego, CA, USA) software.
  The external elastic membrane and luminal borders were contoured for each frame 
(median interslice distance, 0.40 mm). Degree and phenotype of the atherosclerotic plaque 
were assessed. Plaque volume was defined as the percent of the volume of the external 
elastic membrane occupied by atheroma, i.e. percent atheroma volume. Plaque burden was 
defined as plaque and media cross-sectional area divided by external elastic membrane cross-
sectional area. A coronary lesion was defined as a segment with a plaque burden of more than 
40% in at least 3 consecutive frames. Using VH-IVUS, the composition of the atherosclerotic 
plaques was characterized into 4 different tissue types: fibrous (FI), fibro-fatty (FF), dense 
calcium (DC) and necrotic core (NC) [13]. These tissue type components were expressed as 
percentages of total plaque volume. Three types of high-risk lesions were identified: 1. VH-
IVUS derived thin-cap fibroatheroma (TCFA) lesion, defined as a lesion with presence of 
>10% confluent necrotic core in direct contact with the lumen; 2. Lesion with large plaque 
burden, defined as a lesion with a plaque burden of ≥70%; 3. Stenotic lesion, defined as a 
lesion with a minimal luminal area of ≤4.0 mm2 [13,14]. In addition, remodeling index was 
calculated and expressed as the external elastic membrane cross-sectional area at the site 
of minimal luminal area divided by the reference external elastic membrane cross-sectional 
area. The reference site was selected <10 mm proximal to the lesion. Positive remodeling 
(arterial expansion) was defined as a remodeling index of >1.05, and negative remodeling 
(arterial shrinkage) was defined as a remodeling index of <0.95.
Statistical analysis
Categorical data are presented as numbers and percentages. Normality of the distributions 
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of continuous variables was examined by visual inspection of the histogram and by normal 
Q-Q plots. Continuous data are presented as mean±standard deviation (SD) or as median 
and interquartile range (IQR), depending on their distribution. Plaque volume, percentage 
fibro-fatty volume (% FF) and percentage dense calcium volume (% DC) appeared to be non-
normally distributed and were therefore ln-transformed for further analyses.
  Baseline clinical and procedural characteristics of current smokers and those who had 
never smoked were compared using the independent Student’s t-test for continuous variables 
and using the χ² test for categorical variables. Subsequently, to account for differences in 
baseline characteristics between current smokers and those who had never smoked, we 
performed a matching procedure. Every current smoker was matched to a never smoker by 
age (±5 years), gender and indication for catheterization (acute coronary syndrome or stable 
angina pectoris).
  In the matched set, baseline clinical, procedural and (VH-)IVUS characteristics of 
current smokers and never smokers were compared using the paired samples t-test for 
continuous variables and the McNemar test or marginal homogeneity test for categorical 
variables, whichever was appropriate. 
  Subsequently, we performed conditional logistic regression to examine the associations 
between smoking status and high plaque burden (above versus below the median), as well as 
smoking status and the three types of high-risk lesions (VH-IVUS derived TCFA, lesion with 
plaque burden ≥70%, lesion with minimal luminal area ≤4.0 mm2).
  Finally, to examine effect modification by age and indication for catheterization, we 
stratified on these variables and repeated all the above described analyses in subgroups. 
For this purpose, we divided age into tertiles (based on age of the smokers). All data were 
analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, USA). All statistical tests 
were two-tailed and p-values <0.050 were considered statistically significant.
Results
Baseline characteristics
Baseline clinical and procedural characteristics of the total patient population are presented in 
Table 1. Current (n=169) and never smokers (n=307) differed significantly at baseline. Current 
smokers, on average, were significantly younger (55.7±10.8 years vs. 64.4±10.8, p<0.001) than 
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the never smokers. Significantly more men were present among the current smokers (79.3% 
vs. 70.7%, p=0.041), and current smokers were less likely to have predisposing risk factors 
such as hypertension (p<0.001), dyslipidemia (p=0.030) and diabetes mellitus (p=0.038). 
Furthermore, the indication for coronary angiography or PCI also differed significantly 
between the two groups. Current smokers more often underwent catheterization for ACS and 
less often for stable CAD compared to the never smokers (p<0.001).
  After the matching procedure, baseline clinical and procedural characteristics were 
similarly distributed between the two groups (Table 2).
Table 1. Baseline clinical and procedural characteristics, before matching.
Current smokers Never smokers P-value(n = 169) (n = 307)
Patient characteristics
Age, years 55.7 ± 10.8 64.4 ± 10.8 <0.001
Male gender, n (%) 134 (79.3) 217 (70.7) 0.041
Hypertension, n (%) 63 (37.5) 171 (55.7) <0.001
Dyslipidemia, n (%) 80 (47.6) 178 (58.0) 0.030
Diabetes mellitus, n (%) 20 (11.8) 59 (19.2) 0.038
Positive family history, n (%) 86 (51.2) 158 (51.5) 0.95
Peripheral artery disease, n (%) 12 (7.1) 15 (4.9) 0.32
Previous MI, n (%) 38 (22.5) 103 (33.6) 0.011
Previous PCI, n (%) 37 (21.9) 103 (33.6) 0.008
Previous CABG, n (%) 1 (0.6) 12 (3.9) 0.034
Previous stroke, n (%) 4 (2.4) 16 (5.2) 0.14
History of renal insufficiency, n (%) 8 (4.7) 17 (5.5) 0.71
Procedural characteristics
Indication for catheterization <0.001
Acute coronary syndrome, n (%) 119 (72.1) 151 (49.5)
Stable angina pectoris, n (%) 46 (27.9) 154 (50.5)
Coronary artery disease 0.24
     No significant stenosis, n (%) 9 (5.3) 27 (8.8)
1-vessel disease, n (%) 90 (53.3) 151 (49.2)
2-vessel disease, n (%) 56 (33.1) 91 (29.6)
3-vessel disease, n (%) 14 (8.3) 38 (12.4)
Vessel imaged by VH-IVUS 0.15
LAD , n (%) 71 (42.0) 101 (33.1)
RCA , n (%) 44 (26.0) 95 (31.1)
LCX , n (%) 54 (32.0) 109 (35.7)
CABG=coronary artery bypass grafting; LAD=left anterior descending artery; LCX=left circumflex artery; MI=myocardial 
infarction; PCI=percutaneous coronary intervention; RCA=right coronary artery. Values are mean ± SD or n (%). P-values were 
obtained by independent samples t-test or Chi-squared test, whichever was appropriate.
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Table 2. Baseline clinical and procedural characteristics, after matching.
Current smokers Never smokers P-value(n = 140) (n = 140)
Patient characteristics
Age, years 57.9 ± 9.7 58.1 ± 9.5 MV
Male gender, n (%) 108 (77.1) 108 (77.1) MV
Hypertension, n (%) 58 (41.4) 73 (52.1) 0.10
Dyslipidemia, n (%) 74 (52.9) 74 (52.9) 1.00
Diabetes mellitus, n (%) 19 (13.6) 28 (20.0) 0.21
Positive family history, n (%) 68 (48.9) 75 (53.6) 0.53
Peripheral artery disease, n (%) 12 (8.6) 7 (5.0) 0.36
Previous MI, n (%) 33 (23.6) 35 (25.0) 0.89
Previous PCI, n (%) 33 (23.6) 45 (32.1) 0.11
Previous CABG, n (%) 0 (0.0) 3 (2.1) 0.25
Previous stroke, n (%) 4 (2.9) 7 (5.0) 0.51
History of renal insufficiency, n (%) 6 (4.3) 11 (7.9) 0.33
Procedural characteristics
Indication for catheterization MV
Acute coronary syndrome, n (%) 96 (68.6) 96 (68.6)
Stable angina pectoris, n (%) 44 (31.4) 44 (31.4)
Coronary artery disease 0.33
No significant stenosis, n (%) 6 (4.3) 14 (10.0)
1-vessel disease, n (%) 74 (52.9) 76 (54.3)
2-vessel disease, n (%) 47 (33.6) 36 (25.7)
3-vessel disease, n (%) 13 (9.3) 14 (10.0)
Vessel imaged by VH-IVUS 0.51
LAD , n (%) 56 (40.0) 50 (35.7)
RCA , n (%) 40 (28.6) 43 (30.7)
LCX , n (%) 44 (31.4) 47 (33.6)
CABG=coronary artery bypass grafting; LAD=left anterior descending artery; LCX=left circumflex artery; MI=myocardial 
infarction; MV=matching variable; PCI=percutaneous coronary intervention; RCA=right coronary artery. Values are mean ± SD 
or n (%). P-values were obtained by paired samples t-test, McNemar test or Marginal Homogeneity, whichever was appropriate.
Degree of coronary atherosclerosis
To assess differences in degree of atherosclerosis between current smokers and never 
smokers, plaque volume and plaque burden were examined in the coronary segments. Plaque 
volume (median [IQR]) was similar for current and never smokers (221.8 [134.6 - 312.5]mm3 
versus 207.5 [134.5 - 293.2]mm3) (Table 3). On the other hand, with regard to plaque burden, 
there was a tendency towards higher values in current smokers (Table 3). Plaque burden 
(mean±SD) was 38.6±12.5% in current smokers versus 36.4±11.0% in never smokers, 
p=0.080 (Figure 1).  
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Figure 1. Difference in plaque burden between current and never smokers.
The odds ratio (OR) (95% confidence interval (CI)) of current smoking for plaque burden 
above the median versus below the median was 1.69 (1.04 - 2.75),  p=0.033 (Table 4). After 
stratification on age, this tendency towards higher plaque burden in current smokers was 
only present in the lower age tertile (37.8±12.6% versus 33.9±11.1%, p=0.09). However, 
the OR for plaque burden above the median versus below the median was not significant in 
this subgroup (Supplementary Tables 1 and 2). Furthermore, after stratification on indication 
for catheterization, plaque burden was significantly higher in current smokers presenting 
with ACS (38.3±12.8% versus 35.0±11.2%, p=0.049 and OR 1.88 (1.02 - 3.44), p=0.042) 
(Supplementary Tables 3 and 4).
  The number of patients with ≥1 lesions was similar in current and never smokers (85.7% 
vs. 87.9%, p=0.72) (Table 3). The odds ratio of having one or more lesions with plaque 
burden ≥70% was also similar (OR (95% CI): 1.47 (0.76 - 2.83)), as was the odds ratio of 
having one or more lesions with a minimal luminal area of ≤4.0 mm2 (Table 4). Subgroup 
analysis did not provide additional insights.
  As described above, we found a borderline association with plaque burden, but no 
association with plaque volume. This seeming discrepancy may be due to the fact that plaque 
burden is not a direct measure of three dimensional plaque volume, but rather a two dimensional 
measure that also accounts for arterial wall remodeling. Specifically, the discrepancy may be 
explained by an association with negative remodeling. Therefore, we examined associations 
of smoking with remodeling in a post-hoc analysis. Smoking displayed a tendency toward 
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a positive association with negative remodeling (OR (95% CI): 1.58 (0.89 - 2.81),  p=0.12), 
as well as a tendency toward a negative association with positive remodeling (OR (95% CI): 
0.47 (0.21 - 1.05), p=0.065).
Table 3. (VH-)IVUS segment and lesion characteristics, after matching.
Current smokers Never smokers P-value(n = 140) (n = 140)
(VH-)IVUS segment parameters
Segment length, mm 45.4 ± 15.4 44.7 ± 13.2 0.67
Degree of atherosclerosis
Plaque volume, mm3 221.8 [134.6 - 312.5] 207.5 [134.5 - 293.2] 0.60
Plaque burden, % 38.6 ± 12.5 36.4 ± 11.0 0.080
Composition of atherosclerosis
% FI volume 57.7 ± 10.5 60.4 ± 12.6 0.050
% FF volume 9.6 [6.0 - 13.7] 8.6 [5.8 - 12.2] 0.039
% NC volume 21.6 ± 8.0 20.8 ± 8.8 0.37
% DC volume 7.6 [4.7 - 13.9] 8.0 [4.3 - 13.3] 0.62
(VH-)IVUS lesion parameters
≥1 Lesions, n (%) 120 (85.7) 123 (87.9) 0.73
Presence of high risk lesions, n (%) 91 (64.3) 83 (59.3) 0.46
High risk lesion type:
Degree of atherosclerosis
    ≥1 Lesion with plaque burden ≥70%, n (%) 32 (22.1) 27 (19.3) 0.65
    ≥1 Lesion with MLA ≤4.0mm2, n (%)                           43 (30.7) 42 (30.0) 1.00
Composition of atherosclerosis
   ≥1 TCFA, n (%) 57 (40.7) 57 (40.7) 1.00
FI=fibrous; FF=fibro-fatty; NC=necrotic core; DC=dense calcium; MLA=minimal lumen area; TCFA=thin-cap fibroatheroma. 
Values are mean ± SD, median [interquartile range], or n (%). P-values were obtained by paired samples t-test or McNemar test, 
whichever was appropriate.
 
Table 4. Odds ratios of current smoking for high plaque burden and for presence of high risk lesion types.
OR (95% CI) P-value
(VH-)IVUS segment parameters
Plaque burden
Below the median 1.00 (reference)
Above the median 1.69 (1.04 - 2.75) 0.033
(VH-)IVUS lesion parameters
≥1 Lesion with plaque burden  ≥70%                       1.20 (0.66 - 2.17) 0.55
≥1 Lesion with MLA ≤4.0mm2                             1.03 (0.63 - 1.71) 0.90
≥1 TCFA 1.00 (0.63 - 1.60) 1.00
OR=odds ratio; CI=confidence interval; MLA=minimal lumen area; TCFA=thin-cap fibroatheroma. P-values were obtained by 
conditional logistic regression.
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Composition of coronary atherosclerosis
VH-IVUS segment and lesion characteristics of the matched smokers and never smokers 
are listed in Table 3. Percentage of fibrous tissue (% FI) volume in the examined coronary 
segment tended to be lower in current smokers (57.7±10.5% vs. 60.4±12.6%, p=0.050), which 
was driven by the lower age tertile (56.5±10.4% vs. 61.4±12.8%, p=0.042) (Supplementary 
Table 1). Percentage of fibro-fatty tissue volume was higher in current smokers (9.6 [6.0 
- 13.7]% vs. 8.6 [5.8 - 12.2]%, p=0.039) (Table 3 and Figure 2), which was driven by the 
upper age tertile (11.1 [6.3 - 15.3]% vs. 8.3 [5.8 - 12.3], p=0.08) (Supplementary Table 1). 
However, differences in percentage necrotic core (% NC) volume and dense calcium volume 
could not be demonstrated, and prevalence of ≥1 TCFA lesions was the same in current and 
never smokers (both 40.7%, Tables 3 and 4). After stratification on age, TCFA lesions tended 
to occur less often in current smokers in the upper age tertile (23.4% vs 44.7%, p=0.06; OR 
0.41 (0.17 - 0.99, p=0.048) (Supplementary Tables 1 and 2).
Figure 2. Difference in composition of coronary atherosclerosis between current and never smokers, after 
matching. 
FI=fibrous; FF=fibro-fatty; DC=dense calcium; NC=necrotic core.
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Discussion
This study investigated the associations of cigarette smoking with coronary atherosclerotic 
plaque burden, volume and composition as determined by (VH-)IVUS of a non-culprit section 
of a coronary artery in patients undergoing coronary angiography. Cigarette smoking showed 
a tendency towards higher coronary plaque burden, which was driven by an association in 
the subgroup of patients presenting with ACS. The magnitude of this effect was very modest. 
Furthermore, while smoking was associated with higher percentage of fibro-fatty plaque 
volume, no associations could be demonstrated with percentage necrotic core volume, nor 
with VH-IVUS derived TCFA lesions, suggesting that smoking has no major influence on 
plaque vulnerability.
  Although several studies have examined the association between smoking and degree 
of coronary atherosclerosis as measured by IVUS [9–11,15–17], so far only one large study has 
applied virtual histology (VH-IVUS) to assess its association with composition of coronary 
atherosclerosis and plaque vulnerability. Philipp et al [10] found that smoking was not 
associated with plaque composition in a sample of 990 consecutive, non-selected patients, 
which is in line with our findings. However, they did not perform a lesion-based analysis, 
or a categorization into high-risk lesions such as TCFA, as we did. Missel et al [9] examined 
a subset of 473 male patients with de novo culprit coronary lesions from the same registry, 
and found a higher NC/DC ratio, a measure of plaque vulnerability, in smokers. Other VH 
parameters were not significantly influenced by smoking. A post-hoc analysis in our dataset 
showed no relation between smoking and NC/DC ratio (results not shown). In a small, 
underpowered study of 30 patients with stable angina Sano et al [11] found no association of 
plaque characteristics with smoking either. Remarkably, in our subgroup analysis, we found 
that TCFA lesions tended to occur less often in current smokers in the upper age tertile. A 
healthy survivor effect may pose a potential explanation for this finding. 
  With regard to degree of coronary atherosclerosis as assessed by IVUS, previous studies 
have rendered contradicting results. Nicholls et al [16] demonstrated that smoking was a weak 
independent predictor of percent plaque volume in 654 patients with a clinical indication for 
diagnostic coronary angiography. Furthermore, Von Birgelen et al [17] found an association 
between smoking and progression of plaque plus media cross-sectional area in 56 patients 
with de novo, hemodynamically nonsignificant plaques. In contrast, Kahlon et al concluded 
that smoking was not correlated with plaque burden in 897 consecutive patients undergoing 
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IVUS investigation [15]. In our total study population, the association between smoking and 
plaque burden as well as plaque volume was not substantial. However, we did find such 
an association in the subgroup of patients presenting with ACS. In this subgroup, current 
smokers showed a higher plaque burden than never smokers. These findings concur with 
the fact that smoking is associated with both greater degrees of stenosis and an increased 
likelihood of acute plaque events [18], as well as with the fact that smoking is associated 
with reduced fibrinolytic potential and thus a pro-thrombotic phenotype [18]. Nevertheless, 
it should be recognized that the magnitude of the difference in degree of atherosclerosis 
between current and never smokers presenting with ACS was modest in our study, and that 
both pathophysiologic and clinical relevance of the findings may be questioned. Previous 
studies on smoking and degree of atherosclerosis on IVUS have not stratified their results on 
indication for angiography.
  Our results do not support the hypothesis that smoking is associated with coronary 
plaque vulnerability. This may be explained by the possibility that plaque erosion, and not as 
much vulnerable plaque rupture, is the intermediate between smoking and cardiac adverse 
events. Histopathological studies have shown that luminal thrombosis may result from two 
different pathologies, namely plaque rupture and plaque erosion [19–22]. Plaque rupture seems 
to be highly associated with TCFAs and causes thrombotic coronary occlusion. Plaque 
erosion is characterized by an acute thrombus in direct contact with the intimal plaque, rich in 
smooth muscle cells with surrounding proteoglycan matrix and minimal inflammation. The 
lesions tend to be eccentric, infrequently calcified and cause less severe narrowing at sites of 
thrombosis [20,21]. Most eroded lesions have an absent or poorly defined necrotic core, which, 
when present, is not in close proximity to the luminal thrombus. Studies have shown that 
smoking is associated with plaque erosion and frequently causes coronary thrombosis [20,21]. 
This may possibly explain the general absence of an association of smoking with coronary 
plaque composition as assessed by VH-IVUS in the literature, and the inconsistent findings 
with regard to smoking and degree of coronary atherosclerosis as assessed by grayscale 
IVUS. We found that current smokers tend to have a slightly lower percentage fibrous plaque 
volume (driven by the lower age tertile), and that they have a somewhat higher percentage 
fibro-fatty plaque volume; however, this trend did not persist with regard to percentage 
necrotic core or presence of TCFA. These findings do not preclude plaque erosion as the 
underlying mechanism. Moreover, histopathological studies examining coronary arteries 
suggest that smoking predisposes patients to coronary thrombosis rather than promoting 
- 39 -
2
PART I
the progression of atherosclerosis [21,23,24]. These findings are supported by clinical patient 
studies showing that smokers seem to have a more favourable response to fibrinolytic therapy 
compared to nonsmokers, which may be attributed to their hypercoagulable state [25–27]. In the 
present study, we did not focus on the influence of smoking on blood coagulation.
  Smoking displayed a tendency toward a positive association with negative remodeling, 
as well as a tendency toward a negative association with positive remodeling. A possible 
explanation for these seemingly counterintuitive findings lies in the interpretation of the 
early phases of remodeling. Modest positive lesion remodeling may be considered as a 
physiological, and thus favourable, response to progression of atherosclerotic plaque (also 
known as the Glagov adaptive phenomenon) [28]. In this light, smoking may point towards a 
lower adaptive capacity to atherosclerotic burden. 
  Some aspects of this study warrant consideration. A single non-culprit coronary vessel 
was imaged. This study design of ATHEROREMO-IVUS was based on the hypothesis that 
such a non-stenotic segment adequately reflects the state of the coronary wall of the larger 
coronary tree [12]. Both ex vivo and in vivo studies using IVUS in patients presenting with 
myocardial infarction have demonstrated the existence of additional TCFAs other than 
the culprit lesion in the culprit artery, as well as TCFAs in other arteries than the culprit 
artery [29]. Accordingly, the results of ATHEROREMO-IVUS, which we published earlier, 
have confirmed that the characteristics of the coronary wall of this non-culprit coronary 
vessel are strongly associated with subsequent cardiovascular outcome [30]. In addition, 
previous studies evaluating IVUS have similarly demonstrated that the coronary wall of 
comparable non-culprit, non-stenotic segments of a single vessel does reflect larger coronary 
disease burden and is associated with subsequent events [31,32]. Nevertheless, simultaneous 
assessment of the culprit vessel might have provided additional insights into the underlying 
disease mechanisms. Another limitation of this study is that IVUS is formally not capable of 
detecting the TCFA according to histopathological definitions [33,34]. Nonetheless, a concept 
of VH-IVUS derived TCFA has been postulated for plaques with a plaque burden  ≥40% and 
a confluent necrotic core ≥10% in direct contact with the lumen in at least three VH-IVUS 
frames [14,33], and we have demonstrated earlier that such VH-IVUS derived TCFA lesions 
strongly and independently predict the occurrence of major adverse cardiac events within 
the current study population [30]. Furthermore, smoking status was determined by self-report 
in this cross-sectional study. To minimize the risk of misclassification, we excluded former 
smokers from our study. Finally, a matching procedure was necessary because of differences 
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in baseline characteristics between smokers and never smokers. Since part of the smokers 
(n=29) could not be matched to a never smoker, this study design entailed some loss of 
statistical power. Moreover, statistical power for the stratified analyses was limited.
  In conclusion, we were not able to demonstrate a clear and strong association of cigarette
smoking with degree of atherosclerosis and coronary plaque vulnerability as assessed by VH-
IVUS in the current study. Additional studies, using various intravascular imaging modalities, 
are needed to further describe the association between smoking and in-vivo degree and 
composition of coronary plaque, and to herewith discern the mechanisms underlying the 
association between smoking and cardiac adverse events.
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Supplementary Table 2. Odds ratios of current smoking for high plaque burden and for presence of high risk 
lesion types, stratified on age. 
Lower age tertile 
[34.12 – 52.96 years]
Middle age tertile 
[53.07 – 61.68 years]
Upper age tertile 
[61.73 – 85.03 years]
OR (95% CI) P OR (95% CI) P OR (95% CI) P
(VH-)IVUS segment parameters
Plaque burden
 Below the median 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Above the median 1.67 (0.73 – 3.81) 0.23 1.44 (0.62 – 3.38) 0.40 2.00 (0.86 – 4.67) 0.11
(VH-)IVUS lesion parameters
 ≥1 Lesion with plaque burden ≥70% 2.33 (0.60 – 9.02) 0.22 0.50 (0.15 – 1.66) 0.26 1.44 (0.62 – 3.38) 0.40
 ≥1 Lesion with MLA ≤4.0mm2 1.43 (0.54 – 3.75) 0.47 0.62 (0.26 – 1.49) 0.28 1.30 (0.57 – 2.97) 0.53
 ≥1 TCFA 1.75 (0.73 – 4.17) 0.21 1.40 (0.62 – 3.15) 0.42 0.41 (0.17 – 0.99) 0.048
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Supplementary Table 4. Odds ratios of current smoking for high plaque burden and for presence of high risk 
lesion types, stratified on indication.
ACS patients SAP patients
OR (95% CI) P OR (95% CI) P
(VH-)IVUS segment parameters
Plaque burden
     Below the median 1.00 (reference) 1.00 (reference)
     Above the median 1.88 (1.02 – 3.44) 0.042 1.40 (0.62 – 3.15) 0.42
(VH-)IVUS lesion parameters
     ≥1 Lesion with plaque burden ≥70% 1.46 (0.72 – 2.96) 0.29 0.71 (0.23 – 2.25) 0.57
     ≥1 Lesion with MLA ≤4.0mm2                             0.86 (0.46 – 1.61) 0.63 1.44 (0.62 – 3.38) 0.40
     ≥1 TCFA 0.84 (0.47 – 1.50) 0.56 1.40 (0.62 – 3.15) 0.42
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Fibrinogen in relation to degree 
and composition of coronary 
plaque on intravascular 
ultrasound in patients 
undergoing coronary angiography. 3
Abstract
Rationale: The aim of this study was to provide additional insight into the role of fibrinogen 
in coronary artery disease by investigating the associations between plasma fibrinogen with 
both degree and composition of coronary atherosclerosis as determined by virtual histology 
intravascular ultrasound.
Methods & Results: In 581 patients undergoing coronary angiography for acute coronary 
syndrome (ACS) or stable angina pectoris, preprocedural blood samples were drawn for 
fibrinogen, C-reactive protein (CRP), interleukin-6, and plasminogen activator inhibitor-1 
measurements, and virtual histology-intravascular ultrasound of a non-culprit coronary artery 
was performed. The degree [plaque volume, plaque burden (PB), and lesions with PB≥70%] 
and the composition of coronary atherosclerotic plaque (fibrous, fibrofatty, dense calcium, 
necrotic core tissue, and thin-cap fibroatheroma lesions) were assessed. Fibrinogen showed 
a tendency toward a positive association with PB [β (95% CI): 2.55 (-0.52 - 5.61) increase 
in PB per ln(g/l) fibrinogen, p=0.09], which was driven significantly by an association in 
the ACS subgroup [β (95% CI): 4.11 (0.01 - 8.21) increase in PB per ln(g/l) fibrinogen, 
p=0.049]. Fibrinogen was also related to the presence of lesions with PB 70% or more in 
both the full cohort [OR (95% CI): 2.27 (1.17 - 4.43), p=0.016] and ACS patients [OR 
Buljubasic N, Akkerhuis KM, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, de 
Boer SP, Regar E, van Geuns RM, Serruys PW, Boersma E, Kardys I.
Coron Artery Dis 2017; 28(1): 23-32. doi: 10.1097/MCA.0000000000000442.
Fibrinogen in relation to degree and 
composition of coronary plaque on 
intravascular ultrasound in patients 
undergoing coronary angiography. 
3
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(95% CI): 2.92 (1.17 - 7.29), p=0.022]. All associations were independent of established 
cardiovascular risk factors, but not CRP. Interleukin-6 and plasminogen activator inhibitor-1 
did not provide incremental value to fibrinogen when examining the associations with degree 
of atherosclerosis. Substantial associations with plaque composition were absent.
Conclusions: Fibrinogen is associated with degree of coronary atherosclerosis, especially in 
ACS patients. However, whether this association is independent of CRP might be questioned 
and needs further investigation.
Introduction
Elevated plasma fibrinogen levels have been associated with coronary events both in 
apparently healthy individuals [1–3] and in patients with manifest coronary artery disease 
(CAD) [4-7]. Underlying mechanisms that may account for this association have not been 
fully elucidated as yet, but fibrinogen is known to play an important role in thrombosis [8] and 
might as well influence the progression of atherosclerotic plaque formation [9,10]. In addition, 
clinical evidence has shown that fibrinogen is correlated with the severity of atherosclerosis 
on both coronary angiography and carotid ultrasonography [11-15]. These noninvasive imaging 
techniques evaluate the unobstructed part of the lumen and have not contributed toward 
elucidating potential mechanisms of the involvement of fibrinogen in atherosclerosis. In 
contrast,  invasive assessment of coronary plaque by virtual histology-intravascular ultrasound 
(VH-IVUS) not only accurately quantifies coronary atherosclerosis but also enables in-vivo 
analysis of coronary plaque composition as well as plaque vulnerability. Thus, this technique 
provides information on the structure and composition of the arterial wall itself and could add 
insights into the pathophysiology of coronary atherosclerosis [16].
  Until now, the association between fibrinogen and in-vivo coronary plaque characteristics 
has only been examined in two IVUS studies [17,18]. The first study had a modest study sample 
size of 60 patients and applied grayscale IVUS to quantify coronary atherosclerosis, which 
did not allow for assessment of the composition and vulnerability of the coronary plaques 
[17]. The second study did use VH-IVUS, but again had limited sample size (only 75 patients) 
[18]. Furthermore, although this study examined necrotic core (NC), it did not assess plaque 
vulnerability by determining thin-cap fibroatheromas (TCFAs) [18]. 
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Therefore, we investigated the association of plasma fibrinogen with the degree, composition, 
and vulnerability of coronary atherosclerosis as determined by VH-IVUS, as well as with 
1-year cardiovascular outcome, in a relatively large study population consisting of 581 
patients undergoing coronary angiography. In addition, to provide a broader view on the 
pathophysiological relationship between fibrinogen and coronary atherosclerosis, we 
examined the incremental value of the inflammatory and prothrombotic markers C-reactive 
protein (CRP), interleukin-6 (IL-6), and plasminogen activator inhibitor-1 (PAI-1) to 
fibrinogen.
Methods
The rationale and design of the European Collaborative Project on Inflammation and 
Vascular Wall Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-
IVUS) study have been approved by the medical ethics committee of the Erasmus MC 
(Rotterdam, the Netherlands) and are described in detail elsewhere [19]. The study is registered 
on ClinicalTrials.gov, number NCT01789411. Briefly, 581 patients undergoing diagnostic 
coronary angiography or percutaneous coronary intervention for acute coronary syndrome 
(ACS) or stable angina pectoris (SAP) were included. Written informed consent was 
obtained from all included patients. Baseline clinical and procedural characteristics were 
derived from medical records. Blood plasma samples were drawn before the procedure and 
stored at a temperature of −80°C. Frozen EDTA-plasma samples were transported under 
controlled conditions to Myriad RBM (Austin, Texas, USA), where fibrinogen, IL-6, and 
PAI-1 levels were measured successfully in 570 samples (ACS, n=309; SAP, n=261) using 
a validated, quantitative, multiplexed immunoassay (Custom HumanMAP; Myriad RBM). 
CRP measurements were performed in serum samples at the clinical laboratory of Erasmus 
MC using an immunoturbidimetric high-sensitivity assay (Roche Diagnostics Ltd, Rotkreuz, 
Switzerland) on the Cobas 8000 Modular Analyzer Platform (Roche Diagnostics Ltd). 
Coefficients of variation were 8% or less, 10% or less, 11% or less, and 4% or less for 
fibrinogen, IL-6, PAI-1, and CRP, respectively. Following the standard coronary angiography, 
VH-IVUS data were acquired in a non-culprit coronary artery with the Volcano s5/s5i 
Imaging System (Volcano Corp., San Diego, California, USA) using a Volcano Eagle Eye 
Gold IVUS catheter (20 MHz) [19]. The degree and composition of the atherosclerotic plaque 
- 52 -
3
PART I
were assessed offline in a dedicated core-lab as described previously [19]. Plaque volume 
was defined as the total volume of the external elastic membrane occupied by atheroma and 
was normalized for the length of the imaged segment. Plaque burden (PB) was defined as 
plaque and media cross-sectional area divided by external elastic membrane cross-sectional 
area and is presented as a percentage. Atherosclerotic plaque composition was characterized 
into fibrous (FI), fibrofatty, dense calcium, and NC. Three types of high-risk lesions were 
identified: (i) VH-IVUS-derived TCFA lesions (presence of >10% confluent NC in direct 
contact with the lumen); (ii) lesions with large PB (≥70%); and (iii) lesions with a minimal 
luminal area 4.0mm2 or less.
  Clinical follow-up started at inclusion and lasted 1 year. The primary clinical endpoint 
consisted of major adverse cardiovascular events (MACEs), which was a composite of death, 
ACS, or unplanned coronary revascularization [19]. ACS was defined as the clinical diagnosis of 
non-ST-segment elevation myocardial infarction or unstable angina pectoris [20,21]. Unplanned 
coronary revascularization was defined as any repeat percutaneous coronary intervention or 
coronary artery bypass grafting that was not foreseen at the index procedure. Endpoints were 
adjudicated by a clinical events committee on the basis of original source data.
  Normally distributed continuous variables are presented as mean±SD, whereas non-
normally distributed continuous variables are presented as median [interquartile range]. 
Categorical variables are presented as numbers and percentages. Variables with non-normal 
distributions, determined by visual inspection of the histograms, were natural logarithmically 
(ln) transformed or were transformed using the square root for further analyses. First, statistical 
analyses were carried out in the full cohort. Subsequently, they were stratified on indication 
for catheterization (ACS vs. SAP) to account for potential differences in pathophysiology. 
Associations of fibrinogen with segment VH-IVUS parameters were examined using linear 
regression analyses with continuous ln-transformed fibrinogen as the independent variable. 
The results are presented as β increase in (transformed) segment VH-IVUS parameter per unit 
increase in ln-transformed fibrinogen concentration, with 95% confidence intervals (CIs). 
Logistic regression analyses were carried out for associations between fibrinogen and the 
presence of high-risk lesions with continuous ln-transformed fibrinogen as the independent 
variable. The results are presented as odds ratios (ORs) per unit increase in ln-transformed 
fibrinogen concentration, with 95% CIs. All statistical analyses were carried out univariably 
(model 1) and multivariably (models 2 and 3). Potential confounders were selected on the 
basis of previous literature (age, sex, smoking, diabetes mellitus, dyslipidemia, hypertension, 
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indication for catheterization) and entered as covariates into the multivariable models 
(model 2). Subsequently, CRP was added to the models (model 3) as CRP is the most widely 
studied inflammatory marker in cardiovascular disease and has been suggested to carry 
similar predictive value for MACE as fibrinogen [22]. Afterwards, we examined whether the 
inflammatory markers IL-6 and CRP and the prothrombotic marker PAI-1 provide incremental 
value to elevated levels of fibrinogen with respect to the degree of atherosclerosis. For this 
purpose, these markers were dichotomized [CRP and PAI-1: below and above the median; 
IL-6: detectable (37.7%) vs. nondetectable (62.3%) levels], and degree of atherosclerosis 
was examined in patients according to both the categories of these markers and dichotomized 
categories of fibrinogen (above and below median). ANOVA trend tests were used to discern 
trends across the categories. Finally, we examined associations of fibrinogen with clinical 
endpoints after 1 year of follow-up with Cox proportional hazard regression analyses.
Results
Baseline clinical and procedural characteristics are presented in Table 1. The mean±SD age 
of the patients was 61.5±11.4 years (75% were men); 54% of the patients were admitted with 
ACS and 46% had SAP. The median [interquartile range] fibrinogen level was 3.5 [2.9 - 4.4] 
g/l in the full cohort. In ACS and SAP patients, this was 3.6 [3.0 - 4.5] and 3.4 [2.8 - 4.3] g/l, 
respectively (p=0.028). 
Table 1. Baseline patient and procedural characteristics.
Full cohort ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Patient characteristics
Age, years 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Male gender, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Dyslipidemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Diabetes mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Positive family history, n (%) 293 (51.5) 140 (45.5) 153 (58.6)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
Previous myocardial infarction, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
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Table 1 continued.
Full cohort ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Patient characteristics
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
Fibrinogen, g/L 3.5 [2.9-4.4] 3.6 [3.0-4.5] 3.4 [2.8-4.3]
Procedural characteristics
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
Indication for catheterization
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) NA
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) NA
Stable angina pectoris, n (%) 261 (45.8) NA 261 (100)
Coronary artery disease
     No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
CABG=coronary artery bypass grafting; NA=not applicable; PCI=percutaneous coronary intervention. Values are mean ± SD, 
median [interquartile range] or n (%).
The results of the univariable and multivariable analyses for the associations between plasma 
fibrinogen level and degree and composition of coronary atherosclerosis are shown in Table 2 
for the full cohort, in Table 3 for ACS, and in Table 4 for SAP. The degree of atherosclerosis 
in each group is graphically presented per fibrinogen tertile in Figures 1 and 2. There seemed 
to be a trend toward higher segment PB (p for trend=0.008 full cohort; p for trend=0.014 
ACS subgroup) and a higher prevalence of lesions with PB 70% or more (p for trend=0.002 
full cohort; p for trend=0.001 ACS subgroup) with increasing fibrinogen levels. Specifically, 
fibrinogen showed a tendency toward a positive association with segment PB [β (95% CI): 
2.55 (-0.52 - 5.61) increase in %PB per ln(g/l) fibrinogen, p=0.09] in the full cohort (Table 
2, model 2, Figure 1), which was driven by a significant association in the ACS subgroup 
[β (95% CI): 4.11 (0.01 - 8.21) increase in %PB per ln(g/l) fibrinogen, p=0.049] (Table 3, 
model 2, Figure 1). Fibrinogen was also associated with the presence of lesions with PB 
70% or more in both the full cohort [OR (95% CI): 2.27 (1.17 - 4.43), p=0.016] (Table 2, 
model 2, Figure 2) and ACS patients [OR (95% CI): 2.92 (1.17 - 7.29), p=0.022] (Table 3, 
model 2, Figure 2). This association did not reach statistical significance in the SAP subgroup 
[OR (95% CI): 1.69 (0.62 - 4.59), p=0.30] (Table 4, model 2, Figure 2). After additional 
adjustment for CRP, statistical significance was no longer reached for any of the associations 
(model 3 in Tables 2-4).   
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Figure 1. Segment plaque burden (%) in relation to fibrinogen tertiles.
ACS=acute coronary syndrome; SAP=stable angina pectoris. Observed absolute values of segment plaque burden (%) per fibrinogen 
tertile in the full cohort and stratified groups. The ANOVA trend test was used to calculate the p-values for trend and thus to discern 
trends across the categories. 
Figure 2. Presence of lesions with plaque burden 70% or more in relation to fibrinogen tertiles.
ACS=acute coronary syndrome; SAP=stable angina pectoris. Observed numbers of lesions with plaque burden 70% or more per 
fibrinogen tertile in the full cohort and stratified groups. The ANOVA trend test was used to calculate the p-values for trend and thus 
to discern trends across the categories.
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With respect to the composition and vulnerability of atherosclerosis, in the full cohort, 
fibrinogen was associated positively with NC volume [β (95% CI): 0.83 (0.11 - 1.54)mm3 
increase in NC volume per ln(g/l) fibrinogen, p=0.024] and FI tissue [β (95% CI): 0.99 
(0.01 - 1.96)mm3 increase in FI volume per ln(g/l) fibrinogen, p=0.047] (Table 2, model 2). 
However, fibrinogen was not associated with the presence of VH-TCFA lesions (i.e. rupture-
prone coronary plaques). No associations with composition were present in the ACS and SAP 
subgroups. After additional adjustment for CRP, again, statistical significance was no longer 
reached for any of the associations (model 3 in Tables 2-4).
  We have described the individual associations of CRP, IL-6, and PAI-1 with the degree, 
composition, and vulnerability of atherosclerosis in this cohort in earlier reports [23–25]. 
Briefly, we found that CRP was associated with degree, but not composition or vulnerability 
of atherosclerosis, and IL-6 and PAI-1 did not show significant associations with any of 
the plaque characteristics. In the present study, trend analysis showed that patients with 
both elevated fibrinogen and CRP levels have higher segment PB (p for trend=0.041) and 
a higher prevalence of lesions with PB 70% or more (p for trend=0.090), especially in the 
ACS subgroup (p for trend=0.001) (Figures 3 and 4). Such a trend could not be found for 
fibrinogen in combination with IL-6 or PAI-1 (Figures 5-8). 
  With respect to clinical outcome (results not shown), in the full cohort as well as in 
the individual ACS and SAP subgroups, no association was found between fibrinogen 
and MACE. A borderline significant univariable association between fibrinogen and the 
secondary, composite endpoint of death, or ACS was present in the full cohort [HR (95% 
CI): 2.69 (0.99 - 7.30), p=0.052]. After adjustment for age and sex, the association became 
nonsignificant, although the effect estimate remained materially the same [HR (95% CI): 
2.36 (0.80 - 6.93), p=0.12]. With further adjustment for CRP, the HR became closer to the 
null [HR (95% CI): 0.73 (0.20 - 2.64), p=0.64]. 
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Figure 3. Segment plaque burden (%) in relation to combined dichotomized CRP and fibrinogen levels.
ACS=acute coronary syndrome; CRP=C-reactive protein; SAP=stable angina pectoris. Observed absolute values of segment plaque 
burden (%) per category of CRP (above or under median) and fibrinogen (above or under median) together in the full cohort and 
stratified groups. The ANOVA trend test was used to calculate the p-values for trend and thus to discern trends across the categories.
Figure 4. Presence of lesions with plaque burden 70% or more in relation to combined dichotomized CRP 
and fibrinogen levels.
ACS=acute coronary syndrome; CRP=C-reactive protein; SAP=stable angina pectoris. Observed numbers of lesions with plaque 
burden 70% or more per category of CRP (above or under median) and fibrinogen (above or under median) together in the full 
cohort and stratified groups. The ANOVA trend test was used to calculate the p-values for trend and thus to discern trends across 
the categories. 
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Figure 5. Segment plaque burden (%) in relation to combined dichotomized IL-6 and fibrinogen levels.
ACS=acute coronary syndrome; IL-6=interleukin-6; SAP=stable angina pectoris. Observed absolute values of segment plaque 
burden (%) per category of IL-6 (detectable or nondetectable) and fibrinogen (above or under median) together in the full cohort 
and stratified groups.
Figure 6. Presence of lesions with plaque burden 70% or more in relation to combined dichotomized IL-6 
and fibrinogen levels.
ACS=acute coronary syndrome; IL-6=interleukin-6; SAP=stable angina pectoris. Observed numbers of lesions with plaque burden 
70% or more per category of IL-6 (detectable or nondetectable) and fibrinogen (above or under median) together in the full cohort 
and stratified groups. 
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Figure 7. Segment plaque burden (%) in relation to combined dichotomized PAI-1 and fibrinogen levels. 
ACS=acute coronary syndrome; PAI-1=plasminogen activator inhibitor type-1; SAP=stable angina pectoris. Observed absolute 
values of segment plaque burden (%) per category of PAI-1 (above or under median) and fibrinogen (above or under median) together 
in the full cohort and stratified groups. 
Figure 8. Presence of lesions with plaque burden 70% or more in relation to combined dichotomized PAI-1 
and fibrinogen levels. 
ACS=acute coronary syndrome; PAI-1=plasminogen activator inhibitor type-1; SAP=stable angina pectoris. Observed numbers of 
lesions with plaque burden 70% or more per category of PAI-1 (above or under median) and fibrinogen (above or under median) 
together in the full cohort and stratified groups.
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Discussion
This is the first large study that has investigated the association between plasma fibrinogen 
level and the degree, composition, and vulnerability of coronary atherosclerotic plaque as 
assessed by VH-IVUS. Thus, our study provides additional insight into the nature of the 
relationship between fibrinogen and CAD. We found that fibrinogen was associated with 
PB and presence of large lesions, both significantly driven by patients presenting with ACS. 
Conversely, we could not find substantial associations between fibrinogen and atherosclerotic 
plaque composition, including VH-IVUS-derived TCFA lesions (i.e. rupture-prone coronary 
plaques). The latter agrees with an earlier study, which could not find an association between
fibrinogen and rupture-prone carotid plaques on ultrasonography [26]. Altogether, these findings 
might indicate that fibrinogen plays a pathogenic role in the progression of atherosclerotic 
plaque formation rather than in plaque vulnerability, especially in ACS patients.
  Although several studies using different modalities have examined the association between 
fibrinogen and atherosclerosis, so far, only two studies have applied the IVUS technique [17,18]. 
Hartmann et al. [17] examined this association with grayscale IVUS in only 60 patients and 
concluded that fibrinogen levels correlate with plaque progression on IVUS, which is in line 
with our findings. Yet, the grayscale IVUS technique did not enable examination of plaque 
composition or plaque vulnerability. The other study published recently by Corban et al. [18], 
used the VH-IVUS technique as we did, but the study size was again modest with 75 patients. 
They concluded that fibrinogen degradation products are associated with larger plaques that 
have a larger NC. Although they did not stratify their study population by clinical diagnosis 
(ACS vs. SAP), their findings concur with our results in the full cohort. Here, the authors 
suggest that fibrinogen may play a role in plaque vulnerability, which should be confirmed 
in studies that determined TCFAs. However, as the study population was relatively small 
and consisted of patients with nonobstructive CAD, this study contained a low number of 
TCFAs. Therefore, the authors could not investigate further whether fibrinogen is associated 
with plaque vulnerability. In our study, with a relatively large sample size, we could examine 
the relationship between fibrinogen and TCFAs, but the results did not confirm a relationship 
with fibrinogen. Therefore, we hypothesize that fibrinogen might rather play a pathogenic 
role in atherosclerotic plaque formation than in plaque vulnerability.
  A potential association of fibrinogen with degree of coronary plaque is in line with earlier 
studies, proposing a mechanism by which fibrinogen, as a major determinant of thrombus 
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formation, could directly contribute toward the progression of coronary atherosclerosis 
[8,27]. Fibrinogen is believed to be involved in an underlying process of multiple consecutive 
mild episodes of mural thrombosis in response to subclinical rupture [28], leading to repeated 
incorporation of small thrombi and eventually resulting in gradual progression of an 
atherosclerotic plaque [29]. This hypothesis is further supported by clinical evidence showing 
that high fibrinogen levels are positively correlated with the extent of atheroma on coronary 
angiography [11,14,30,31]. Another study that measured the progress of carotid atherosclerosis 
by high-resolution duplex ultrasound found a temporal relationship between fibrinogen and 
advanced atherosclerosis rather than with early (inflammatory) stages of the disease [13]. In 
addition, immunohistochemical studies have shown the presence of fibrinogen in atherosclerotic 
plaques, indicating that fibrinogen may be directly involved in plaque progression [32].
  According to autopsy studies [33], repeated, healed silent plaque ruptures with incorporated 
organized thrombi are predominantly found in patients with ACS, indicating episodic plaque 
growth and thereby contributing toward the progression of advanced atherosclerotic plaques 
in these patients. This might explain the fact that we found a positive association of fibrinogen 
with degree of coronary atherosclerosis in ACS patients in particular. Rupture-prone, soft, 
lipid-rich plaques have previously been found to be more common in patients presenting 
with ACS compared with SAP patients [34]. Taken together with reported findings of increased 
fibrinogen levels in patients with established advanced CAD [35,36], the unstable lipid-rich 
plaques in ACS patients may be more thrombogenic than stable FI plaques in SAP patients 
[37,38]. Thus, ACS patients with increased fibrinogen levels are likely to have experienced 
multiple consecutive mild episodes of mural thrombosis previously, eventually leading to a 
higher degree of atherosclerotic plaque compared with SAP patients.
  Another prothrombotic factor that we investigated was PAI-1, which has led to 
paradoxical results in previous studies [39]. Conflicting results exist with respect to the role 
of PAI-1 in both promoting and preventing plaque development because of its complex 
multilevel functions [39,40]. We could not find higher or lower degree of coronary plaque in 
patients with elevated levels of both fibrinogen and PAI-1.
  The observed associations of fibrinogen with degree of atherosclerosis were not 
independent of CRP. CRP has been associated with the presence and degree of atherosclerosis 
[23,41], and both fibrinogen and CRP are linked to vascular inflammation [42,43]. In line with our 
current results, Hartmann et al. [17] found a positive, but not independent, correlation between 
fibrinogen levels and plaque progression on IVUS. Furthermore, in our study, a higher degree 
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of atherosclerosis was present in patients with both high levels of CRP and high levels of 
fibrinogen, suggesting a synergistic effect on coronary atherosclerosis.
  Inflammatory processes result in the release of numerous mediators, including IL-6, 
which is the principal procoagulant cytokine [42]. Although the exact interaction is unknown, 
it is suggested that IL-6 on its part can increase plasma concentrations of both fibrinogen 
and CRP, which further amplify inflammatory and procoagulant responses [42]. However, as 
we have reported earlier, in the current cohort, we found no associations between IL-6 and 
coronary plaque characteristics [25]. Also, in the current investigation, we could not find any 
trend toward a higher degree of coronary atherosclerosis in patients with both high fibrinogen 
and high IL-6 levels.
  Finally, our data suggest that fibrinogen may be associated with the incidence of all-
cause mortality or ACS. The fact that the association became nonsignificant after adjustment 
for age and sex may have resulted from limited statistical power (56 events after 1-year of 
follow-up) as the effect estimate remained large after adjustment. However, after additional 
adjustment for CRP, the associations disappeared completely. Again, common inflammatory 
grounds may have played a role here. Although population-based studies have shown that 
fibrinogen is associated with adverse outcome independent of CRP [1], studies in patients 
with known CAD are fewer in number [4,5,44] and not all of them have taken CRP into account.
  Some limitations of this study must be acknowledged. First, the possibility that 
fibrinogen as an acute-phase reactant may be the result of clinical presentation rather than 
its cause, particularly in patients with ACS, cannot be excluded. Our study design does not 
enable causal inference. Nevertheless, our study does provide novel data on fibrinogen in 
relation to in-vivo assessment of the arterial wall (i.e. more accurate measures of coronary 
atherosclerosis) [45] and may thus serve to be hypothesis generating. Second, VH-IVUS 
imaging data were acquired in a non-culprit coronary artery segment only. This approach 
was based on the hypothesis that such a non-culprit target segment adequately reflects the
patient’s overall state of coronary wall pathophysiology of the larger coronary vasculature [19]. 
This hypothesis has been confirmed by several IVUS studies that showed that the coronary 
wall of a non-culprit segment in a single vessel does reflect larger coronary disease burden 
and is associated with subsequent cardiovascular events [46,47].
  In conclusion, our findings support the hypothesis that fibrinogen is associated with 
coronary atherosclerotic PB, especially in patients presenting with ACS. However, whether 
this association is independent of CRP may be questioned and warrants further investigation.
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Adiponectin in relation to 
coronary plaque characteristics 
on radiofrequency intravascular 
ultrasound and cardiovascular 
outcome. 4
Abstract
 
Rationale: Prospective data on the associations of adiponectin with in-vivo measurements 
of degree, phenotype and vulnerability of coronary atherosclerosis are currently lacking. 
The objective is to investigate the association of plasma adiponectin with virtual histology 
intravascular ultrasound (VH-IVUS)-derived measures of atherosclerosis and with major 
adverse cardiac events (MACE) in patients with established coronary artery disease. 
Methods & Results: In 2008-2011, VH-IVUS of a non-culprit non-stenotic coronary 
segment was performed in 581 patients undergoing coronary angiography for acute coronary 
syndrome (ACS, n=318) or stable angina pectoris (SAP, n=263) from the atherosclerosis-
intravascular ultrasound (ATHEROREMO-IVUS) study. Blood was sampled prior to coronary 
angiography. Coronary plaque burden, tissue composition, high-risk lesions, including 
VH-IVUS-derived thin-cap fibroatheroma (TCFA), were assessed. All-cause mortality, 
ACS, unplanned coronary revascularization were registered during a 1-year-follow-up. All 
statistical tests were two-tailed and p-values <0.05 were considered statistically significant. 
In the full cohort, adiponectin levels were not associated with plaque burden, nor with the 
Marino BCA, Buljubasic N, Akkerhuis M, Cheng JM, Garcia-Garcia HM, Regar 
E, Geuns RV, Serruys PW, Boersma E, Kardys I.
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various VH-tissue types. In SAP patients, adiponectin levels (median [IQR]: 2.9 [1.9 - 3.9] 
μg/mL) were positively associated with VH-IVUS derived TCFA lesions, (OR (95% CI): 
1.78 (1.06 - 3.00), p=0.030), and inversely associated with lesions with minimal luminal area 
(MLA) ≤4.0 mm2 (OR (95% CI): 0.55 (0.32 - 0.92), p=0.025). In ACS patients, adiponectin 
levels (median [IQR]: 2.9 [1.8 - 4.1] μg/mL) were not associated with plaque burden, nor 
with tissue components. Positive association of adiponectin with death was present in the 
full cohort (HR (95% CI): 2.52 (1.02 - 6.23), p=0.045) and (borderline) in SAP patients 
(HR (95% CI): 8.48 (0.92 - 78.0), p=0.058). In ACS patients, this association lost statistical 
significance after multivariable adjustment (HR (95% CI): 1.87 (0.67 - 5.19), p=0.23). 
Conclusions: In the full cohort, adiponectin levels were associated with death but not with 
VH-IVUS atherosclerosis measures. In SAP patients, adiponectin levels were associated 
with VH-IVUS-derived TCFA lesions. Altogether, substantial role for adiponectin in plaque 
vulnerability remains unconfirmed.
Introduction 
Coronary plaque rupture has been described as the main mechanism through which mildly 
stenotic coronary atherosclerosis can lead to acute coronary thrombosis and myocardial 
infarction [1]. High-risk plaques that are vulnerable to such rupture demonstrate distinct 
morphological characteristics [2]. They can be differentiated from lesions responsible for 
stable coronary artery disease (CAD) by their large necrotic cores, thin inflamed fibrous caps, 
and positive remodeling [2]. Because plaque vulnerability is associated with inflammation, 
neovascularization, and necrotic core formation, circulating mediators of these processes 
may aid in detection of high-risk patients and therefore warrant investigation [3]. One 
important inflammatory mediator of CAD is adiponectin. Adiponectin is a protein mainly 
produced in white adipose tissue, involved in several antioxidant, anti-inflammatory, and anti-
atherosclerotic processes [4-6]. Several studies have demonstrated associations of adiponectin 
with clinical adverse coronary events [7-10]. Yet, prospective data on the associations of 
adiponectin with in-vivo measurements of degree, phenotype and vulnerability of coronary 
atherosclerosis are currently lacking. To further elucidate the pathophysiology of adiponectin 
in patients with established CAD, we investigated the association of adiponectin with virtual 
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histology intravascular ultrasound (VH-IVUS)-derived measures of degree and composition 
of coronary atherosclerosis, and with major adverse cardiac events (MACE), in patients 
undergoing coronary angiography.
Methods 
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study 
has been described in detail elsewhere [11,12]. In brief, 581 patients who underwent diagnostic 
coronary angiography or percutaneous coronary intervention (PCI) for acute coronary 
syndrome (ACS, n=318) or stable angina pectoris (SAP, n=263) have been included between 
2008 and 2011 in the Erasmus University Medical Center (Erasmus MC), Rotterdam, the 
Netherlands. The ATHEROREMO-IVUS study was approved by the medical ethics committee 
of Erasmus MC. The study was performed in accordance with the criteria described in the 
declaration of Helsinki. Written informed consent was obtained from all included patients. 
This study is registered in ClinicalTrials.gov, number NCT01789411.
  Blood samples for biomarker measurements were drawn from the arterial sheath prior 
to coronary angiography and were available in 570 patients for the current study. The blood 
samples were stored at the clinical laboratory of Erasmus MC at a temperature of -80°C 
within 2 hours after blood collection. C-reactive protein (CRP) was measured in serum 
samples using an immunoturbidimetric high sensitivity assay (Roche Diagnostics Ltd., 
Rotkreuz, Switzerland) on the Roche Cobas 8000 modular analyzer platform. These analyses 
were performed in the clinical laboratory of Erasmus MC. Frozen EDTA plasma samples 
were transported under controlled conditions (at a temperature of -80°C) to Myriad RBM, 
Austin, Texas, USA, where adiponectin was measured using a validated multiplex assay 
(Custom Human Map, Myriad RBM).
  Following the standard coronary angiography or PCI procedure, intravascular ultrasound 
(IVUS) imaging took place in a target segment of a non-culprit coronary artery which was 
required to be at least 40mm in length and without significant luminal narrowing (<50% 
stenosis) as assessed by on-line angiography. Selection of the non-culprit vessel was predefined 
in the study protocol. The order of preference for selection of the non-culprit vessel was: (1) 
left anterior descending (LAD) artery; (2) right coronary artery (RCA); (3) left circumflex 
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(LCX) artery. All IVUS data were acquired with the Volcano s5/s5i Imaging System (Volcano 
Corp., San Diego, California) using a Volcano Eagle Eye Gold IVUS catheter (20MHz). An 
automatic pullback system was used with a standard pullback speed of 0.5mm per second. 
The IVUS images were analyzed offline by an independent core laboratory (Cardialysis BV, 
Rotterdam, the Netherlands) blinded for clinical and biomarker data. The IVUS gray-scale 
and IVUS radiofrequency analyses, also known as VH-IVUS, were performed using pcVH 
2.1 and qVH (Volcano Corp., San Diego, California) software. The external elastic membrane 
and luminal borders were contoured for each frame (median inter-slice distance, 0.40 mm). 
Extent and phenotype of the atherosclerotic plaque were assessed. Plaque volume was defined 
as the total volume of the external elastic membrane occupied by atheroma [13]. Plaque burden 
was defined as plaque and media cross-sectional area divided by external elastic membrane 
cross-sectional area and is presented as a percentage. The composition of the atherosclerotic 
plaque was characterized into four different tissue types: fibrous, fibrofatty, dense calcium 
and necrotic core [14]. A coronary lesion was defined as a segment with a plaque burden of 
more than 40% in at least three consecutive frames. 
The following types of VH-IVUS high-risk lesions were identified: 
(1) Thin-cap fibroatheroma (TCFA) lesions: lesions with presence of >10% confluent 
necrotic core in direct contact with the lumen [15,16]
(2) TCFA lesions with a plaque burden of at least 70% 
(3) Lesions with a plaque burden of at least 70%
(4) Lesions with a minimal luminal area (MLA) of ≤4.0 mm2 [11]
Follow-up started at inclusion and lasted 1 year. Post-discharge survival status was obtained 
from municipal civil registries. Post-discharge rehospitalizations were prospectively assessed 
during follow-up. Questionnaires focusing on the occurrence of MACE were sent to all living 
patients. Subsequently, hospital discharge letters were obtained, and treating physicians and 
institutions were contacted for additional information whenever necessary. ACS was defined 
as the clinical diagnosis of ST-segment elevation myocardial infarction (STEMI), non-
STEMI or unstable angina pectoris in accordance with the guidelines of the European Society 
of Cardiology [17-19]. Unplanned coronary revascularization was defined as unplanned repeat 
PCI or coronary artery bypass grafting (CABG). The primary clinical endpoint was MACE, 
defined as all-cause mortality, ACS or unplanned coronary revascularization. Secondary 
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endpoints included acute MACE (defined as the composite of all-cause mortality or ACS) and 
all-cause mortality. The endpoints were adjudicated by a clinical event committee blinded for 
biomarker and IVUS data.
Statistical analysis 
The distributions of continuous variables, including adiponectin levels and IVUS 
parameters, were evaluated for normality by visual examination of the histogram. Normally 
distributed variables are presented as mean±standard deviation (SD), while non-normally 
distributed variables are presented as median and interquartile range [IQR]. Adiponectin 
concentration was not normally distributed and was therefore ln-transformed for further 
analysis. Categorical variables are presented in percentages. We examined associations of 
adiponectin concentrations with plaque burden, plaque volume, necrotic core fraction, dense 
calcium fraction, fibro-fatty fraction, and fibrous tissue fraction in the imaged coronary 
segment by linear regression, with continuous ln-transformed adiponectin concentration 
as the independent variable. Furthermore, we examined the relation between adiponectin 
concentrations and the presence of high-risk lesions using logistic regression analyses, 
with continuous ln-transformed adiponectin concentration as the independent variable. 
Cox proportional hazards regression analyses were performed to evaluate the relationship 
between adiponectin concentration and MACE. Clinical variables age, gender, diabetes 
mellitus, hypertension, and indication for coronary angiography were considered as potential 
confounders and were entered into the full model. These covariates were a priori chosen 
based on existing literature and taking into account the number of events available. CRP was 
also entered into the full model, as it is the most widely investigated inflammatory marker 
in CAD, and has been shown to be (inversely) associated with plasma adiponectin levels [10]. 
When analyzing the association of adiponectin with the secondary, composite endpoint of 
death and ACS, and death alone, we only adjusted for age and gender because of the limited 
number of endpoints.
  First, statistical analyses were performed in the full cohort. Then, we included interaction 
terms (adiponectin multiplied by indication for angiography) into the models to investigate 
possible effect modification by indication. Subsequently, we repeated the analyses separately 
in patients with SAP and patients with ACS. All data were analyzed with SPSS software 
(SPSS 20.0, IBM corp., Armonk, New York). All statistical tests were two-tailed and p-values 
<0.05 were considered statistically significant. 
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Results 
Mean age of the patients was 61.5±11.4 years, 75.4% were men, 17.4% had diabetes mellitus, 
and median adiponectin concentration was 2.8 [1.9 - 4.0] μg/mL (Table 1). Coronary 
angiography or PCI was performed for ACS in 309 (54.2%) patients and for SAP in the 
remaining 261 (45.8%). Median adiponectin concentration was 2.9 [1.8 - 4.1] μg/mL in ACS 
patients and 2.9 [1.9 - 3.9]  μg/mL in SAP patients. A total of 239 (41.9%) patients had at least 
1 VH-IVUS-derived TCFA, including 69 (12.1%) patients with at least 1 VH-IVUS-derived 
TCFA with a plaque burden ≥70%. 
  In the full cohort, adiponectin levels were not associated with composition or burden 
of atherosclerosis on multivariable analysis (Tables 2 and 3). Adiponectin levels were not 
associated with MACE after adjustment for age, gender and indication for angiography 
(Table 4). After further multivariable adjustment, effect estimates remained non-significant 
(data not shown). Adiponectin levels tended to be univariably associated with acute MACE, 
(median [IQR] 1.16 [0.82 - 1.62] μg/mL, vs. 1.02 [0.64 - 1.38] μg/mL; HR (95% CI): 1.77 
(0.96 - 3.23), p=0.069), but after further adjustment this tendency disappeared. Adiponectin 
levels were independently associated with occurrence of death (median [IQR] 1.48 [1.03 - 
1.79] μg/mL vs. 1.02 [0.64 - 1.36] μg/mL, HR (95% CI): 2.52 (1.02 - 6.23), p=0.045).
 
Table 1. Baseline characteristics.
Full cohort ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Patient characteristics
Age, years 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Male gender, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Diabetes mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Positive family history, n (%) 293 (51.4) 140 (45.3) 153 (58.6)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
Previous myocardial infarction, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
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Table 1 continued.
Full cohort ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Procedural characteristics
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
Indication for catheterization
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
IVUS characteristics
Segment length, mm 44.1 [33.7 - 55.4] 43.9 [32.9 - 54.1] 44.8 [34.2 - 57.2] 
Plaque burden, % 39.2 [30.0 - 46.4] 37.2 [28.0 - 45.5] 40.2 [31.8 - 47.8] 
Presence lesion with MLA ≤4.0mm2, n (%) 176 (30.9) 88 (28.7) 88 (33.7) 
Presence of VH-TCFA, n (%) 239 (41.9) 140 (45.3) 99 (37.9) 
Presence of VH-TCFA with PB ≥70%, n (%) 69 (12.1) 32 (10.4) 37 (14.2)
Serum biomarker concentrations
C-reactive protein, mg/L 2.1 [0.8 - 5.3] 2.8 [1.1 - 7.0] 1.5 [0.6 - 3.1] 
Adiponectin, μg/mL 2.8 [1.9 - 4.0] 2.9 [1.8 - 4.1] 2.9 [1.9 - 3.9] 
ACS=acute coronary syndrome; SAP=stable angina pectoris; PCI=percutaneous coronary intervention; CABG=coronary artery 
bypass grafting; IVUS=intravascular ultrasound; MLA=minimal luminal area; VH-TCFA=virtual histology thin-cap fibroatheroma; 
PB=plaque burden. Values are mean ± SD, median [interquartile range] or n (%).
 
Table 2. Association of adiponectin plasma levels with segment intravascular ultrasound characteristics in the 
total study cohort, acute  coronary syndrome and stable angina patients.
(VH-)IVUS segment 
characteristics
Unadjusted model P-value Multivariable model
a
P-value
β (95% CI)b β (95% CI)b
Full cohort (n = 570) Segment plaque burden -0.40 (-2.04 – 1.23) 0.62 -0.95 (-2.74 – 0.85) 0.30 
Dense calcium fraction % 1.35 (0.27 – 2.44) 0.001 0.36 (-0.86 – 1.58) 0.56
Necrotic core fraction % 0.43 (-0.71 – 1.58) 0.46 0.39 (-0.92 – 1.70) 0.56
Fibrofatty tissue fraction % -0.62 (-1.51 – 0.27) 0.17 -0.46 (-1.46 – 0.55) 0.37
Fibrous tissue fraction % -1.17 (-2.81 – 0.48) 0.17 -0.29 (-2.16 – 1.58) 0.76
ACS patients (n = 309) Segment plaque burden 0.03 (-2.27 – 2.33) 0.98 -0.89 (-3.42 – 1.63) 0.49
Dense calcium fraction % 2.53 (0.92 – 3.78) 0.001 1.10 (-0.50 – 2.70) 0.18
Necrotic core fraction % 0.56 (-1.12 – 2.24) 0.51 0.23 (-1.69 – 2.16) 0.81
Fibrofatty tissue fraction % -1.47 (-2.78 – -0.15) 0.029 -0.99 (-2.49 – 0.50) 0.19
Fibrous tissue fraction % -1.45 (-3.78 – 0.89) 0.22 -0.35 (-3.00 – 2.30) 0.80
SAP patients (n = 261) Segment plaque burden -0.71 (-3.00 – 1.58) 0.54 -0.87 (-3.46 – 1.73) 0.51
Dense calcium fraction % 0.39 (-1.25 – 2.01) 0.64 -0.41 (-2.28 – 1.47) 0.67
Necrotic core fraction % 0.24 (-1.29 – 1.77) 0.76 0.57 (-1.20 – 2.35) 0.52
Fibrofatty tissue fraction % 0.38 (-0.80 – 1.57) 0.52 0.01 (-1.32 – 1.34) 0.99
Fibrous tissue fraction % -1.01 (-3.31 – 1.30) 0.39 -0.17 (-2.82 – 2.48) 0.90
IVUS=intravascular ultrasound; CI=confidence interval of 95%; ACS=acute coronary syndrome; SAP=stable angina pectoris; 
CRP=C-reactive protein. aAdjusted for age, gender, diabetes, hypertension, and C-reactive protein (CRP). Additionally adjusted for 
indication for coronary angiography in the total cohort. bBeta per unit increase in ln-transformed adiponectin concentration. 
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Table 3. Association of adiponectin with presence of virtual histology intravascular ultrasound-derived high-
risk lesions in the total cohort, acute coronary syndrome and stable angina patients.
(VH-)IVUS lesion 
characteristics
Unadjusted model P-value Multivariable model
a
P-valueOR (95% CI)b OR (95% CI)b
Full cohort (n = 570) TCFA 1.11 (0.84 – 1.49) 0.44 1.23 (0.88 – 1.71) 0.23
TCFA PB ≥70% 0.88 (0.57 – 1.37) 0.55 0.81 (0.50 – 1.33) 0.42
Lesion with MLA ≤4.0 mm2 0.84 (0.62 – 1.14) 0.25 0.70 (0.49 – 1.00) 0.052
Lesion with PB ≥70% 1.02 (0.72 – 1.44) 0.93 0.93 (0.63 – 1.39) 0.73
ACS patients (n = 309) TCFA 0.85 (0.58 – 1.26) 0.42 0.90 (0.58 – 1.42) 0.66
TCFA PB ≥70% 0.90 (0.57 – 1.42) 0.66 0.77 (0.37 – 1.58) 0.48 
Lesion with MLA ≤4.0 mm2 1.13 (0.74 – 1.74) 0.57 0.87 (0.53 – 1.44) 0.59 
Lesion with PB ≥70% 1.25 (0.76 – 2.07) 0.38 1.08 (0.60 – 1.94) 0.80 
SAP patients (n = 261) TCFA 1.54 (0.99 – 2.38) 0.057 1.78 (1.06 – 3.00) 0.030 
TCFA PB ≥70% 0.86 (0.48 – 1.52) 0.60 0.87 (0.45 – 1.69) 0.68 
Lesion with MLA ≤4.0 mm2 0.62 (0.40 – 0.97) 0.035 0.55 (0.32 – 0.93) 0.025 
Lesion with PB ≥70% 0.86 (0.54 – 1.39) 0.54 0.85 (0.49 – 1.47) 0.56 
IVUS=intravascular ultrasound; OR=odds ratio; CI=confidence interval of 95%; TCFA=thin-cap fibroatheroma; PB=plaque burden; 
MLA=minimal luminal area; ACS=acute coronary syndrome; SAP=stable angina pectoris. aAdjusted for age, gender, diabetes, 
hypertension, and C-reactive protein (CRP). Additionally adjusted for indication for coronary angiography in the total cohort. bOdds 
ratio per unit increase in ln-transformed biomarker concentration.
Table 4. Association of adiponectin with major adverse cardiac events, secondary endpoints and death. 
Clinical outcome Unadjusted model P-value
Adjusted for age 
and gendera P-value
HR (95% CI)b HR (95% CI)b
Full cohort (n = 570) MACE (n = 56) 1.28 (0.81 – 2.02) 0.29 1.19 (0.71 – 1.99) 0.52
Acute MACE (n = 32) 1.77 (0.96 – 3.23) 0.069 1.36 (0.68 – 2.72) 0.38
Death (n = 19) 3.36 (1.49 – 7.59) 0.004 2.52 (1.02 – 6.23) 0.045
ACS patients (n = 309) MACE (n = 56) 1.29 (0.66 – 2.50) 0.46 1.02 (0.48 – 2.19) 0.95
Acute MACE (n = 32) 1.75 (0.81 – 3.72) 0.14 1.40 (0.59 – 3.29) 0.44
Death (n = 19) 2.44 (0.98 – 6.06) 0.055 1.87 (0.67 – 5.19) 0.23
SAP patients (n = 261) MACE (n = 56) 1.30 (0.69 – 2.46) 0.42 1.43 (0.69 – 2.98) 0.34
Acute MACE (n = 32) 1.75 (0.61 – 4.94) 0.29 1.33 (0.41 – 4.28) 0.64
Death (n = 19) 8.15 (1.49 – 44.68) 0.016 8.48 (0.92 – 78.03) 0.058
HR=hazard ratio; CI=confidence interval of 95%; MACE=major adverse cardiac events; ACS=acute coronary syndrome; SAP=stable 
angina pectoris; Acute MACE=composite of death or acute coronary syndrome (secondary endpoints). aAdditionally adjusted for 
indication for coronary angiography in the total cohort. bHazard ratio per unit increase in ln-transformed biomarker concentration. 
Signs of interactions between adiponectin and indication for angiography were present for 
associations with TCFA (p for interaction 0.050 (univariable) and 0.029 (multivariable)), with 
lesions with MLA ≤4.0mm2 (p for interaction 0.058 (univariable) and 0.10 (multivariable)), 
and with fibrofatty tissue fraction (p for interaction 0.042 (univariable) and 0.082 
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(multivariable)). The remaining interaction terms were not significant (data not shown). 
In patients with SAP, adiponectin levels were associated with the presence of VH-IVUS-
derived TCFA lesions (median [IQR] 1.16 [0.72 - 1.48] μg/mL vs. 0.95 [0.62 - 1.30] μg/mL; 
OR (95% CI) per 1 unit increase in ln-transformed-adiponectin: 1.78 (1.06 - 3.00), p=0.030) 
(Table 3). Furthermore, adiponectin levels were inversely associated with presence of lesions 
with MLA ≤4.0 mm2 (median [IQR] 0.95 [0.49 - 1.30] μg/mL vs. 1.06 [0.69 - 1.41] μg/
mL; OR (95% CI): 0.55 (0.32 - 0.93), p=0.025) (Table 3). Finally, adiponectin levels were 
associated with death (median [IQR] 1.62 [1.32 - 1.84] μg/mL vs. 1.02 [0.64 - 1.36] μg/mL; 
HR (95% CI): 8.15 (1.49 - 44.68)). After adjustment for age and gender, the HR remained 
similar in magnitude, although statistical significance was lost (HR (95% CI): 8.48 (0.92 - 
78.03), p=0.058). 
  In patients with ACS, no associations were present between adiponectin and composition 
or burden of atherosclerosis. Although no associations were present with MACE or acute 
MACE, a tendency toward a univariable association with death was present (median [IQR] 
1.39 [0.90 - 1.86] μg/mL vs. 1.01 [0.60 - 1.38] μg/mL; HR (95% CI): 2.44 (0.98 - 6.06), 
p=0.055). After adjustment for age and gender, statistical significance was lost (HR (95% 
CI): 1.87 (0.67 - 5.19), p=0.23).
  Given the positive associations we found between adiponectin and death, we performed 
a post-hoc analysis to explore whether a synergistic effect of adiponectin and TCFA was 
present on death. For this purpose, we entered interaction terms into the models that consisted 
of adiponectin multiplied by presence of TCFA lesions. However, no effect modification 
could be demonstrated (interaction terms were not significant).
Discussion 
To our best knowledge, this is the largest study that correlates circulating adiponectin with 
in-vivo measurements of coronary atherosclerosis using VH-IVUS in patients with known 
coronary disease. We found that in the full cohort, adiponectin levels were associated with 
death during 1-year follow-up, but not with VH-IVUS measures of atherosclerosis. In patients 
with SAP, adiponectin levels were positively associated with presence of VH-IVUS-derived 
TCFA lesions and were inversely associated with presence of lesions with MLA ≤ 4.0 mm2; 
while the association with death was borderline significant. In ACS patients we only found a 
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tendency toward an association with death during follow-up.
Fundamental experiments, animal models and human studies on vascular function in 
subjects free of symptomatic cardiovascular disease have all demonstrated associations of 
adiponectin with vasoprotective mechanisms, including insulin-sensitizing characteristics 
and anti-oxidative and anti-inflammatory properties [4-6,8,10]. In line with this, higher levels 
of adiponectin have been linked to decreased prevalence of CAD in healthy individuals and 
have demonstrated an inverse association with risk of myocardial infarction [20,21]. However, 
in patients with manifested CAD, adiponectin seems to play a different role. When elevated 
in patients with symptomatic CAD, this adipocytokine becomes associated with an increased 
risk of cardiovascular events; a phenomenon that has been described under the term “reverse 
epidemiology” [22-25]. To explain these conflicting findings, it has been proposed that increased 
adiponectin levels reflect a compensatory and vasculoprotective mechanism [25]. Specifically, 
in conditions characterized by a marked systemic pro-inflammatory state and endothelial 
dysfunction, adiponectin levels increase as an attempt to counter-regulate or compensate 
for this systemic inflammation. Consequently, the protective effects of adiponectin are 
superseded by the underlying disease [25]. 
  In a cohort of 981 patients with stable ischemic heart disease, with average follow-up of 
7.1 years, an association was found between higher adiponectin and adverse cardiovascular 
events (death, heart failure), but after adjustment for cardiac disease severity, the association 
was no longer statically significant [24]. Another cohort with median follow-up of 2.5 years 
found that higher adiponectin levels were associated with future cardiovascular death or 
nonfatal myocardial infarction in SAP patients (n=1130), but found no association in ACS 
patients (n=760) [22]. Our results, demonstrating an association of adiponectin with death 
in SAP patients, comply with these findings. The lack of statistical significance for this 
association in ACS patients in our study may, in part, have been caused by a limited number 
of clinical events. Moreover, pathophysiological differences may possibly have contributed 
to the difference we found between SAP and ACS. While in SAP patients, atherosclerosis 
appears to be a slowly progressing disorder, in ACS patients, coronary plaque rupture may be 
present, and the latter is accompanied by the production of tissue factor and other homeostatic 
factors that increase the risk of thrombosis [3]. Plasma adiponectin levels have been inversely 
correlated with markers of platelet activation [26,27]. This might have possibly influenced the 
association between adiponectin and clinical outcome in these patients.
  Adipose tissue produces both pro- and anti-inflammatory adipocytokines [10], and 
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adiponectin has shown in vitro and in vivo anti-inflammatory effects [28]. However, little is 
known about the clinical significance of adiponectin for coronary plaque stability in vivo. 
Only a few studies have been performed on this topic, all of which at the University of Kobe, 
Japan. Sample size of these studies was modest. In a randomized trial of 54 patients with type 
2 diabetes and stable angina, treated with pioglitazone, adiponectin was found to be associated 
with a reduction of necrotic core components as assessed by VH-IVUS [29]. A case control 
study of 63 ACS and 43 non-ACS patients showed that serum adiponectin was inversely 
associated with necrotic core evaluated by VH-IVUS in both culprit and non-culprit lesions 
in patients with ACS, but not in those with stable angina [30]. In 50 men with stable CAD, low 
plasma adiponectin was associated with presence of TCFA [31]. Altogether, these studies point 
toward an inverse association of adiponectin with plaque vulnerability. In contrast, in our 
study, we found a positive association of adiponectin with VH-IVUS TCFA in SAP patients. 
This finding is in line with the association of adiponectin with death, as well as the association 
of VH-IVUS TCFA with adverse outcome which we demonstrated earlier [12]. However, 
the exact mechanism behind the positive association between adiponectin and VH-IVUS-
derived TCFA lesions warrants further investigation. With regard to the discrepancy between 
our study and the Japanese ones, differences in study population and sample size could have 
played a part. Ethnic differences in adiponectin levels are of particular interest in this context. 
The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study and 
the Multi-Ethnic Study of Atherosclerosis (MESA) have shown that adiponectin levels are 
lowest in persons from South Asian or Chinese descent compared to other ethnic groups 
[32]. Moreover, polymorphisms in the adiponectin gene have been found to be associated 
with adiponectin levels [33]. Some of these polymorphisms have also shown associations with 
insulin resistance, metabolic syndrome and the onset of CAD [32-34]. Finally, while we found a 
positive association of adiponectin with VH-IVUS TCFA, we could not demonstrate such an 
association with necrotic core fraction. This seeming discrepancy may be explained by the 
fact that these measures reflect somewhat different aspects of atherosclerosis. Size of necrotic 
core fraction alone may not be able to fully capture the properties of rupture-prone plaques; 
the definition of VH-IVUS TCFA on its part incorporates additional plaque properties, such 
as confluence of the necrotic core and direct contact of the necrotic core with the lumen.
  Some limitations of this study need to be acknowledged. The spatial resolution of VH-
IVUS (200mm) is insufficient to exactly replicate histopathological definitions of a thin 
fibrous cap (<65mm) [13]. Therefore, VH-IVUS tends to over-estimate the number of TCFA 
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lesions. Nevertheless, the presence of VH-IVUS-detected TCFA lesions carries prognostic 
information [12] and is therefore clinically relevant. Furthermore, VH-IVUS imaging was 
performed in a prespecified single target segment of a single non-culprit coronary artery [35]. 
This approach was chosen because previous studies have demonstrated that such segments 
reflect larger coronary disease burden and are associated with subsequent cardiac events [12,36]. 
Finally, adiponectin was associated with mortality, but the number of deaths in our dataset 
was small.
  In conclusion, in the full cohort, adiponectin levels were associated with death but 
not with VH-IVUS measures of atherosclerosis. In SAP patients, adiponectin levels were 
associated with VH-IVUS derived TCFA lesions, while the association with death was 
borderline significant. Altogether, a substantial role for adiponectin in plaque vulnerability 
remains unconfirmed and warrants investigation by other, large studies.
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Abstract
Rationale: To investigate relations of several circulating chemokines with extent and 
phenotype of coronary atherosclerosis and with 1-year clinical outcome.
Methods & Results: Intravascular ultrasound virtual histology (IVUS-VH) imaging of a 
coronary artery was performed in 581 patients. Monocyte chemoattractant protein-1 (MCP-
1), macrophage inflammatory protein-1a (MIP-1a), MIP-1b and regulated upon activation 
normal T cell expressed and secreted (RANTES) were measured in plasma. Higher MCP-1, 
MIP-1a and lower RANTES were associated with coronary plaque burden. Higher MCP-1, 
MIP-1a and lower RANTES were associated with the presence of IVUS-VH-derived thin-
cap fibroatheroma lesions. RANTES was associated with major adverse cardiac events.
Conclusions: RANTES is a promising biomarker that is inversely associated with coronary 
plaque burden and vulnerability, as well as with death and acute coronary syndrome.
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Introduction
Inflammation has been recognized as an important contributing factor in all phases of 
atherosclerosis [1-3]. In particular, inflammation is believed to play a crucial role in the 
development and rupture of vulnerable plaques, resulting in major cardiovascular problems 
such as myocardial infarction and stroke [1-3]. Circulating inflammatory biomarkers may 
potentially improve prognostication of patients with atherosclerotic cardiovascular disease [4]. 
Chemokines are involved in the recruitment of various leukocytes, such as monocytes, 
macrophages and T lymphocytes, into the atherosclerotic plaque [5,6]. Monocyte 
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1a (MIP-1a), MIP-
1b and regulated upon activation normal T cell expressed and secreted (RANTES) are typical 
C-C motif chemokines that have been studied extensively [5,6]. Several studies have shown 
that these chemokines have an important role throughout the entire atherosclerotic process 
from atherogenesis to plaque destabilization [5,6]. However, their clinical utility as biomarker 
remains unclear [5,6]. Furthermore, prospective data on associations of these biomarkers 
with in-vivo measurements of extensiveness, phenotype and vulnerability of coronary 
atherosclerosis is currently lacking. This study aims to evaluate the usefulness of MCP-1, 
MIP-1a, MIP-1b and RANTES by investigating their relations with intravascular ultrasound 
virtual histology (IVUS-VH)-derived measures of coronary plaque burden, quantity of 
necrotic core, and presence of thin-cap fibroatheroma (TCFA) lesions, and by investigating 
their prognostic value for major adverse cardiac events.
Methods
Study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study 
has been described in detail elsewhere [7,8]. In brief, 581 patients who underwent diagnostic 
coronary angiography or percutaneous coronary intervention (PCI) for acute coronary 
syndrome (ACS) or stable angina pectoris (SAP) have been included between 2008 and 
2011 in the Erasmus MC, Rotterdam, the Netherlands (Supplementary Figure 1). The 
ATHEROREMO-IVUS study was approved by the medical ethics committee of the Erasmus 
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MC. The study was performed in accordance with the criteria described in the declaration 
of Helsinki. Written informed consent was obtained from all included patients. This study is 
registered in ClinicalTrials.gov, number NCT01789411.
Data collection
Baseline characteristics of all patients were collected prospectively by trained research 
physicians. These physicians reviewed the medical charts of the patients at the time of 
inclusion in the study, and extracted variables regarding demographics, medical history, 
cardiovascular risk factors and procedural characteristics. Medical history and cardiovascular 
risk factors are a routine part of clinical patient assessment at the department of Cardiology. 
Thus, presence of diabetes mellitus, hypertension, hypercholesterolemia, history of renal 
insufficiency and history of heart failure were defined as a clinical diagnosis of these 
conditions as reported by the treating physician in the medical chart. Smoking was defined 
as current smoking, reported by the patient. Procedural characteristics were prospectively 
extracted from the catheterization report.
Biomarkers
Blood samples were drawn from the arterial sheath prior to the diagnostic coronary 
angiography or PCI procedure. The blood samples were transported to the clinical laboratory 
of Erasmus MC for further processing and storage at temperature of -80 oC within 2h after 
blood collection. MCP-1, MIP-1a, MIP-1b and RANTES were measured in the stored 
EDTA-plasma samples (n=570) using a validated multiplex assay (Custom Human Map, 
Myriad RBM, Austin, TX).
Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS data were acquired 
in a non-culprit coronary vessel. Selection of the non-culprit vessel was predefined in the 
study protocol. The order of preference for selection of the non-culprit vessel was: (1) left 
anterior descending (LAD) artery; (2) right coronary artery (RCA); 3. left circumflex (LCX) 
artery. All IVUS data were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., 
San Diego, CA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic 
pullback system was used with a standard pull back speed of 0.5mm per second. The IVUS 
images were analyzed offline by an independent core laboratory (Cardialysis BV, Rotterdam, 
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the Netherlands) that had no knowledge of clinical data. The IVUS gray-scale and IVUS 
radiofrequency analyses, also known as IVUS virtual histology, were performed using pcVH 
2.1 and qVH (Volcano Corp., San Diego, CA) software. The external elastic membrane and 
luminal borders were contoured for each frame (median inter-slice distance, 0.40mm). Extent 
and phenotype of the atherosclerotic plaque were assessed. Plaque burden was defined as 
plaque and media cross-sectional area divided by external elastic membrane cross-sectional 
area and is presented as a percentage. The composition of the atherosclerotic plaque was 
characterized into four different tissue types: fibrous, fibrofatty, dense calcium and necrotic 
core [9]. A coronary lesion was defined as a segment with a plaque burden of more than 40% 
in at least three consecutive frames (Supplementary Figure 2). A TCFA lesion on IVUS-VH 
was defined as a lesion with presence of >10% confluent necrotic core in direct contact with 
the lumen (Figure 1) [10,11]. TCFA lesions with a plaque burden of at least 70% were classified 
as large TCFA lesions.
Figure 1. Thin-cap fibroatheroma lesion on intravascular ultrasound virtual histology. Thin-cap fibroatheroma 
lesion on intravascular ultrasound virtual histology is defined as a lesion with presence of >10% confluent necrotic 
core (red) in direct contact with the lumen. White indicates dense calcium, light green indicates fibrofatty tissue, 
dark green indicates fibrous tissue.
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Study endpoints
In this study, follow-up started at inclusion and lasted up to 1 year. Post-discharge survival 
status was obtained from municipal civil registries. Post-discharge rehospitalizations were 
prospectively assessed during follow-up. Questionnaires focusing on the occurrence of 
major adverse cardiac events (MACE) were sent to all living patients. Treating physicians 
and institutions were contacted for additional information whenever necessary. ACS was 
defined as the clinical diagnosis of ST segment elevation myocardial infarction (STEMI), 
non-STEMI or unstable angina pectoris in accordance with the guidelines of the European 
Society of Cardiology [12-14]. Unplanned coronary revascularization was defined as unplanned 
repeat PCI or coronary artery bypass grafting (CABG). All events were adjudicated as related 
to a coronary site that was treated during the index procedure (culprit lesion related event) 
or as related to the coronary site that was not treated during the index procedure (non-culprit 
lesion related event). Events that were related to both the culprit lesion and a non-culprit site 
(e.g. revascularization of multiple vessels with CABG) were classified into both categories. 
When information was not sufficient to classify an event as either culprit lesion related or 
non-culprit lesion related, the event was classified as indeterminate.
  The primary endpoint was MACE, defined as non-culprit lesion related or indeterminate 
all-cause mortality, ACS or unplanned coronary revascularization. The secondary endpoint 
was defined as the composite of non-culprit lesion related or indeterminate all-cause mortality 
or ACS. Definite culprit lesion related events were excluded from the primary and secondary 
endpoints, because the pathophysiology of culprit lesions related events (e.g. in-stent 
restenosis or in-stent thrombosis) differs from our primary research focus on spontaneous 
plaque rupture leading to unanticipated, spontaneous MACE. The endpoints were adjudicated 
by a clinical event committee that had no knowledge of biomarkers and IVUS data.
Statistical analysis
The distributions of the continuous variables, including biomarker levels and the IVUS 
parameters, were tested for normality by visual examination of the histogram. Normally 
distributed continuous variables are presented as mean±standard deviation (SD), while non-
normally distributed continuous variables are presented as median and interquartile range 
(IQR). MCP-1, MIP-1a, MIP-1b and RANTES concentrations were not normally distributed 
and were therefore ln-tranformed for further analysis. Categorical variables are presented in 
percentages. We examined associations of biomarker concentrations with plaque burden and 
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necrotic core fraction in the imaged coronary segment. Specifically, we calculated means of 
plaque burden and necrotic core fraction according to tertiles of biomarker concentration. 
To test for trends, we used linear regression analyses with continuous ln-transformed 
biomarker concentrations as the independent variable. The final results are presented as b 
(per SD increase in ln-transformed biomarker concentration) with 95% confidence interval 
(95% CI). Furthermore, we have examined the relation between biomarker concentrations 
and the presence of IVUS-VH derived TCFA lesions using logistic regression analyses 
with continuous ln-tranformed biomarker concentration as the independent variable. The 
final results are presented as odds ratio (OR) per SD increase in ln-transformed biomarker 
concentration with 95% CI.
  Patients lost to follow-up were considered at risk until the date of last contact, at 
which time-point they were censored. Cumulative event rates were estimated according 
to the Kaplan–Meier method. Cumulative Kaplan–Meier event curves were compared by 
log-rank test. Cox proportional hazards regression analyses were performed to evaluate 
the relationship between biomarker concentration and clinical endpoints. Biomarkers 
that were significantly associated with occurrence of MACE in univariable analysis were 
further evaluated in multivariable analyses. The variables age, gender, diabetes mellitus, 
hypertension, hypercholesterolemia, smoking, statin use, history of MI and indication for 
coronary angiography were considered as potential confounders and were entered into 
the full model. These covariates were a priori chosen, taking into account the number of 
events available. Subsequently, C-reactive protein (CRP) was also entered into the model 
to evaluate whether the associations between biomarkers and MACE were independent of 
CRP concentration. The final results are presented as hazard ratio (HR) per SD increase in 
ln-transformed biomarker concentration with 95% CI.
  All statistical analyses were primarily performed in the overall study population. 
Heterogeneity in effect estimates between patients with ACS and patients with stable angina 
were examined using the Z-test for heterogeneity. If there was no heterogeneity, conclusions 
were based on the effect estimates belonging to the total study population. If there was 
significant heterogeneity between patients admitted with and without ACS, conclusions were 
based on effect estimates of the separate groups.
  All data were analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY). All 
statistical tests were two-tailed and p values < 0.05 were considered statistically significant.
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Results
Baseline characteristics
Mean age of the patients was 61.5±11.4 years, 75.4% were men and 17.4% had diabetes 
mellitus (Table 1). Coronary angiography or PCI was performed for various indications: 159 
(27.9%) patients had an acute myocardial infarction, 150 (26.3%) patients had unstable angina 
pectoris and 261 (45.8%) patients had stable angina pectoris. Some patients had biomarker 
concentrations beneath the lowest detection limit of the assay, which especially pertains to 
MIP-1a (measurable in 84% of patients). The median length of the imaged coronary segment 
was 44.1 [33.7 – 55.4] mm. On basis of radiofrequency IVUS, a total of 239 (41.9%) patients 
had at least 1 IVUS-VH-derived TCFA, including 69 (12.1%) patients with at least 1 IVUS-
VH-derived TCFA with a plaque burden ≥70%.
Table 1. Baseline characteristics. 
Total ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Patient characteristics
Age, years 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Male gender, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Diabetes mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Positive family history, n (%) 293 (51.4) 140 (45.3) 153 (58.6)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
Previous myocardial infarction, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
C-reactive protein, mg/L 2.1 [0.8–5.3] 2.8 [1.1–7.0] 1.5 [0.6–3.1]
Statin use, n (%) 359 (63.0) 146 (47.2) 213 (81.6)
Procedural characteristics
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
Indication for catheterization
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
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Table 1 continued.
Total ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Procedural characteristics
IVUS segment characteristics
Imaged coronary artery
Left anterior descending, n (%) 204 (35.8) 117 (37.9) 87 (33.3)
Left circumflex, n (%) 190 (33.3) 107 (34.6) 83 (31.8)
Right coronary artery, n (%) 176 (30.9) 85 (27.5) 91 (34.9)
Segment length, mm 44.1 [33.7-55.4] 43.9 [32.9-54.1] 44.8 [34.2-57.2] 
Presence of at least 1 TCFA, n (%) 239 (41.9) 140 (45.3) 99 (37.9) 
Presence of at least 1 TCFA with PB ≥70%, n (%) 69 (12.1) 32 (10.4) 37 (14.2)
Serum biomarker concentrations
MCP-1, pg/mla 91 [70–122] 92 [70–133] 88 [71–111]
MIP-1a, pg/mlb 16.0 [12.0–21.9] 15.0 [12.0–21.9] 17.0 [12.0–21.9]
MIP-1b, pg/mla 123 [92–165] 130 [95–179] 114 [89–146]
RANTES, ng/mlc 11.0 [6.4–19.0] 14.0 [7.6–23.0] 9.1 [5.0–14.3]
ACS=acute coronary syndrome; CABG=coronary artery bypass grafting; IVUS=intravascular ultrasound; MCP-1, monocyte 
chemoattractant protein-1; MIP-1a, macrophage inflammatory protein-1a; MIP-1b, macrophage inflammatory protein-1b; 
MLA=minimal luminal area; PB=plaque burden; PCI=percutaneous coronary intervention; RANTES, Regulated upon Activation 
Normal T cell Expressed and Secreted; SAP=stable angina pectoris; TCFA=thin-cap fibroatheroma. Values are mean ± SD, median 
[interquartile range] or n (%). aMeasurable in >99% of patients; below limit of detection in <1% of patients. bMeasurable in 84% of 
patients; below limit of detection in 16% of patients. cMeasurable in all patients. 
  
Associations with coronary atherosclerosis
In patients who were admitted with stable angina pectoris, higher plasma MCP-1 
concentrations were associated with higher coronary plaque burden (per SD increase of ln-
transformed MCP-1: β=2.56, 95% CI 0.91 - 4.21, p=0.002) and a higher fraction of plaque 
consisting of necrotic core (per SD increase of ln-transformed MCP-1: β=1.14, 95% CI 0.02 
- 2.25, p=0.045) (Table 2). Higher MCP-1 concentrations also seemed to be associated with 
the presence of IVUS-VH derived TCFA lesions (OR per SD increase in ln-transformed 
MCP-1 1.90, 95% CI 1.00 - 3.61, p=0.052) in patients who were admitted with stable angina 
pectoris (Table 3).
  Higher MIP-1a concentrations were associated with higher plaque burden (per SD 
increase of ln-transformed MIP-1a: β=1.66, 95% CI 0.72 - 2.61, p=0.001), higher necrotic 
core fraction (per SD increase of ln-transformed MIP-1a: β=0.89, 95% CI 0.23 - 1.55, 
p=0.008) and with the presence of IVUS-VH derived TCFA lesions with plaque burden 
≥70% (OR per SD increase in ln-transformed MIP-1a 1.75, 95% CI 1.09 - 2.81, p=0.021) in 
the total study population.
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In patients who were admitted with ACS, lower RANTES concentrations were associated 
with higher plaque burden (per SD increase of ln-transformed RANTES: β=1.57, 95% CI 
-2.94 - -0.20, p=0.025) (Figure 2). Furthermore, lower RANTES concentrations also seemed 
to be associated with the presence of IVUS-VH derived TCFA lesions with plaque burden 
≥70% in the overall patient population (OR per SD increase in ln-transformed RANTES 
0.76, 95% CI 0.57 - 1.02, p=0.067).
Major adverse cardiac events
Vital status was acquired for 569 (99.8%) patients. Response rate of the questionnaires that 
were sent to all living patients was 92.3%. After 1 year of follow-up, 56 patients had at least one 
event (Supplementary Table 1). A total of 11 patients had a definite culprit lesion related event, 
while 27 patients had a definite non-culprit lesion related event. Another 18 patients had an event 
that could not be judged to be either culprit lesion related or non-culprit lesion related and were 
therefore classified as having an indeterminate event. The cumulative Kaplan–Meier incidences 
of the 30-d, 6-month and 1-year composite of non-culprit lesion related or indeterminate death, 
ACS or unplanned coronary revascularization were 0.7%, 4.7%, and 7.9%, respectively. The 
cumulative Kaplan–Meier incidences of the 30-d, 6-month and 1-year composite of non-culprit 
lesion related or indeterminate death or ACS were 0.7%, 3.2%, and 4.9%, respectively. 
Table 3. Associations with presence of intravascular ultrasound virtual histology-derived thin-cap 
fibroatheroma lesions. 
Total study 
population (n = 570)
ACS patients 
(n = 309)
SAP patients 
(n = 261)
P-value for 
heterogeneity
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Presence of at least 1 thin-cap fibroatheroma
MCP-1 1.03 (0.74–1.45) 0.85 0.77 (0.51–1.17) 0.22 1.90 (1.00–3.61) 0.052 0.022
MIP-1α 0.87 (0.63–1.21) 0.42 0.94 (0.61–1.42) 0.75 0.83 (0.49–1.39) 0.47 0.72
MIP-1β 1.16 (0.85–1.60) 0.36 1.18 (0.79–1.76) 0.42 0.97 (0.55–1.70) 0.91 0.69
RANTES 0.97 (0.80–1.18) 0.75 0.87 (0.66–1.15) 0.33 0.98 (0.72–1.33) 0.90 0.57
Presence of at least 1 thin-cap fibroatheroma with plaque burden ≥70%
MCP-1 1.23 (0.75–2.04) 0.41 0.94 (0.48–1.83) 0.86 2.16 (0.95–4.93) 0.067 0.12
MIP-1α 1.75 (1.09–2.81) 0.021 2.15 (1.13–4.09) 0.020 1.29 (0.63–2.66) 0.49 0.30
MIP-1β 0.89 (0.54–1.47) 0.66 0.91 (0.47–1.78) 0.79 1.01 (0.46–2.20) 0.98 0.85
RANTES 0.76 (0.57–1.02) 0.067 0.73 (0.47–1.15) 0.17 0.84 (0.55–1.28) 0.41 0.67
ACS=acute coronary syndrome; MCP-1=monocyte chemoattractant protein-1; MIP-1a=macrophage inflammatory protein-1a; MIP-
1b=macrophage inflammatory protein-1b; RANTES=Regulated upon Activation Normal T cell Expressed and Secreted; SAP=stable 
angina pectoris. Odds ratios are per standard deviation increase in ln-transformed biomarker concentration.
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Figure 2. Associations of circulating RANTES concentrations with coronary atherosclerosis and clinical 
outcome.
ACS=acute coronary syndrome; PB=plaque burden; RANTES=Regulated upon Activation Normal T cell Expressed and Secreted; 
TCFA=thin-cap fibroatheroma. (A) Association with intravascular ultrasound-derived measures of coronary plaque burden in 
patients admitted with acute coronary syndrome. (B) Association with presence of TCFA with plaque burden ≥70% as assessed 
by intravascular ultrasound virtual histolgy. (C) Association with occurrence of non-culprit lesion related and indeterminate death, 
acute coronary syndrome or coronary revascularization. The lowest RANTES tertile was associated with the highest event rate 
(lowest tertile versus middle tertile p=0.006; lowest tertile versus highest tertile p=0.042; middle tertile versus highest tertile p=0.50; 
logrank p for trend=0.026). (D) Association with occurrence of non-culprit lesion related and indeterminate death or acute coronary 
syndrome. The lowest RANTES tertile was associated with the highest event rate (lowest tertile versus middle tertile p=0.004; lowest 
tertile versus highest tertile p=0.039; middle tertile versus highest tertile p=0.86; logrank p for trend=0.019). 
Associations with non-culprit lesion related and indeterminate events
In univariable analysis, RANTES (HR per SD increase of ln-transformed RANTES 0.67, 
95% CI 0.50 - 0.89, p=0.005) was associated with occurrence of the primary endpoint of non-
culprit lesion related and indeterminate MACE during follow-up (Table 4, Figure 2). There 
was no heterogeneity in the HR estimate between ACS patients and patients with stable angina 
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(heterogeneity p=0.39). RANTES (HR per SD increase of ln-transformed RANTES 0.64, 
95% CI 0.45 - 0.91, p=0.013) was also significantly associated with the composite of non-
culprit lesion related and indeterminate death or ACS only. After adjustment for conventional 
cardiovascular risk factors in multivariable analysis, RANTES remained independently 
predictive for non-culprit lesion related and indeterminate MACE (HR per SD increase of ln-
transformed RANTES 0.69, 95% CI 0.52 - 0.93, p=0.016) and for non-culprit lesion related 
and indeterminate death or ACS only (HR per SD increase of ln-transformed RANTES 0.60, 
95% CI 0.41 - 0.88, p=0.010) (Table 5). RANTES also remained independently associated 
with MACE (HR per SD increase of ln-transformed RANTES 0.69, 95% CI 0.51 - 0.93, 
p=0.014) and the composite of death or ACS only (HR per SD increase of ln-transformed 
RANTES 0.59, 95% CI 0.40 - 0.88, p=0.010) after additional adjustment for baseline CRP 
levels. Subgroup analysis showed that the inverse association between RANTES level and 
MACE was present in all patient subgroups (Figure 3). There was no significant heterogeneity 
in the HR estimate between the evaluated patient subgroups.
Table 4. Associations with non-culprit lesion related and indeterminate major adverse cardiac events.
Total study 
population (n = 570)
ACS patients 
(n = 309)
SAP patients 
(n = 261)
P-value for 
heterogeneity
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Major adverse cardiac events (primary endpoint)
MCP-1 0.87 (0.64–1.18) 0.37 0.81 (0.55–1.20) 0.29 1.00 (0.61–1.65) 1.00 0.51
MIP-1α 1.13 (0.85–1.49) 0.40 1.16 (0.82–1.66) 0.40 1.06 (0.69–1.64) 0.80 0.74
MIP-1β 1.00 (0.74–1.34) 0.99 1.15 (0.82–1.62) 0.42 0.82 (0.50–1.34) 0.42 0.26
RANTES 0.67 (0.50–0.89) 0.005 0.77 (0.50–1.18) 0.23 0.59 (0.40–0.88) 0.009 0.39
Composite of death or acute coronary syndrome (secondary endpoint)
MCP-1 0.73 (0.48–1.09) 0.12 0.74 (0.47–1.16) 0.19 0.69 (0.31–1.53) 0.36 0.88
MIP-1α 1.11 (0.77–1.58) 0.58 1.12 (0.73–1.70) 0.61 1.11 (0.59–2.09) 0.74 0.99
MIP-1β 1.11 (0.78–1.57) 0.57 1.34 (0.98–1.84) 0.071 0.48 (0.24–0.98) 0.043 0.010
RANTES 0.64 (0.45–0.91) 0.013 0.58 (0.36–0.94) 0.028 0.62 (0.35–1.10) 0.10 0.86
ACS=acute coronary syndrome; MCP-1=monocyte chemoattractant protein-1; MIP-1a=macrophage inflammatory protein-1a; MIP-
1b=macrophage inflammatory protein-1b; RANTES=Regulated upon Activation Normal T cell Expressed and Secreted; SAP=stable 
angina pectoris. Hazard ratios are per standard deviation increase in ln-transformed biomarker concentration.
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Figure 3. Association between RANTES level and major adverse cardiac events stratified by patient subgroups. 
ACS=acute coronary syndrome; CAD=coronary artery disease; HR=hazard ratio; MI=myocardial infarction; RANTES=Regulated 
upon Activation Normal T cell Expressed and Secreted. Hazard ratios (95% confidence intervals) are per standard deviation increase 
in ln-transformed RANTES concentration. Red dotted line indicates the hazard ratio estimate in the total study population. 
Discussion
This study investigated the relations of circulating chemokine concentrations with 
extensiveness of coronary atherosclerosis, amount of necrotic core, the presence of IVUS-VH 
derived TCFA lesions and occurrence of future MACE in patients who underwent coronary 
angiography for ACS or stable angina pectoris. To our best knowledge, this is the first study 
that correlates circulating chemokines with in-vivo measurements of coronary atherosclerosis 
using IVUS-VH. Higher plasma MCP-1, MIP-1a, and lower RANTES concentrations were 
all associated with higher coronary plaque burden and more advanced plaque phenotypes as 
determined by IVUS-VH (Figure 4). However, only RANTES was found to be independently 
predictive for the occurrence of MACE, particularly of death and ACS.
- 101 -
5
PART I
 Figure 4. Circulating chemokine concentrations as biomarkers for phenotype of coronary atherosclerosis and 
risk of plaque rupture.
MCP-1=monocyte chemoattractant protein-1; MIP-1a=macrophage inflammatory protein-1a; RANTES=Regulated upon Activation 
Normal T cell Expressed and Secreted; TCFA=thin-cap fibroatheroma. Hypothesized model based on findings in this study. Plasma 
MCP-1, MIP-1a and RANTES concentrations were all associated with coronary plaque burden and different plaque phenotypes. 
RANTES was associated with major adverse cardiac events that were most probably caused by plaque rupture. *Only for patients 
with stable angina pectoris. ↑ indicates higher biomarker concentrations. ↓ indicates lower biomarker concentrations.
 
Chemokines are small cytokines that have the ability to induce directed chemotaxis of nearby 
leukocytes. MCP-1, MIP-1a, MIP-1b and RANTES belong to the C-C motif chemokine 
ligand (CCL) family and are also known as CCL2, CCL3, CCL4 and CCL5, respectively [5,6]. 
Pathologic studies have shown that these chemokines are highly expressed in atherosclerotic 
plaques [15-17]. Animal studies have shown that these chemokines are actively involved in 
atherogenesis and plaque destabilization [5,6]. Furthermore, several epidemiological studies 
have indicated that serum or plasma levels of MCP-1, MIP-1a, MIP-1b and RANTES may 
predict future cardiac events [5]. However, their clinical utility as biomarker for cardiovascular 
risk stratification remains unclear [5,6]. We sought to further elucidate the correlations 
of circulating chemokine concentrations with in-vivo measurements of extensiveness, 
phenotype and vulnerability of coronary atherosclerosis by using IVUS-VH. 
  Grayscale IVUS allows for in-vivo measurements of coronary plaque burden. 
Additionally, radiofrequency IVUS allows for differentiation of the composition of 
the atherosclerotic plaque and is therefore also known as IVUS-VH [10]. Necrotic core is 
often found in the more advanced and rupture-prone plaques [18]. The Providing Regional 
Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study has 
demonstrated that TCFA lesions as determined by IVUS-VH are associated with MACE [19]. 
The strong and independent associations (adjusted HR’s ranging from 1.79 to 3.35) of IVUS-
VH-derived TCFA with MACE emphasize its biological importance [18-20]. However, there 
are several reasons why IVUS is currently not suitable for use as diagnostic and prognostic 
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tool in the overall population of patients with coronary artery disease [19]. Its invasiveness is 
probably the most important limitation in this respect. Therefore, circulating biomarkers may 
have an important role in cardiovascular risk assessment.
  In our study, lower plasma RANTES concentrations were independently associated 
with adverse outcomes during 1 year of follow-up. The association was independent of 
CRP. Its association with acute cardiac events (death or ACS; HR 0.59) seemed to be even 
stronger than with all MACE (death, ACS or unplanned coronary revascularization; HR 
0.69). This may indicate that RANTES is especially predictive for plaque rupture rather than 
plaque growth. Our finding that low serum RANTES concentrations, rather than high, are 
associated with adverse coronary events may seem counterintuitive, since animal studies 
have shown that RANTES and its receptor are actively involved in atherogenesis and that 
RANTES was found to be highly expressed within atheromatous lesions [6,21]. However, the 
inverse associations of RANTES may be explained by increased deposition of RANTES on 
the vascular endothelium, resulting in lower free-circulating serum concentrations [22,23]. The 
inverse associations of RANTES are also consistent with observations from previous studies. 
A large case–control study reported that serum RANTES levels were lower in coronary heart 
disease patients compared with age- and gender-matched controls [23]. Another study reported 
that low plasma RANTES levels were independently associated with cardiac mortality in 389 
male patients who underwent coronary angiography [22]. Such an association was not found 
in a population-based case-cohort study that included 363 individuals with incident coronary 
events and 1908 non-cases [24].
  We found that higher plasma MCP-1 concentrations were associated with higher 
coronary plaque burden in patients who were admitted with stable angina pectoris. These 
findings are in line with a previous study that measured MCP-1 concentrations in blood from 
the coronary sinus and found that these levels were associated with the extent of coronary 
atherosclerosis as assessed on the coronary angiogram [25]. Although we observed that high 
MCP-1 concentrations were associated with a more advanced plaque phenotype (i.e. higher 
necrotic core fraction) and with the presence of IVUS-VH derived TCFA lesions, MCP-1 
was not predictive for future events. Previous epidemiological studies have shown that the 
ability of MCP-1 to predict subclinical coronary artery disease is somewhat disappointing, 
but that MCP-1 may have some value in predicting cardiovascular events in patients with 
overt coronary artery disease [5]. For example, a previous study found that MCP-1 was 
independently associated with the composite of death or myocardial infarction in a large 
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cohort of 4244 patients with ACS [26]. This study also demonstrated that high MCP-1 values 
at 4 months after the initial ACS were still predictive for long-term mortality afterwards. 
A major difference with our study is that both culprit lesion related and non-culprit lesion 
related events were included in their study endpoints, while definite culprit lesion related 
events were excluded from our study endpoints. Furthermore, we may have lacked statistical 
power to detect the previously reported association.
  MIP-1a has been studied less extensively. We found that MIP-1a was associated with 
coronary plaque burden, necrotic core fraction and with the presence of large TCFA lesions 
on IVUS-VH. However, we did not observe a correlation between MIP-1a concentration 
and occurrence of MACE. Another study, however, found that MIP-1a was predictive for 
recurrent ACS in a relatively small cohort of 54 patients with unstable angina pectoris [27]. 
Further research is required to elucidate the role of MIP-1a in patients with coronary artery 
disease.
Conclusions
Higher circulating MCP-1, MIP-1a, and lower RANTES concentrations were associated 
with a higher extent, a more advanced phenotype and a higher vulnerability of coronary 
atherosclerosis. Such associations were not present for MIP-1b. In addition, RANTES 
was independently associated with occurrence of MACE, particularly of death and ACS. 
Its prognostic value was similar in patients with and without ACS. Its inverse associations 
are consistent with observations from previous studies and may be explained by increased 
deposition of RANTES on the endothelium, resulting in lower free-circulating concentrations. 
The findings in this study demonstrate that RANTES may be a useful biomarker for 
assessment of cardiovascular risk. Further research on the incremental prognostic value of 
RANTES over established clinical covariates in large, prospective studies is warranted.
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Supplementary files
Supplementary Table 1. Patients with major adverse cardiac events.
Culprit 
lesion 
related 
events, n
Non-culprit 
lesion 
related 
events, n
Indeterminate 
events, n
Non-culprit 
lesion 
related and 
indeterminate 
events 
combined, n
All 
events, 
n
Composite of major adverse cardiac events 11 27 18 45 56
Death from any cause, n 1 1 16 17 18
Definite cardiac or unexplained sudden death, n 1 1 6 7 8
Acute coronary syndrome, n 3 9 2 11 14
Myocardial infarction, n 2 3 2 5 7
Elective coronary revascularization, n 7 17 0 17 24
Composite of death or acute coronary syndrome, n 4 10 18 28 32
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Supplementary Figure 1. Patient inclusion.  
IBIS-2=Integrated Biomarker and Imaging Study-2; IVUS=intravascular ultrasound; NIRS=near-infrared spectroscopy.
Patients were included in the current study analyses when the following criteria were met: 1. not participating in the IBIS-2 trial; 2. 
IVUS of a non-culprit coronary artery was performed; and 3. plasma samples were available for biomarker measurements. In patients 
who were additionally included at Erasmus MC (n=768), IVUS of a non-culprit coronary artery was performed in 581 patients (red 
shaded). In these patients, blood samples were available in 570 patients.
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Supplementary Figure 2. Methodology for detection of lesion and reference segments.
MLA=minimal luminal area; REF=reference segments; ROI=region of interest.
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Abstract
Rationale: We investigated whether concentrations of TNF-α, TNF-β, TNF-receptor 2, 
interferon-γ, IL-6, IL-8, IL-10 and IL-18 are associated with extent and composition of 
coronary atherosclerosis determined by grayscale and virtual histology (VH)- intravascular 
ultrasound (IVUS).
Methods & Results: Between 2008 and 2011, IVUS(-VH) imaging of a non-culprit coronary 
artery was performed in 581 patients (stable angina pectoris (SAP), n=261; acute coronary 
syndrome (ACS), n=309) undergoing coronary angiography from the ATHEROREMO-IVUS 
study. Plaque burden, presence of VH-IVUS-derived thin-cap fibroatheroma (TCFA) lesions, 
and presence of VH-TCFA lesions with plaque burden ≥70% were assessed. Blood samples 
for cytokine measurement were drawn from the arterial sheath prior to the angiography 
procedure. We applied linear and logistic regression. TNF-α levels were positively associated 
with plaque burden (beta (β) (95% CI): 4.45 (0.99 - 7.91), for highest vs lowest TNF-α 
tertile) and presence of VH-TCFA lesions (odds ratio (OR) (95% CI) 2.30 (1.17 - 4.52), 
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highest vs lowest TNF-α tertile) in SAP patients. Overall, an inverse association was found 
between IL-10 concentration and plaque burden (β (95% CI): -1.52 (-2.49 - -0.55), per ln (pg/
mL) IL-10) as well as IL-10 and VH-TCFA lesions with plaque burden ≥70% (OR: 0.31 (0.12 
- 0.80),  highest vs lowest IL-10 tertile). These effects did not reach statistical significance in 
the separate SAP and ACS groups.
Conclusions: Higher circulating TNF-α was associated with higher plaque burden and VH-
TCFA lesions in SAP patients. Lower circulating IL-10 was associated with higher plaque 
burden and large VH-TCFA lesions. These in-vivo findings suggest a role for these cytokines 
in extent and vulnerability of atherosclerosis.
Introduction 
Inflammation is known to play a major role in atherosclerosis [1-3]. The development of 
atherosclerosis includes, among others, expression of adhesion molecules by inflamed 
endothelium, migration of leukocytes into the intima, uptake of modified lipoprotein 
particles, and formation of lipid-laden macrophages [4]. During the evolution of atherosclerotic 
lesions, T-lymphocytes join the macrophages in the intima [4]. This T-cell infiltrate produces 
proinflammatory cytokines (including tumor necrosis factors (TNFs), interferons (IFNs), and 
interleukins (ILs), but may also stimulate a T helper cell type 2 (Th2) response which can 
promote anti-inflammatory actions (and cytokines such as IL-10 and transforming growth 
factor β) [2,5]. This dual role of cytokines is believed to control the subsequent development 
and destabilization of atherosclerotic plaques in coronary (among other) arteries [6], potentially 
leading to plaque rupture or erosion and ultimately resulting in adverse clinical events such as 
myocardial infarction or sudden cardiac death [7].
  While previous research has provided ample insights into the signaling cascades of 
cytokines and their roles in the pathogenesis of atherosclerosis, studies on the associations 
of cytokines with in-vivo determined extent and particularly composition of coronary 
atherosclerosis are currently scarce. Cytokines are located both inside the affected vessel 
walls and in the circulation [8]. We hypothesize that circulating cytokines are associated with 
in-vivo measures of plaque burden and features of plaque vulnerability, and consequently 
may be useful for clinical risk stratification with regard to cardiovascular outcome.
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The aim of this study is to examine the associations of the cytokines TNF-α, TNF-β, 
interferon-γ (IFN-γ), IL-6, IL-8, IL-10 and IL-18 and of circulating TNF receptor 2 (TNF 
R2) with the extent and composition of coronary atherosclerosis as determined in-vivo by 
intravascular ultrasound (IVUS) and IVUS-virtual histology (IVUS-VH), in a non-culprit 
vessel in patients undergoing coronary angiography.
Methods
Study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMO-IVUS) study 
has been described elsewhere [9]. In brief, 581 patients who underwent diagnostic coronary 
angiography or percutaneous coronary intervention (PCI) for acute coronary syndrome(ACS; 
n=309) or stable angina pectoris (SAP; n=261) have been included from November 2008 
to January 2011 in the Erasmus MC, Rotterdam, the Netherlands. Intravascular ultrasound 
(IVUS) of a non-culprit coronary artery was performed subsequent to angiography. The 
ATHEROREMO-IVUS study has been approved by the human research ethics committee of 
Erasmus MC, Rotterdam, The Netherlands. Written informed consent was obtained from all 
included patients and the study protocol conforms to the ethical guidelines of the Declaration 
of Helsinki.
Biomarkers
Blood samples were drawn from the arterial sheath prior to the diagnostic coronary 
angiography or PCI procedure, and were available in 570 patients for the current study. 
The blood samples were transported to the clinical laboratory of Erasmus MC for further 
processing and storage at a temperature of -80 oC within 2h after blood collection. 
  C-reactive protein (CRP) was measured in serum samples using an immunoturbidimetric 
high sensitivity assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the Cobas 8000 
modular analyzer platform (Roche Diagnostics Ltd., Rotkreuz, Switzerland). These analyses 
were performed in the clinical laboratory of Erasmus MC. 
  Frozen EDTA-plasma samples were transported under controlled conditions (at 
a temperature of -80 oC) to Myriad RBM, Austin, Texas, USA, where the concentrations 
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of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 were determined using a 
validated multiplex assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). While 
TNF-α, TNF R2, IL-6, and IL-8 were determined in the full cohort of 570 patients, TNF-β, 
IFN-γ, IL-10 and IL-18 were determined in a random subset of 473 patients. This difference 
in numbers resulted from batch-wise handling of the samples in combination with an update 
of the composition of the multiplex assay by the manufacturer in-between two batches. None 
of the biomarker laboratories had knowledge of clinical or intracoronary imaging data.
Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS data were acquired 
in a non-culprit, non-treated, coronary vessel, without significant luminal narrowing. The 
order of preference for selection of the non-culprit vessel was: 1. Left anterior descending 
(LAD) artery; 2. Right coronary artery (RCA); 3. Left circumflex (LCX) artery. All IVUS 
data were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA, 
USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic pullback 
system was used with a standard pull back speed of 0.5mm per second. The IVUS images 
were analyzed offline by an independent core laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) that had no knowledge of clinical or biomarker data. The IVUS gray-scale 
and IVUS radiofrequency analyses, also known as IVUS virtual histology (IVUS-VH), 
were performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. 
The external elastic membrane and luminal borders were contoured for each frame (median 
interslice distance, 0.40mm). Extent and phenotype of the atherosclerotic plaque were 
assessed.
  Plaque burden was defined as the plaque and media cross-sectional area divided by the 
external elastic membrane cross-sectional area and is presented as a percentage. A coronary 
lesion was defined as a segment with a plaque burden of 40% in at least three consecutive 
frames [9]. Using IVUS-VH, the composition of the atherosclerotic plaque was characterized 
into 4 different types: fibrous, fibro-fatty, dense calcium and necrotic core [10]. A VH-IVUS-
derived thin-cap fibroatheroma (TCFA) lesion was defined as a lesion with presence of >10% 
confluent necrotic core in direct contact with the lumen [11].
Statistical analysis
Categorical variables are presented in percentages. The distributions of continuous variables, 
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including biomarker levels and IVUS parameters, were examined for normality by visual 
inspection of the histogram and calculation of the skewness coefficient. Normally distributed 
continuous variables are presented as mean±standard deviation (SD), while non-normally 
distributed continuous variables are presented as median and interquartile range [IQR]. For 
reasons of uniformity, all biomarkers are presented as median [IQR].
  In further analyses, biomarker concentrations were examined both as continuous and 
as categorical variables (the latter by dividing the variables into tertiles). Biomarkers with 
a non-normal distribution were ln-transformed. Biomarkers in which the concentrations 
were too low to detect in more than 20% of the patients, were not examined as continuous 
variables. They were examined as tertiles, or else as dichotomous variables (measurable vs 
not measurable).
  To take into account possible effect modification by indication for coronary angiography, 
we performed all analyses separately in patients with SAP and patients with ACS. We also 
present the results for the full cohort, in order to evaluate the effect of higher statistical power 
in those cases where associations were present in both groups of patients.
  First, we examined associations of biomarker concentrations with the extent of 
atherosclerosis according to IVUS. We applied linear regression analyses with biomarker 
concentrations as the independent variable (ln-transformed or categorized when appropriate) 
and segmental plaque burden in the imaged coronary segment as the dependent variable. 
The results are presented as β’s (per unit increase in ln-transformed biomarker concentration 
or per category of biomarker concentration) with 95% confidence intervals (95% CI). 
Subsequently, we examined the associations between biomarker concentrations and 
composition of atherosclerosis, specifically the presence of VH-TCFA lesions as well as VH-
TCFA lesions with plaque burden ≥70%. We used logistic regression analyses with biomarker 
concentrations as the independent variable (ln-transformed or categorized when appropriate). 
The results are presented as odds ratios (ORs) per unit increase in ln-transformed biomarker 
concentration or per category of biomarker concentration, with 95% CI’s.
  First, all above-described analyses were performed univariably. Subsequently, we 
adjusted for age, gender, indication for coronary angiography, diabetes, hypertension and 
CRP. All data were analyzed with SPSS software (IBM SPSS Statistics for Windows, Version 
21.0. Armonk, NY, USA). All statistical tests were two-tailed and p-values <0.05 were 
considered statistically significant.
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Results
Baseline characteristics
Baseline characteristics are summarized in Table 1. Mean age was 61.5±11.4 years and 75.4% 
were men. Coronary angiography or PCI was performed for several indications: 159 (27.9%) 
patients had an acute myocardial infarction, 150 (26.3%) patients had unstable angina pectoris 
and 261 (45.8%) had SAP. The median length of the imaged coronary segment was 44.1 
[33.7 - 55.4] mm. Based on IVUS-VH, a total of 239 (41.9%) patients had at least 1 TCFA 
lesion, including 69 (12.1%) patients with at least 1 TCFA lesion with a plaque burden ≥70%. 
Concentrations of IFN-γ, TNF R2, IL-8, IL-10 and IL-18 were not normally distributed; 
these biomarkers were therefore ln-transformed for further analyses. TNF-α, TNF-β and IL-
6 were too low to detect in a large part of the patients, and thus were not examined as 
continuous variables in the statistical models. TNF-α was too low to detect in 24%, and 
hence was categorized into tertiles for further analyses. TNF-β and IL-6 were too low to 
detect in 92% and 62% of the patients, respectively, and these markers were dichotomized 
into measurable versus not measurable for further analyses. IL-10 concentrations could be 
measured in 99%. TNF R2, IL-8, IL-18 and IFN-γ were measurable in all patients.  
Table 1. Baseline characteristics.  
Total ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Patient characteristics
Age, years 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Male gender, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Diabetes mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Positive family history, n (%) 293 (51.4) 140 (45.3) 153 (58.6)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
Previous myocardial infarction, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
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Table 1 continued.
Total ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Procedural characteristics
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
Indication for coronary angiography
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease
No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
IVUS segment characteristics
Segment length, mm 44.1 [33.7-55.4] 43.9 [32.9-54.1] 44.8 [34.2-57.2] 
Plaque burden, % 39.2 [30.0-46.4] 37.2 [28.0-45.5] 40.2 [31.8-47.8]
Presence of VH-TCFA, n (%) 239 (41.9) 140 (45.3) 99 (37.9) 
Presence of VH-TCFA with PB ≥70%, n (%) 69 (12.1) 32 (10.4) 37 (14.2)
Serum biomarker concentrations
C-reactive protein, mg/L 2.1 [0.8-5.3] 2.8 [1.1-7.0] 1.5 [0.6-3.1]
Tumor necrosis factor-α, pg/mLa 2.0 [1.4-2.9] 1.8 [1.4-2.6] 2.0 [1.4-3.3]
Tumor necrosis factor-β, pg/mLb,c 35.0 [18.0-116.0] 20.5 [16.5-44.3] 36.5 [27.0-152.8]
Tumor necrosis factor receptor 2, ng/mLd 4.5 [3.6-5.7] 4.4 [3.5-5.8] 4.5 [3.7-5.6]
Interferon-γ, pg/mLc.e 5.1 [3.9-7.3] 4.8 [3.8-6.6] 5.7 [4.2-8.2]
Interleukin-6, pg/mLf 3.5 [2.2-5.8] 3.7 [2.5-6.8] 2.5 [2.1-4.1]
Interleukin-8, pg/mLc,d 8.9 [6.8-12.0] 9.9 [7.1-12.6] 8.3 [6.5-10.3]
Interleukin-10, pg/mLc,d 5.2 [3.6-9.4] 6.9 [4.1-15.0] 4.4 [3.0-6.0]
Interleukin-18, pg/mLe 171.0 [132.3-215.0] 173.0 [133.0-216.3] 169.5 [130.5-211.3]
ACS=acute coronary syndrome; CABG=coronary artery bypass grafting; IVUS=intravascular ultrasound; PB=plaque burden; 
PCI=percutaneous coronary intervention; RANTES, Regulated upon Activation Normal T cell Expressed and Secreted; SAP=stable 
angina pectoris; VH-TCFA=virtual-histology thin-cap fibroatheroma. aMeasurable in 76% of patients, too low to detect in 24%. 
bMeasurable in 8% of patients, too low to detect in 92%. cTNFβ, IFN-γ, IL-10 and IL 18: total n=473, ACS n=309, SAP n=261. 
dMeasurable in >99% of patients, too low to detect in <1%. eMeasurable in all patients. fMeasurable in 38% of patients, too low to 
detect in 62%.  
Biomarkers and extent of atherosclerosis
The results of the analyses for plaque burden of the entire measured segment are shown in 
Figure 1 and Supplementary Table 1A, 1B and 1C. Higher TNF-α was associated with higher 
coronary plaque burden in patients with SAP (β (95% CI): 4.45 (0.99 - 7.91), for the highest vs 
the lowest tertile of TNF-α). Such an effect could not be demonstrated in patients with ACS.
  Furthermore, lower IL-10 concentrations were associated with higher coronary plaque 
burden in the full cohort (β (95% CI): -3.88 (-6.00 - -1.76), for the highest vs the lowest tertile 
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of IL-10). This effect was driven by both the SAP patients and the ACS patients. Although 
effect estimates for the highest tertile of IL-10 were similar in both groups SAP: -2.95 (-6.23 - 
0.33), ACS: -3.42 (-6.57 - -0.27), in the SAP patients the estimates, as well as the linear trend, 
did not reach statistical significance.
  After multivariable adjustment, associations remained essentially the same for both 
TNF-α and IL-10.
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Figure 1. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with segment plaque 
burden in all patients, patients with stable AP and patients with ACS. 
Biomarkers and composition of atherosclerosis
The results of the analyses for VH-TCFA lesions are displayed in Figure 2 and Supplementary 
Table 2A, 2B and 2C. High TNF-α was positively associated with presence of VH-TCFA lesions 
in patients with SAP (OR (95% CI): 2.30 (1.17 - 4.52) for the highest vs the lowest tertile of 
TNF-α). Such an effect was absent in patients with ACS. Furthermore, higher IL-8 seemed 
to confer lower risk of VH-TCFA in ACS patients; however, this effect was mainly driven by 
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tertile 2. No associations were present between any of the other biomarkers and VH-TCFA.
  Higher TNF-α was positively associated with presence of VH-TCFA lesions with a 
plaque burden ≥70% in the full cohort (OR (95% CI): 2.85 (1.28 - 6.31) for the highest 
vs the lowest tertile of TNF-α) (Figure 3). This effect was driven by both patients with 
SAP and patients with ACS. Although the effect estimate reached statistical significance in 
the full cohort, this was not the case in the SAP and ACS groups. Nevertheless, the effect 
estimates for the highest tertile of TNF-α were similar in magnitude in both groups (SAP: 
3.44 (0.89 - 13.29), ACS: 2.39 (0.89 - 6.45)). Higher IL-10 displayed an inverse association 
with presence of VH-TCFA lesions with a plaque burden ≥70% in the full cohort (OR (95% 
CI): 0.31 (0.12 - 0.80) for the highest vs the lowest tertile of IL-10, p for trend=0.037). Again, 
effect estimates did not reach statistical significance in these separate groups.
  After multivariable adjustment, associations remained essentially the same. 
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Figure 2. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with presence of VH-
TCFA in all patients, patients with stable AP and patients with ACS.
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Figure 3. Association of TNF-a, TNF-b, TNF R2, INFg, IL-6, IL-8, IL-10 and IL-18 with presence of VH-
TCFA with plaque burden ≥70% in all patients, patients with stable AP and patients with ACS. 
Discussion
This study examined whether circulating cytokine concentrations are associated with extent 
and composition of coronary atherosclerosis, as determined by IVUS and IVUS-VH in a non-
culprit vessel, in patients with SAP or ACS undergoing coronary angiography. In patients 
with SAP, higher concentrations of TNF-α were associated with higher coronary plaque 
burden and with presence of VH-TCFA lesions, and displayed a tendency towards a positive 
association with presence of VH-TCFA lesion with a plaque burden ≥70%. Overall, higher 
concentrations of IL-10 were inversely associated with coronary plaque burden and with 
presence of VH-TCFA with a plaque burden ≥70%. These effects of IL-10 did not reach 
statistical significance in the separate groups.
  Inflammation is known to play a major role in atherosclerosis. In a previous study in 
the current patient population, we have demonstrated an association between CRP and IVUS 
characteristics [12]. TNF-α is a proinflammatory cytokine that is secreted from activated innate 
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immunity cells and is capable of inducing a cascade with a broad range of effects, including 
immunological activation, apoptosis, and procoagulative and antifibrinolytic actions, all of 
which can have an effect on the course of atherosclerosis [5,13]. Experimental studies on the 
role of TNF-a in plaque development and stability in mice have rendered inconsistent results, 
some finding anti-atherogenic effects and others finding pro-atherogenic effects [5]. This 
discrepancy in results may be due to differences in underlying mechanisms of atherogenesis 
in different types of mouse models. A recent study [14] in human saphenous vein organ culture, 
to which a combination of TNF-a and LDL was applied, demonstrated phenotypic changes 
characteristic of the initial development of atherosclerotic plaques. Clinical studies on the 
role of TNF-α in cardiovascular disease have also rendered inconsistent results. A prior 
study found an increase of serum TNF-α in patients with MI and unstable angina pectoris 
compared to healthy subjects [15]. Ridker et al. [16] found that plasma concentrations of TNF-α 
are persistently elevated among post-MI patients at increased risk for recurrent coronary 
events [17]. Furthermore, Naranjo et al. [18] found that TNF-α therapy was associated with 
a lower incidence of cardiovascular events in patients with rheumatoid arthritis, who are 
known to be at high cardiovascular risk. On the other hand, Cherneva et al. [19] and Sukhija 
et al. [20] examined the prognostic abilities of TNF-α in patients with known coronary artery 
disease, but did not find any associations between TNF-α and patient outcome. In the current 
study, we found that higher TNF-α level are associated with both extent of atherosclerosis 
and with plaque vulnerability in patients with SAP, which is in line with the presumed 
proinflammatory nature of this cytokine.
  IL-10 is an anti-inflammatory cytokine that is produced by macrophages and 
lymphocytes [6]. This cytokine is capable of inhibiting many cellular processes that may play 
an important role in atherosclerotic lesion development and in the modulation of plaque 
composition [6,21]. Mallat et al. [21] investigated atherosclerotic lesions in IL-10 deficient mice 
and showed increased infiltration of inflammatory cells, increased production of IFN-γ, 
and decreased collagen content, which resulted in development of atheromatous lesions 
with signs of increased vulnerability. Several clinical studies have been performed on IL-
10 and cardiovascular disease. Heeschen et al. [22] demonstrated that a reduced serum IL-
10 level in patients with ACS is indicative of a poor prognosis. Most subsequent studies 
on the association of elevated circulating IL-10 levels with cardiovascular outcome have 
demonstrated positive associations with better prognosis [23-27]. In line with this, we found an 
inverse association between IL-10 and coronary plaque burden as well as between IL-10 and 
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presence of large, vulnerable plaques (i.e., VH-TCFA lesions with a plaque burden ≥70%) in 
the overall study population. However, we did not find an association of IL-10 with presence 
of TCFA lesions in general. These results suggest that IL-10 may in particular be associated 
with lower extent of coronary atherosclerosis and slower growth of VH-TCFAs. In any case, 
these findings further support the hypothesis of a protective role of IL-10 in atherosclerosis.
  The associations of TNF-α and IL-10 with extent and composition of atherosclerosis 
demonstrated in the current study, suggest that these cytokines may potentially be useful for 
clinical risk stratification with regard to cardiovascular outcome. However, we did not find 
any associations between the cytokines we investigated and major adverse cardiac events 
during 1-year follow-up, adjusting for clinical covariates (Supplementary Table 4A-C). 
Possible explanations may include the fact that the magnitude of the effects of TNF-α and 
IL-10 may be relatively small in the context of this multifactorial disease, or that the current 
study lacks statistical power to expose these effects.
  We did not find any associations between several cytokines we examined and the extent 
or composition of atherosclerosis. Analysis of some of the biomarkers (TNF-β and IL-6) 
was complicated by the fact that over 50% of the measurements were too low to detect. 
Cytokine assays are generally known to display limitations in terms of % detectability [28,29]. 
This makes clinical investigations into the pathophysiological role and the prognostic value 
of these biomarkers challenging. In line with this, few clinical studies have been performed 
on circulating TNF-β. Furthermore, IL-6 is known to have large circadian variations, and 
a relatively short half-life of less than 6h [30], which also makes this marker difficult to 
investigate. Clinical studies on circulating TNF R2, IFN-γ, and IL-8 in patients with coronary 
artery disease are also limited in number. IL-18 has been examined more often, and has been 
suggested to be associated with the presence and severity of coronary atherosclerosis [31,32]. In 
the present study, we could not demonstrate such an association. 
  Some aspects of this study warrant consideration. Our study population consisted of 
patients with SAP as well as patients with ACS. The group of patients with ACS is likely 
to be more heterogeneous, which may have influenced the findings. To account for this, we 
have performed the analyses separately in both groups. Furthermore, VH-IVUS imaging 
took place of a prespecified single target segment of a single non-culprit coronary artery, 
based on the assumption that such a non-stenotic segment adequately reflects coronary wall 
pathophysiology of the larger coronary tree. Although this assumption may be debated, 
previous studies evaluating IVUS have demonstrated that the coronary wall of comparable 
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non-culprit, non-stenotic segments of a single vessel does reflect coronary disease burden at 
large and is associated with subsequent cardiovascular outcome [33-35]. Moreover, it is important 
to note that IVUS is formally not capable of detecting the most rupture prone of all plaque 
phenotypes, the TCFA [36,37], because the spatial resolution of IVUS is insufficient for thin cap 
detection [23, 24]. Nonetheless, a concept of VH-IVUS derived TCFA has been postulated for 
plaques with a plaque burden >40% and a confluent necrotic core ≥10% in direct contact with 
the lumen in at least three VH-IVUS frames [13, 23]. Notably, we have recently demonstrated 
that such VH-IVUS derived TCFA lesions are strongly and independently predictive of the 
occurrence of major adverse cardiac events within the current study population [33].
  In conclusion, in patients undergoing coronary angiography, higher circulating TNF-α 
was associated with higher plaque burden and with presence of VH-TCFA lesions in patients 
with SAP. Overall, lower circulating IL-10 was associated with higher plaque burden and 
with presence of VH-TCFA lesions with a plaque burden ≥70%. The latter effects did not 
reach statistical significance in the separate SAP and ACS groups. These in-vivo findings 
illustrate that TNF-α and IL-10 appear to play a role in both extent and vulnerability of 
coronary atherosclerosis, which is in line with experimental studies.
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Supplementary Table 1A. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
segment plaque burden in all patients.
Segment plaque burden
 Unadjusted model Multivariable modela
beta (95% CI) P beta (95% CI) P
TNF-α
Tertile 1 reference reference
Tertile 2 2.39 (-0.10-4.88) 0.060 1.94 (-0.52-4.39) 0.12
Tertile 3 3.67 (1.10-6.23) 0.005 3.13 (0.63-5.62) 0.014
TNF-β       
Not measurable  reference   reference  
Measurable  -0.88 (-4.78-3.03) 0.66  -1.39 (-5.25- -2.47) 0.48
TNF R2
Tertile 1 reference reference
Tertile 2 1.34 (-0.96-3.64) 0.25 -0.56 (-2.89-1.76) 0.63
Tertile 3 0.48 (-1.92-2.88) 0.69 -1.73 (-4.29-0.82) 0.18
Ln (TNF R2) 0.61 (-1.98-3.20) 0.65 -2.43 (-5.15-0.29) 0.080
Interferon-γ       
Tertile 1  reference   reference  
Tertile 2  1.29 (-1.02 -3.61) 0.27  0.41 (-1.86-2.67) 0.73
Tertile 3  2.24 (-0.05-4.53) 0.055  0.51 (-1.98-2.99) 0.69
Ln (Interferon-γ)  1.61 (-0.15-3.37) 0.072  0.11 (-1.71-1.92) 0.91
IL-6 
Not measurable reference reference
Measurable -1.40 (-3.36-0.56) 0.16 -0.70 (-2.74- 1.35) 0.50
IL-8       
Tertile 1  reference   reference  
Tertile 2  -0.96 (-3.29-1.36) 0.42  -0.78 (-3.06-1.49) 0.50
Tertile 3  -0.89 (-3.27-1.50) 0.46  -1.63 (-4.08-0.82) 0.19
Ln (IL-8)  -0.07 (-2.22-2.09) 0.95  -0.54 (-2.70-1.62) 0.63
IL-10
Tertile 1 reference reference
Tertile 2 0.37 (-2.00-2.73) 0.76 0.63 (-1.73-3.00) 0.60
Tertile 3 -3.88 (-6.00- -1.76) <0.001 -3.27 (-5.55- -0.99) 0.005
Ln (IL-10) -1.52 (-2.49- -0.55) 0.002 -1.25 (-2.26- -0.24) 0.016
IL-18       
Tertile 1  reference   reference  
Tertile 2  0.77 (-1.52-3.06) 0.51  1.04 (-1.24-3.33) 0.37
Tertile 3  -0.14 (-2.50-2.21) 0.91  0.14 (-2.15-2.42) 0.91
Ln (IL-18)  -0.84 (-3.17-1.48) 0.48  -0.53 (-2.80-1.74) 0.65
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP. 
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Supplementary Table 1B. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
segment plaque burden in patients with stable AP.
Segment plaque burden  Unadjusted model Multivariable model
a
beta (95% CI) P beta (95% CI) P
TNF-α
Tertile 1 reference reference
Tertile 2 0.86 (-2.58-4.30) 0.62 0.33 (-3.09-3.74) 0.85
Tertile 3 4.45 (0.99-7.91) 0.012 4.64 (1.11-8.16) 0.010
TNF-β       
Not measurable  reference   reference  
Measurable  -1.94 (-6.61-2.73) 0.41 -1.63 (-6.27-3.00) 0.49
TNF R2
Tertile 1 reference reference
Tertile 2 1.54 (-1.71-4.80) 0.35 -0.16 (-3.49-3.18) 0.93
Tertile 3 2.26 (-1.22-5.73) 0.20 0.40 (-3.48-4.29) 0.84
Ln (TNF R2) 2.90 (-0.94-6.74) 0.14 0.64 (-3.54-4.82) 0.76
Interferon-γ       
Tertile 1  reference   reference  
Tertile 2  3.08 (-0.31-6.47) 0.075 2.57 (-0.92-6.05) 0.15
Tertile 3  1.60 (-1.79-4.99) 0.35 0.40 (-3.22-4.02) 0.83
Ln (Interferon-γ)  1.39 (-1.01-3.80) 0.26 0.44 (-2.07-2.95) 0.73
IL-6 
Not measurable reference reference
Measurable 0.44 (-2.68-3.57) 0.78 0.47 (-2.76-3.70) 0.78
IL-8       
Tertile 1  reference   reference  
Tertile 2  0.56 (-2.50-3.63) 0.72 0.17 (-2.90-3.23) 0.91
Tertile 3  0.57 (-3.04-4.17) 0.76 -0.18 (-3.87-3.50) 0.92
Ln (IL-8)  2.03 (-1.11-5.16) 0.21 1.10 (-2.08-4.28) 0.50
IL-10 
Tertile 1 reference reference
Tertile 2 0.28 (-2.76-3.32) 0.86 0.34 (-2.65-3.33) 0.82
Tertile 3 -2.95 (-6.23-0.33) 0.078 -3.30 (-6.64-0.04) 0.053
Ln (IL-10) -1.03 (-3.02-0.95) 0.31 -1.34 (-3.34-0.66) 0.19
IL-18       
Tertile 1  reference   reference  
Tertile 2  0.07 (-3.33-3.47) 0.97 -0.34 (-3.71-3.02) 0.84
Tertile 3  0.99 (-2.30-4.29) 0.55 0.11 (-3.24-3.47) 0.95
Ln (IL-18)  1.72 (-1.83-5.28) 0.34 0.99 (-2.57-4.56) 0.58
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP. 
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Supplementary Table 1C. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
segment plaque burden in patients with ACS. 
Segment plaque burden  Unadjusted model Multivariable model
a
beta (95% CI) P beta (95% CI) P
TNF-α
Tertile 1 reference reference
Tertile 2 3.76 (0.17-7.35) 0.040 2.98 (-0.65-6.61) 0.11
Tertile 3 2.10 (-1.63-5.84) 0.27 1.79 (-1.83-5.41) 0.33
TNF-β       
Not measurable  reference   reference  
Measurable  -0.62 (-7.48-6.24) 0.86 -1.08 (-7.98-5.82) 0.76
TNF R2
Tertile 1 reference reference
Tertile 2 1.01 (-2.26-4.27) 0.54 -1.19 (-4.48-2.10) 0.48
Tertile 3 -1.19 (-4.47-2.09) 0.48 -3.37 (-6.86-0.13) 0.059
Ln (TNF R2) -1.18 (-4.67-2.30) 0.51 -4.53 (-8.17- -0.89) 0.015
Interferon-γ       
Tertile 1  reference   reference  
Tertile 2  -0.37 (-3.47-2.74) 0.82 -0.96 (-4.01-2.08) 0.53
Tertile 3  2.40 (-0.87-5.67) 0.15 0.58 (-2.89-4.05) 0.74
Ln (Interferon-γ)  1.09 (-1.51-3.70) 0.41 -0.22 (-2.89-2.46) 0.87
IL-6 
Not measurable reference reference
Measurable -1.58 (-4.22-1.07) 0.24 -1.49 (-4.18-1.20) 0.28
IL-8       
Tertile 1  reference   reference  
Tertile 2  -2.44 (-5.96-1.07) 0.17 -2.25 (-5.71-1.22) 0.20
Tertile 3  -1.27 (-4.58-2.03) 0.45 -2.77 (-6.12-0.59) 0.11
Ln (IL-8)  -0.99 (-3.99-2.02) 0.52 -2.02 (-5.02-0.97) 0.19
IL-10
Tertile 1 reference reference
Tertile 2 0.81 (-3.01-4.63) 0.68 1.31 (-2.65-5.28) 0.51
Tertile 3 -3.42 (-6.57- -0.27) 0.034 -3.12 (-6.24-0.01) 0.051
Ln (IL-10) -1.30 (-2.52- -0.08) 0.038 -1.27 (-2.48- -0.05) 0.041
IL-18       
Tertile 1  reference   reference  
Tertile 2  1.40 (-1.72-4.52) 0.38 2.11 (-1.14-5.35) 0.20
Tertile 3  -0.93 (-4.23-2.37) 0.58 0.07 (-3.21-3.34) 0.97
Ln (IL-18)  -2.30 (-5.35-0.75) 0.14 -1.52 (-4.55-1.51) 0.32
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP.
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Supplementary Table 2A. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
presence of VH-TCFA in all patients.
VH-TCFA  Unadjusted model Multivariable model
a
OR (95% CI) P OR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.13 (0.69-1.84) 0.63 1.12 (0.68-1.83) 0.67
Tertile 3 1.76 (1.10-2.81) 0.018 1.82 (1.13-2.93) 0.014
TNF-β  
Not measurable  1 (reference)   1 (reference)
Measurable  0.59 (0.29-1.23) 0.16 0.70 (0.33-1.47) 0.34
TNF R2
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.69 (0.46-1.04) 0.079 0.68 (0.44-1.04) 0.078
Tertile 3 0.85 (0.57-1.28) 0.45 0.84 (0.54-1.30) 0.43
Ln (TNF R2) 0.87 (0.55-1.37) 0.55 0.85 (0.52-1.40) 0.52
Interferon-γ  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  1.17 (0.75-1.84) 0.50  1.21 (0.76-1.91) 0.42
Tertile 3  1.12 (0.72-1.76) 0.62  1.22 (0.75-1.97) 0.43
Ln (Interferon-γ)  1.08 (0.76-1.52) 0.68  1.15 (0.79-1.66) 0.47
IL-6 
Not measurable 1 (reference) 1 (reference)
Measurable 0.98 (0.69-1.38) 0.90 0.97 (0.67-1.41) 0.87
IL-8  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.70 (0.46-1.05) 0.085  0.69 (0.46-1.06) 0.089
Tertile 3  0.81 (0.54-1.22) 0.81  0.77 (0.50-1.18) 0.23
Ln (IL-8)  0.91 (0.62-1.33) 0.63  0.87 (0.59-1.30) 0.50
IL-10
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.95 (0.60-1.51) 0.84 0.95 (0.59-1.52) 0.83
Tertile 3 1.24 (0.80-1.95) 0.34 1.21 (0.75-1.94) 0.44
Ln (IL-10) 1.15 (0.95-1.39) 0.16 1.13 (0.92-1.39) 0.25
IL-18  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.87 (0.55-1.36) 0.54  0.90 (0.57-1.43) 0.66
Tertile 3  0.77 (0.49-1.21) 0.25  0.76 (0.48-1.20) 0.24
Ln (IL-18)  0.90 (0.57-1.42) 0.64  0.91 (0.57-1.44) 0.67
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP.
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Supplementary Table 2B. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
presence of VH-TCFA in patients with stable AP.
VH-TCFA  Unadjusted model Multivariable model
a
OR (95% CI) P OR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.23 (0.59-2.56) 0.58 1.27 (0.60-2.66) 0.53
Tertile 3 2.30 (1.17-4.52) 0.015 2.31 (1.16-4.59) 0.017
TNF-β  
Not measurable  1 (reference) 1 (reference)
Measurable  0.52 (0.20-1.35) 0.18 0.52 (0.20-1.37) 0.19
TNF R2
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.69 (0.37-1.30) 0.25 0.67 (0.35-1.29) 0.23
Tertile 3 1.21 (0.65-2.24) 0.55 1.14 (0.58-2.23) 0.71
Ln (TNF R2) 1.44 (0.70-2.94) 0.32 1.38 (0.62-3.04) 0.43
Interferon-γ  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  1.02 (0.49-2.15) 0.95 0.96 (0.45-2.05) 0.91
Tertile 3  1.24 (0.62-2.48) 0.55 1.19 (0.57-2.50) 0.64
Ln (Interferon-γ)  1.23 (0.74-2.05) 0.43 1.23 (0.71-2.13) 0.45
IL-6 
Not measurable 1 (reference)   1 (reference)
Measurable 1.03 (0.58-1.84) 0.92 0.95 (0.51-1.76) 0.87
IL-8  
Tertile 1  1 (reference)   1 (reference)
Tertile 2  1.23 (0.69-2.20) 0.48 1.27 (0.70-2.29) 0.44
Tertile 3  1.00 (0.52-1.92) 1.00 0.95 (0.48-1.85) 0.87
Ln (IL-8)  1.15 (0.64-2.05) 0.64 1.08 (0.59-1.97) 0.81
IL-10
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.19 (0.64-2.22) 0.58 1.22 (0.65-2.30) 0.54
Tertile 3 1.10 (0.51-2.40) 0.81 1.06 (0.47-2.36) 0.90
Ln (IL-10) 1.41 (0.93-2.15) 0.11 1.39 (0.90-2.14) 0.14
IL-18  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.91 (0.46-1.79) 0.78 0.88 (0.44-1.76) 0.72
Tertile 3  0.91 (0.46-1.81) 0.78 0.82 (0.41-1.68) 0.60
Ln (IL-18)  1.01 (0.48-2.13) 0.99 0.95 (0.44-2.04) 0.89
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP.
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Supplementary Table 2C. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
presence of VH-TCFA in patients with ACS.
VH-TCFA  Unadjusted model Multivariable model
a
OR (95% CI) P OR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.05 (0.54-2.03) 0.89 0.89 (0.45-1.78) 0.74
Tertile 3 1.35 (0.70-2.64) 0.37 1.43 (0.72-2.84) 0.31
TNF-β  
Not measurable  1 (reference) 1 (reference)
Measurable  0.86 (0.27-2.76) 0.80 0.98 (0.29-3.34) 0.98
TNF R2
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.72 (0.42-1.25) 0.25 0.69 (0.39-1.22) 0.20
Tertile 3 0.66 (0.38-1.14) 0.14 0.62 (0.34-1.12) 0.11
Ln (TNF R2) 0.63 (0.34-1.14) 0.13 0.59 (0.30-1.15) 0.12
Interferon-γ  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  1.35 (0.76-2.41) 0.30 1.38 (0.77-2.49) 0.28
Tertile 3  1.13 (0.61-2.10) 0.69 1.15 (0.60-2.21) 0.68
Ln (Interferon-γ)  1.06 (0.65-1.73) 0.83 1.05 (0.63-1.76) 0.86
IL-6 
Not measurable 1 (reference)   1 (reference)
Measurable 0.83 (0.53-1.30) 0.42 0.96 (0.59-1.55) 0.86
IL-8  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.37 (0.20-0.67) 0.001 0.40 (0.21-0.74) 0.004
Tertile 3  0.55 (0.32-0.95) 0.033 0.60 (0.33-1.08) 0.086
Ln (IL-8)  0.70 (0.42-1.17) 0.17 0.76 (0.44-1.30) 0.31
IL-10
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.69 (0.35-1.37) 0.29 0.76 (0.37-1.54) 0.44
Tertile 3 1.03 (0.56-1.90) 0.93 1.14 (0.61-2.14) 0.68
Ln (IL-10) 1.02 (0.81-1.28) 0.90 1.03 (0.82-1.31) 0.79
IL-18  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.83 (0.45-1.52) 0.55 0.90 (0.48-1.69) 0.75
Tertile 3  0.66 (0.36-1.21) 0.18 0.65 (0.35-1.21) 0.17
Ln (IL-18)  0.82 (0.46-1.46) 0.50 0.82 (0.46-1.49) 0.52
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP.
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Supplementary Table 3A. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
presence of VH-TCFA with plaque burden ≥70% in all patients.
VH-TCFA with PB ≥70%
 Unadjusted model Multivariable modela
OR (95% CI) P OR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference)
Tertile 2 2.10 (0.91-4.85) 0.083 2.11 (0.91-4.93) 0.084
Tertile 3 2.85 (1.28-6.31) 0.01 2.78 (1.24-6.23) 0.013
TNF-β  
Not measurable  1 (reference) 1 (reference)
Measurable  0.41 (0.10-1.75) 0.23  0.41 (0.10-1.78) 0.24
TNF R2
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.78 (0.43-1.43) 0.42 0.67 (0.36-1.25) 0.20
Tertile 3 0.66 (0.35-1.23) 0.19 0.52 (0.26-1.04) 0.064
Ln (TNF R2) 0.65 (0.32-1.30) 0.22 0.50 (0.23-1.09) 0.081
Interferon-γ  
Tertile 1  1 (reference)   1 (reference)
Tertile 2  0.89 (0.39-2.06) 0.79  0.78 (0.34-1.83) 0.57
Tertile 3  1.31 (0.61-2.82) 0.49  0.93 (0.41-2.14) 0.87
Ln (Interferon-γ)  1.21 (0.66-2.21) 0.54  0.93 (0.48-1.80) 0.83
IL-6 
Not measurable 1 (reference) 1 (reference)
Measurable 0.65 (0.37-1.12) 0.12 0.75 (0.42-1.36) 0.35
IL-8  
Tertile 1  1 (reference)   1 (reference)
Tertile 2  0.61 (0.33-1.14) 0.12  0.63 (0.34-1.18) 0.15
Tertile 3  0.62 (0.34-1.14) 0.12  0.64 (0.34-1.22) 0.17
Ln (IL-8)  0.57 (0.32-1.02) 0.059  0.57 (0.31-1.05) 0.069
IL-10
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.92 (0.45-1.87) 0.81 0.97 (0.47-2.02) 0.94
Tertile 3 0.31 (0.12-0.80) 0.016 0.36 (0.13-0.97) 0.043
Ln (IL-10) 0.64 (0.42-0.97) 0.037 0.69 (0.44-1.08) 0.10
IL-18  
Tertile 1  1 (reference)   1 (reference)
Tertile 2  1.07 (0.51-2.24) 0.87  1.09 (0.51-2.32) 0.82
Tertile 3  0.58 (0.24-1.36) 0.21  0.59 (0.25-1.40) 0.23
Ln (IL-18)  0.49 (0.23-1.08) 0.077  0.51 (0.22-1.14) 0.10
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP.
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Supplementary Table 3B. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
presence of VH-TCFA with plaque burden ≥70% in patients with stable AP. 
VH-TCFA with PB ≥70%
 Unadjusted model Multivariable modela
OR (95% CI) P OR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference)
Tertile 2 2.00 (0.69-5.79) 0.20 2.11 (0.72-6.18) 0.17
Tertile 3 2.39 (0.89-6.45) 0.086 2.48 (0.90-6.79) 0.078
TNF-β  
Not measurable  1 (reference) 1 (reference)
Measurable  0.24 (0.03-1.85) 0.17 0.24 (0.03-1.86) 0.17
TNF R2
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.64 (0.27-1.50) 0.30 0.63 (0.26-1.53) 0.31
Tertile 3 0.72 (0.31-1.67) 0.45 0.71 (0.28-1.77) 0.46
Ln (TNF R2) 0.79 (0.29-2.15) 0.65 0.81 (0.27-2.42) 0.70
Interferon-γ       
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.69 (0.22-2.19) 0.53 0.64 (0.20-2.05) 0.45
Tertile 3  0.90 (0.32-2.53) 0.85 0.83 (0.28-2.47) 0.73
Ln (Interferon-γ)  0.96 (0.44-2.09) 0.91 0.90 (0.38-2.12) 0.81
IL-6 
Not measurable 1 (reference) 1 (reference)
Measurable 0.96 (0.43-2.17) 0.93 0.99 (0.42-2.33) 0.99
IL-8  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.88 (0.40-1.95) 0.76 0.91 (0.41-2.04) 0.82
Tertile 3  0.78 (0.31-1.94) 0.59 0.79 (0.31-2.00) 0.62
Ln (IL-8)  0.85 (0.38-1.94) 0.70 0.87 (0.37-2.01) 0.74
IL-10
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.19 (0.50-2.88) 0.69 1.23 (0.50-2.98) 0.66
Tertile 3 0.75 (0.28-2.03) 0.57 0.74 (0.27-2.05) 0.57
Ln (IL-10) 0.66 (0.32-1.36) 0.26 0.64 (0.30-1.36) 0.25
IL-18       
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.89 (0.32-2.45) 0.82 0.87 (0.31-2.42) 0.79
Tertile 3  0.68 (0.23-2.01) 0.48 0.63 (0.21-1.93) 0.42
Ln (IL-18)  0.55 (0.18-1.71) 0.30 0.53 (0.17-1.68) 0.28
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP.
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Supplementary Table 3C. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
presence of VH-TCFA with plaque burden ≥70% in patients with ACS. 
VH-TCFA with PB ≥70%
 Unadjusted model Multivariable modela
OR (95% CI) P OR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference)
Tertile 2 2.37 (0.59-9.53) 0.23 2.07 (0.50-8.65) 0.32
Tertile 3 3.44 (0.89-13.29) 0.073 3.57 (0.90-14.13) 0.070
TNF-β  
Not measurable  1 (reference) 1 (reference)
Measurable  0.78 (0.10-6.25) 0.82 0.86 (0.10-7.15) 0.89
TNF R2
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.92 (0.39-2.17) 0.86 0.66 (0.27-1.66) 0.38
Tertile 3 0.54 (0.21-1.42) 0.22 0.35 (0.12-1.03) 0.056
Ln (TNF R2) 0.51 (0.19-1.39) 0.19 0.30 (0.09-0.97) 0.044
Interferon-γ       
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  1.04 (0.31-3.54) 0.95 1.02 (0.29-3.56) 0.98
Tertile 3  1.61 (0.50-5.22) 0.43 1.12 (0.32-3.86) 0.86
Ln (Interferon-γ)  1.40 (0.53-3.71) 0.50 1.02 (0.37-2.84) 0.97
IL-6 
Not measurable 1 (reference) 1 (reference)
Measurable 0.53 (0.25-1.14) 0.10 0.60 (0.27-1.36) 0.22
IL-8  
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  0.37 (0.14-1.01) 0.052 0.38 (0.13-1.07) 0.066
Tertile 3  0.54 (0.24-1.23) 0.14 0.50 (0.20-1.23) 0.13
Ln (IL-8)  0.42 (0.18-0.96) 0.039 0.38 (0.16-0.91) 0.029
IL-10
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.65 (0.19-2.23) 0.49 0.69 (0.19-2.50) 0.57
Tertile 3 0.49 (0.15-1.59) 0.24 0.53 (0.16-1.79) 0.31
Ln (IL-10) 0.69 (0.40-1.20) 0.19 0.71 (0.41-1.23) 0.22
IL-18       
Tertile 1  1 (reference)   1 (reference)  
Tertile 2  1.33 (0.44-4.02) 0.61 1.37 (0.43-4.42) 0.60
Tertile 3  0.46 (0.11-1.90) 0.28 0.52 (0.12-2.21) 0.37
Ln (IL-18)  0.44 (0.14-1.35) 0.15 0.45 (0.13-1.54) 0.20
aAdjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP.
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Supplementary Table 4A. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
occurrence of major adverse cardiac events in all patients.
MACE Unadjusted model Multivariable model
a Multivariable modelb
HR (95% CI) P HR (95% CI) P HR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 0.95 (0.48-1.90) 0.89 0.88 (0.44-1.77) 0.73 0.96 (0.48-1.93) 0.91
Tertile 3 0.82 (0.40-1.65) 0.57 0.76 (0.37-1.54) 0.44 0.74 (0.36-1.51) 0.40
TNF-β          
       Not measurable  1 (reference)   1 (reference)   1 (reference)  
       Measurable  0.53 (0.13-2.19) 0.38  0.51 (0.12-2.08) 0.34  0.54 (0.13-2.23) 0.40
TNF R2
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 1.06 (0.51-2.19) 0.88 0.88 (0.42-1.86) 0.75 1.01 (0.48-2.09) 0.99
Tertile 3 1.95 (1.02-3.72) 0.042 1.55 (0.77-3.09) 0.22 1.71 (0.88-3.32) 0.11
LN (TNF R2) 2.34 (1.20-4.55) 0.012 1.92 (0.92-3.99) 0.08 1.81 (0.91-3.57) 0.090
Interferon-γ          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  1.52 (0.74-3.10) 0.25  1.38 (0.68-2.84) 0.38  1.47 (0.72-3.01) 0.29
Tertile 3  1.28 (0.61-2.65) 0.51  0.97 (0.45-2.09) 0.94  1.15 (0.55-2.42) 0.72
LN (Interferon-γ)  1.15 (0.67-1.98) 0.62  0.93 (0.52-1.65) 0.79  1.08 (0.63-1.87) 0.78
IL-6 
       Not measurable 1 (reference) 1 (reference) 1 (reference)
       Measurable 0.923 (0.54-1.60) 0.79 1.03 (0.58-1.81) 0.93 0.78 (0.43-1.40) 0.40
IL-8          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  0.71 (0.36-1.41) 0.33  0.71 (0.36-1.40) 0.32  0.66 (0.33-1.32) 0.24
Tertile 3  1.00 (0.54-1.86) 1.00  0.95 (0.50-1.80) 0.87  0.83 (0.43-1.58) 0.56
LN (IL-8)  1.25 (0.69-2.27) 0.47  1.18 (0.64-2.17) 0.60  1.07 (0.58-1.97) 0.84
IL-10
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 1.28 (0.66-2.48) 0.47 1.31 (0.67-2.57) 0.43 1.12 (0.57-2.20) 0.75
Tertile 3 0.77 (0.36-1.62) 0.48 0.83 (0.38-1.81) 0.65 0.74 (0.35-1.57) 0.43
LN (IL-10) 0.98 (0.72-1.32) 0.88 1.03 (0.75-1.42) 0.87 0.98 (0.71-1.34) 0.89
IL-18          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  0.99 (0.49-2.03) 0.98  0.98 (0.48-2.02) 0.96  1.10 (0.53-2.27) 0.81
Tertile 3  1.14 (0.57-2.28) 0.71  1.18 (0.59-2.36) 0.65  1.18 (0.58-2.37) 0.65
LN (IL-18)  1.10 (0.54-2.21) 0.80  1.15 (0.56-2.36) 0.71  1.05 (0.53-2.06) 0.89
aAdjusted for age, gender and indication for coronary angiography. bAdditionally adjusted for diabetes mellitus, hypertension and 
CRP. Two separate models were constructed for adjustment because of limited number of endpoints. 
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Supplementary Table 4B. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
occurrence of major adverse cardiac events in patients with stable AP.
MACE Unadjusted model Multivariable model
a Multivariable modelb
HR (95% CI) P HR (95% CI) P HR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 1.44 (0.55-3.78) 0.46 1.40 (0.53-3.70) 0.50 1.45 (0.55-3.83) 0.46
Tertile 3 0.96 (0.36-2.57) 0.93 0.95 (0.35-2.55) 0.91 0.81 (0.29-2.24) 0.68
TNF-β          
       Not measurable  1 (reference)   1 (reference)   1 (reference)  
       Measurable  0.33 (0.05-2.46) 0.28 0.35 (0.05-2.55) 0.30 0.34 (0.05-2.47) 0.28
TNF R2
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 1.15 (0.40-3.33) 0.79 1.09 (0.37-3.18) 0.88 1.08 (0.37-3.11) 0.89
Tertile 3 2.45 (0.96-6.25) 0.062 2.38 (0.88-6.46) 0.087 2.07 (0.78-5.44) 0.14
LN (TNF R2) 2.99 (1.10-8.13) 0.031 2.80 (0.97-8.07) 0.057 2.29 (0.80-6.53) 0.12
Interferon-γ          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  0.97 (0.33-2.89) 0.96 0.93 (0.31-2.76) 0.89 0.94 (0.31-2.82) 0.91
Tertile 3  1.29 (0.48-3.44) 0.61 1.13 (0.41-3.15) 0.82 1.17 (0.43-3.16) 0.76
LN (Interferon-γ)  1.41 (0.68-2.91) 0.36 1.26 (0.59-2.69) 0.56 1.30 (0.62-2.71) 0.49
IL-6 
       Not measurable 1 (reference) 1 (reference) 1 (reference)
       Measurable 1.13 (0.51-2.55) 0.76 1.19 (0.53-2.68) 0.67 0.87 (0.36-2.10) 0.76
IL-8          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  0.25 (0.08-0.75) 0.014 0.25 (0.08-0.74) 0.012 0.23 (0.07-0.69) 0.009
Tertile 3  0.89 (0.39-2.01) 0.78 0.87 (0.38-1.96) 0.73 0.71 (0.30-1.68) 0.44
LN (IL-8)  1.03 (0.44-2.41) 0.94 0.98 (0.42-2.28) 0.95 0.81 (0.34-1.97) 0.65
IL-10
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 1.09 (0.47-2.53) 0.83 1.11 (0.48-2.57) 0.81 1.08 (0.47-2.51) 0.85
Tertile 3 0.62 (0.18-2.21) 0.47 0.60 (0.17-2.12) 0.42 0.50 (0.13-1.90) 0.31
LN (IL-10) 1.28 (0.73-2.27) 0.39 1.26 (0.71-2.22) 0.43 1.17 (0.65-2.14) 0.60
IL-18          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  1.33 (0.50-3.57) 0.57 1.32 (0.49-3.55) 0.58 1.20 (0.44-3.27) 0.72
Tertile 3  1.39 (0.52-3.74) 0.51 1.32 (0.49-3.55) 0.58 1.15 (0.42-3.18) 0.78
LN (IL-18)  1.78 (0.61-5.19) 0.29 1.70 (0.58-5.02) 0.33 1.49 (0.50-4.44) 0.48
aAdjusted for age, gender and indication for coronary angiography. bAdditionally adjusted for diabetes mellitus, hypertension and 
CRP. Two separate models were constructed for adjustment because of limited number of endpoints.
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Supplementary Table 4C. Association of TNF-α, TNF-β, TNF R2, IFN-γ, IL-6, IL-8, IL-10 and IL-18 with 
occurrence of major adverse cardiac events in patients with ACS.  
MACE Unadjusted model Multivariable model
a Multivariable modelb
HR (95% CI) P HR (95% CI) P HR (95% CI) P
TNF-α
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 0.61 (0.22-1.72) 0.35 0.55 (0.20-1.55) 0.26 0.64 (0.22-1.83) 0.40
Tertile 3 0.69 (0.25-1.94) 0.48 0.61 (0.22-1.73) 0.35 0.62 (0.22-1.79) 0.38
TNF-β          
       Not measurable  1 (reference)   1 (reference)   1 (reference)  
       Measurable  0.95 (0.13-7.02) 0.96 0.96 (0.13-7.09) 0.97 1.01 (0.14-7.52) 0.99
TNF R2
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 0.97 (0.35-2.66) 0.95 0.74 (0.26-2.10) 0.57 0.93 (0.33-2.59) 0.89
Tertile 3 1.51 (0.61-3.76) 0.37 1.01 (0.37-2.72) 0.99 1.27 (0.49-3.31) 0.63
LN (TNF R2) 1.95 (0.77-4.96) 0.16 1.39 (0.48-4.00) 0.54 1.41 (0.53-3.74) 0.49
Interferon-γ          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  2.06 (0.80-5.32) 0.13 1.92 (0.74-4.97) 0.18 1.90 (0.73-4.94) 0.19
Tertile 3  0.88 (0.26-3.00) 0.83 0.68 (0.19-2.37) 0.54 0.77 (0.22-2.73) 0.69
LN (Interferon-γ)  0.80 (0.35-1.83) 0.60 0.65 (0.28-1.51) 0.32 0.75 (0.32-1.78) 0.52
IL-6 
       Not measurable 1 (reference) 1 (reference) 1 (reference)
       Measurable 0.91 (0.42-1.97) 0.82 0.91 (0.42-1.97) 0.81 0.73 (0.32-1.70) 0.47
IL-8          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  2.49 (0.78-7.94) 0.12 2.36 (0.74-7.58) 0.15 2.37 (0.74-7.59) 0.15
Tertile 3  1.94 (0.62-6.09) 0.26 1.48 (0.46-4.80) 0.51 1.56 (0.48-5.07) 0.46
LN (IL-8)  1.70 (0.71-4.06) 0.23 1.38 (0.56-3.41) 0.49 1.43 (0.58-3.51) 0.43
IL-10
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 1.88 (0.58-6.11) 0.29 1.81 (0.55-5.97) 0.33 1.51 (0.45-5.04) 0.51
Tertile 3 1.20 (0.37-3.89) 0.76 1.20 (0.37-3.90) 0.77 1.10 (0.34-3.60) 0.88
LN (IL-10) 0.95 (0.63-1.42) 0.80 0.96 (0.64-1.43) 0.84 0.95 (0.63-1.44) 0.81
IL-18          
Tertile 1  1 (reference)   1 (reference)   1 (reference)  
Tertile 2  0.72 (0.25-2.08) 0.55 0.67 (0.23-1.96) 0.47 0.94 (0.31-2.81) 0.91
Tertile 3  0.95 (0.36-2.54) 0.92 1.04 (0.39-2.77) 0.94 1.09 (0.40-2.96) 0.87
LN (IL-18)  0.77 (0.29-2.00) 0.58 0.82 (0.30-2.23) 0.70 0.76 (0.31-1.89) 0.56
aAdjusted for age, gender and indication for coronary angiography. bAdditionally adjusted for diabetes mellitus, hypertension and 
CRP. Two separate models were constructed for adjustment because of limited number of endpoints.
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Abstract
Rationale: We investigated whether plasma cystatin C (CysC) and neutrophil gelatinase-
associated lipocalin (NGAL) are associated with intravascular ultrasound (IVUS)-derived 
characteristics of coronary atherosclerosis and 1-year adverse coronary events in patients 
with normal and mildly-to-moderately impaired kidney function.
Methods & Results: Between 2008 and 2011, virtual histology (VH)-IVUS of a non-
culprit coronary artery was performed in 581 patients undergoing coronary angiography. 
Creatinine, CysC and NGAL were measured in pre-procedural blood samples. Presence of 
VH-IVUS-derived thin-cap fibroatheroma (TCFA) lesions, lesions with plaque burden (PB) 
≥70% and lesions with minimal luminal area (MLA) ≤4mm2 was assessed. Major adverse 
coronary events (MACE) comprised the composite of all-cause mortality, acute coronary 
syndrome, or unplanned coronary revascularization. Analyses were stratified using eGFRCr 
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of 90 ml/min/1.73m2 as the cut-off. In patients with normal kidney function, those with 
higher CysC levels had fewer lesions with PB ≥70% and fewer VH-TCFA lesions (adjusted 
odds ratios (ORs) and 95% confidence intervals (CIs): 0.46 (0.30-0.69) and 0.59 (0.44-0.83), 
respectively, per standard deviation (SD) ln (ng/mL) CysC). Those with higher NGAL levels 
also had fewer lesions with PB ≥70% (adjusted OR (95% CI): 0.49 (0.29-0.82)) in patients 
with impaired kidneys, no differences in high-risk lesions were observed for CysC or NGAL. 
However, those with higher CysC had higher risk of MACE (hazard ratio (HR): 1.4, 95% CI 
(1.03-1.92)). This was not the case in patients with normal kidney function. NGAL did not 
influence risk of MACE.
Conclusions: Mild-to-moderate kidney dysfunction modifies the relationship between 
CysC and high-risk coronary lesions. This has not been established before, and offers an 
explanation for the difference in findings between experimental and epidemiologic studies.
Introduction
Kidney impairment, as assessed by creatinine-based equations of glomerular filtration rate 
(eGFRCr), is associated with cardiovascular disease independently of established cardiovascular 
risk factors [1]. In persons with mild kidney dysfunction (eGFRCr in the range of 60-89 ml/
min/1.73m2), cystatin C (CysC) may outperform eGFRCr as a predictor of adverse outcome. 
This is illustrated by the fact that CysC displays a linear association with mortality in patients 
with such mild GFR reduction, while eGFRCr has a J-shaped association with mortality, and 
risk only starts to rise when eGFRCr falls beneath 60 ml/min/1.73m2 [2,3]. Although some 
studies have shown linear associations of eGFRCr with adverse outcome, these associations 
were linear only in particular ranges of eGFRCr (specifically, eGFRCr above 60) [4].
  CysC is a cysteine protease inhibitor produced by most nucleated cells, and can be 
detected in serum or plasma [5]. In in vitro and animal experiments, a reduction of CysC 
correlated with increased activity of cysteine proteases cathepsins K and S, which led to 
breakdown of the elastic lamina in the blood vessel wall [6]. Altered CysC expression has been 
identified in diseases which progress by extracellular proteolysis, such as atherosclerosis 
and aortic aneurysms, and metastasis [7,8]. These experiments, pointing towards a favourable 
role for CysC, do not concur with the positive associations of CysC with adverse outcomes 
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found in epidemiological studies. Studies on the in-vivo association between plasma CysC 
and coronary atherosclerosis may provide further insight into this discrepancy, but have not 
yet been performed.
  Neutrophil gelatinase-associated lipocalin (NGAL) is a clinically relevant biomarker in 
acute kidney injury [9] due to its marked increase in plasma and urine after tubulo-interstitial 
kidney damage [10]. Recently, overexpression of plasma NGAL has been found in coronary 
plaques, where NGAL inhibits elimination of matrix metalloproteinase-9 (MMP-9) [11,12]. 
MMP-9 is involved in extracellular matrix degradation, herewith increasing the risk of plaque 
rupture [13]. NGAL and NGAL/MMP-9 complex have been shown to predict major adverse 
cardiovascular events in epidemiological studies [14,15].
  In spite of the above-described associations that have been demonstrated between CysC, 
NGAL and adverse cardiac events, the presence and shape of a relationship between plasma 
CysC, NGAL, and coronary atherosclerosis have not yet been investigated in vivo. To the best 
of our knowledge, we are the first to perform such an investigation, and to herewith provide 
a link between fundamental experiments and epidemiological studies. Specifically, our study 
aimed to investigate whether plasma CysC and NGAL are associated with IVUS-derived 
characteristics of in-vivo coronary atherosclerosis and 1-year adverse coronary events in 
patients with normal and mildly-to-moderately impaired kidney function.
Materials and methods
Study population
We have previously described the design of The European Collaborative Project on 
Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound 
(ATHEROREMOIVUS) [16]. In this study, we included 581 patients undergoing diagnostic 
coronary angiography or percutaneous coronary intervention (PCI) for acute coronary 
syndrome (ACS) or stable angina pectoris (SAP) between 2008 and 2011 in the Erasmus 
MC, Rotterdam, the Netherlands. Following coronary angiography, intravascular ultrasound 
(IVUS) of a non-culprit coronary artery was performed. The human research ethics committee 
of Erasmus MC, Rotterdam, the Netherlands has approved this study. All included patients 
have signed informed consent, and the study protocol conformed to the Declaration of 
Helsinki. This study is registered in ClinicalTrials.gov (number: NCT01789411).
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Kidney function assessment
Estimated Glomerular Filtration Rate (eGFRCr) was assessed by the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation [17]. Patients were categorized according to 
eGFR by using the modified definition from the National Kidney Foundation e Kidney Disease 
Outcome Quality Initiative (K/DOQI) clinical practice guidelines [18]: normal (GFR≥90 ml/
min/1.73m2), mild (GFR 60-89 ml/min/1.73m2), moderate (GFR 30-59 ml/min/1.73m2), and 
severe (GFR 15-29 ml/min/1.73m2) kidney dysfunction, and kidney failure (GFR<15 ml/
min/1.73m2). No patients with kidney failure were present in this study, and only one patient 
had eGFRCr<30 ml/min/1.73m2. The latter was excluded from further analyses. Patients 
were stratified into those with normal kidney function and those with mildly-to-moderately 
impaired kidney function, using an eGFRCr of 90 ml/min/1.73m2 as the cut-off value.
Biomarkers
Arterial blood was taken before the procedure and stored at -80 oC within 2h. Samples were 
available in 570 patients. An immunoturbidimetric high sensitivity assay (Roche Diagnostics 
Ltd., Rotkreuz, Switzerland) on the Roche Cobas 8000 modular analyzer platform was used 
in the Erasmus MC clinical laboratory to measure the level of C-reactive protein (CRP) in 
serum samples. The plasma EDTA samples were transported at a temperature of -80 oC to 
Myriad RBM, Austin, Texas, USA, where cystatin C and NGAL concentrations were assessed 
by a validated multiplex assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). As 
a result of the batch-wise handling of the samples, with an update of the composition of the 
multiplex assay by the manufacturer in between two batches, cystatin C was measured in the 
full cohort of 570 patients, and NGAL in a random subset of 473 patients. Both laboratories 
were blinded to clinical and imaging data.
Grayscale and radiofrequency intravascular ultrasound (IVUS)
Following coronary angiography, we performed IVUS imaging of the most proximal part 
of a non-culprit, non-treated coronary vessel. The non-culprit vessel was selected based on 
the following order: left anterior descending artery; right coronary artery; left circumflex 
artery. We obtained all IVUS data by the Volcano s5/s5i Imaging System (Volcano Corp., 
San Diego, CA, USA) using a Volcano-Eagle-Eye Gold IVUS catheter of 20 MHz with an 
automatic pullback system and a standard pullback speed of 0.5mm/s.
  Subsequently, an independent core laboratory (Cardialysis BV, Rotterdam, the 
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Netherlands) analysed IVUS images offline, blinded for clinical and biomarker data. The 
IVUS virtual histology (IVUSVH) was assessed by pcVH 2.1 and qVH (Volcano Corp., 
San Diego, CA, USA) software. In each frame, the external elastic membrane and luminal 
borders were outlined (median interslice distance, 0.40mm).
  The degree (plaque volume and plaque burden) and composition of the atherosclerotic 
plaque were assessed. Plaque volume was defined as the total volume of the external 
elastic membrane occupied by atheroma [19]. Plaque burden was defined as the plaque and 
media cross-sectional area divided by the external elastic membrane cross-sectional area 
and is presented as a percentage. A coronary lesion as defined as a segment with a plaque 
burden of more than 40% in at least three consecutive frames [16]. The composition of the 
atherosclerotic plaque was characterized into fibrous, fibro-fatty, dense calcium and necrotic 
core [20]. Subsequently, three types of VH-IVUS high-risk lesions were identified: 1. Thin-cap 
fibroatheroma (TCFA) lesion: a lesion with the presence of >10% confluent necrotic core in 
direct contact with the lumen; 2. A lesion with a plaque burden of ≥70%; 3. a lesion with a 
minimal luminal area (MLA) of ≤4.0mm2 [21]. 
Follow-up
Clinical follow-up started at inclusion and lasted one year. The primary clinical endpoint - MACE 
- was the composite of all-cause mortality, ACS, or unplanned coronary revascularization. 
ACS was defined as the clinical diagnosis of ST-segment elevation myocardial infarction 
(STEMI), non-STEMI, or unstable angina pectoris using the guidelines of the European 
Society of Cardiology [22,23]. Unplanned coronary revascularizations were defined as unplanned 
coronary artery bypass grafting or repeat percutaneous coronary intervention. The secondary 
endpoint was the composite of all-cause mortality or ACS. The endpoints were adjudicated by 
a clinical event committee blinded for biomarker and IVUS data.
Statistical analysis
The Kolmogorov-Smirnov test was used to test distributions of continuous variables for 
normality. CysC and CRP were not normally distributed and were ln-transformed for further 
analyses. Categorical variables are presented as numbers and percentages. Continuous 
variables that were normally distributed are presented as mean ± standard deviation (SD); 
non-normally distributed continuous variables are presented as median and interquartile 
range [IQR]. For reasons of uniformity, all biomarkers are presented as median [IQR]. 
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We examined the associations of plasma CysC and NGAL levels with plaque burden, plaque 
volume, and the presence of high-risk coronary lesions. Plaque volume was normalized for 
the imaged segment length. We used linear regression and logistic regression analyses with 
continuous ln transformed CysC and NGAL concentrations consecutively as independent 
variables. To assess the effect of kidney function, we included interaction terms (ln-
transformed CysC or NGAL, respectively, with dichotomized eGFRCr (above or below 90 
ml/min/1.73m2)) into the logistic regression models. Subsequently, we stratified all analyses 
on eGFRCr of 90 ml/min/1.73m2. To test whether effect estimates differed between patients 
with ACS and patients with SAP, Z-tests for heterogeneity were performed.
  Cox proportional hazards regression analyses were performed to evaluate the associations 
between CysC and NGAL and the clinical study endpoints.
  Age, gender, indication for coronary angiography, diabetes mellitus, hypertension, and 
CRP concentration were considered as potential confounders, and were therefore entered 
into the multivariable linear and logistic regression models. Multivariable adjustment of Cox 
proportional hazards models was constrained due to the number of clinical endpoints, and was 
therefore performed in two steps. For MACE, in the first step the adjustment included age, 
gender, and indication for angiography; in the second step, diabetes mellitus, hypertension 
and CRP were added.
  Finally, we determined the cut-off values of CysC and NGAL that carry the optimal 
discriminative ability with respect to presence of high-risk coronary lesions and occurrence 
of MACE. For this purpose, we drew receiver operating characteristic (ROC) curves and 
calculated the Youden index (highest sum of sensitivity and specificity -1) [24]. We considered 
only statistically significant associations.
  All data were analysed with SPSS software (SPSS 20.0; IBM Corp., Armonk, NY). All 
statistical tests were two tailed, and p values <0.05 were considered statistically significant.
 
Results
Baseline characteristics
Mean age was 61.6 ± 11.4 years, 75.7% were men, 54.6% had ACS, and 45.4% had SAP (Table 
1). The imaged coronary segment had a median length of 44.3 [33.8-55.4] mm. A total of 239 
(41.5%) patients had at least one TCFA lesion, 120 (21.0%) had lesions with PB ≥70%, and 175 
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(30.7%) had lesions with MLA≤4mm2. Median eGFRCr was 90 [77-98] ml/min/1.73mm2 in the 
full cohort with similar values in the subset of ACS patients (91 [78-100] ml/min/ 1.73mm2) 
and SAP patients (89 [77-97] ml/min/1.73mm2). A total of 291 (51.8%) patients had normal 
kidney function and 271 (48.2%) patients had mild-to-moderate kidney dysfunction. ACS 
patients exhibited significantly higher NGAL levels compared to patients with SAP, regardless 
of kidney function, whereas plasma CysC levels were similar in both eGFRCr groups (Table 1).
Table 1. Baseline characteristics. 
Total ACS patients SAP patients
 (n = 570) (n = 309) (n = 261)
Patient characteristics
Age, years 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Male gender, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Diabetes mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Positive family history, n (%) 293 (51.4) 140 (45.3) 153 (58.6)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
Previous myocardial infarction, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
Procedural characteristics
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
Indication for coronary angiography
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease a
No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
IVUS segment characteristics
Segment length, mm 44.1 [33.7-55.4] 43.9 [32.9-54.1] 44.8 [34.2-57.2] 
Plaque burden, % 39.2 [30.0-46.4] 37.2 [28.0-45.5] 40.2 [31.8-47.8]
Presence of VH-TCFA, n (%) 239 (41.9) 140 (45.3) 99 (37.9) 
Presence of PB ≥70%, n (%) 120 (21.0) 56 (18.1) 64 (24.5)
Presence of MLA ≤4mm2, n (%) 175 (30.7) 87 (28.2) 88 (33.7)
Renal function
eGFRb,c, ml/min/1.73 m2 90 [77-98] 91 [78-100] 89 [77-97]
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Table 1 continued.
Total ACS patients SAP patients
(n = 570) (n = 309) (n = 261)
Renal function
KDOQI classification, n (%) GFR ≥90 ml/min/1.73 m2 291 (51.8) 165 (54.3) 126 (48.8)
GFR 60-89 ml/min/1.73 m2 231(41.1) 115 (37.8) 116 (45.0)
GFR 30-59 ml/min/1.73 m2 39 (6.9) 23 (7.6) 16 (6.2)
GFR <30 ml/min/1.73 m2 1 (0.1) 1 (0.3) 0 (0.0)
Serum biomarkers
NGAL, ng/mLd 197.0 [143.0-254.0] 204.0 [148.2-274.5] 177.0 [141.5-239.0]
GFRCr ≥90 ml/min/1.73 m2e 183.0 [143.0-227.0] 193.0 [143.0-243.0] 174.0 [125.0-223.0]
GFRCr 30-89 ml/min/1.73 m2e 216.0 [148.0-293.2] 228.5 [149.0-307.0] 197.0 [143.5-257.7]
Cystatin C, ng/mL 796.0 [691.0-923.0] 791.0 [674.5-915.5] 802.0 [712.5-935.5]
GFRCr ≥90 ml/min/1.73 m2 732.0 [644.0-834.0] 729.0 [637.5-841.5] 734.5 [650.7-822.5]
GFRCr 30-89 ml/min/1.73 m2 872.0 [775.7-1032.5] 863.0 [745.0-1040.0] 879.0 [781.0-1030.0]
Creatinine, umol/L 77 [66-86] 77 [65-877] 76 [67-86]
C-reactive protein, mg/L 2.1 [0.8-5.3] 2.8 [1.1-6.9] 1.4 [0.6-3.1]
ACS=acute coronary syndrome; SAP=stable angina pectoris; CABG=coronary artery bypass grafting; PCI=percutaneous coronary 
intervention; CKD=chronic kidney disease; NGAL=neutrophil gelatinase-associated lipocalin; PB=plaque burden; MLA=minimal 
luminal area. aSignificant stenosis was defined as a stenosis >50% of the vessel diameter by visual assessment on the coronary 
angiogram. bEstimated Glomerular Filtration Rate (eGFRCr) using CKD-EPI equation: GFR = 141 × min (Scr /κ, 1)α × max (Scr /κ, 
1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black] where: Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for 
males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr /κ or 1, and max indicates the maximum of Scr 
/κ or 1. cCreatinine available in 99%, Total n=562, ACS n=304, SAP n=258. dMeasurable in sample of total n=473, ACS n=257, SAP 
n=216. eA statistically significant difference in plasma NGAL levels between ACS and SAP patients (for total population, p=0.002; 
if eGFRCr ≥90 ml/min/1.73 m2, p=0.01; if eGFRCr 30-89 ml/min/1.73 m2, p=0.03).
Cystatin C, NGAL and degree of atherosclerosis on grayscale IVUS
Numbers of lesions with plaque burden (PB) ≥70% and minimal luminal area (MLA) 
≤4mm2 according to categories of kidney function are depicted in Supplementary Figure 
3. Significant interactions were found between CysC and eGFRCr in crude (p=0.007) and 
multivariable (p=0.010) models predicting lesions with PB ≥70%. In patients with normal 
kidney function, those with higher CysC had lower risk of lesions with PB ≥70% (per SD 
increase in ln-transformed CysC: OR (95% CI): 0.56 (0.39-0.82), p=0.002) (Table 2, Figure 
1A, 1C, Supplementary Figure 1). After multivariable adjustment including CRP levels, risk 
remained significantly lower (adjusted OR (95% CI): 0.46 (0.30-0.69), p<0.001). A CysC 
level of 773.0 ng/ml was the optimal cut-off value to identify patients who did not have 
lesions with PB ≥70% (CysC ≥773.0 ng/ml) (Supplementary Figure 4). Conversely, in 
patients with mild-to-moderate kidney dysfunction risk did not differ significantly according 
to CysC levels (adjusted OR (95% CI): 0.95 (0.69-1.30), p=0.75). Risk of lesions with PB 
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≥70% displayed a similar pattern in patients with higher NGAL (Table 2). In patients with 
normal kidney function, an NGAL level of 180.0 ng/ml was the optimal cutoff value to 
identify patients without lesions with PB ≥70% (NGAL ≥180.0 ng/ml) (Supplementary 
Figure 5). Risk of lesions with MLA ≤4mm2 was not different for patients with higher CysC 
or NGAL (Table 2).
Figure 1. Plasma cystatin C and presence of VH-IVUS high-risk coronary lesions. 
Images: courtesy of J. Ligthart and K. Witberg, Invasive Imaging, Dpt. of Cardiology, Erasmus MC. FI=fibrous; FF=fibro-fatty; 
NC=necrotic core; DC=dense calcium. aAdjusted for age, gender, diabetes, hypertension, indication for angiography, C-reactive 
protein. (A) Lesion with plaque burden (PB) ≥70%. Plaque burden is defined as plaque and media cross-sectional area (i.e., area 
between yellow contour and red contour) divided by external elastic membrane cross-sectional area (contoured in red); (B) VH-
IVUS derived thin-cap fibroatheroma lesion (VH-TCFA), defined as a lesion (i.e., plaque with a plaque burden >40%) with presence 
of confluent necrotic core >10% in direct contact with the lumen in at least three frames; (C) Odds ratio (OR) per standard deviation 
increase in ln-transformed cystatin C with 95% confidence interval (CI) for lesions with PB ≥70%. (D) Odds ratio (OR) per standard 
deviation increase in ln-transformed cystatin C with 95% confidence interval (CI) for VH-TCFA lesions. 
A
C
B
D
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Table 2. Plasma cystatin C, NGAL and presence of thin-cap fibroatheroma (VH-TCFA) lesions, lesions with 
plaque burden (PB) ≥70% and lesions with minimal luminal area (MLA) ≤4mm2 stratified according to 
kidney function (eGFRCr).
Unadjusted model P Multivariable model
c
POR (95% CI) OR (95% CI)
eGFRCr ≥ 90 mL/min/1.73 m2
VH-TCFA
Cystatin Ca 0.63 (0.46-0.85) 0.002 0.59 (0.44-0.83) 0.002
NGALb 0.77 (0.57-1.04) 0.090 0.72 (0.52-0.98) 0.040
Plaque burden ≥70%
Cystatin Ca 0.56 (0.39-0.82) 0.002 0.46 (0.30-0.69) <0.001
NGALb 0.56 (0.35-0.89) 0.015 0.49 (0.29-0.82) 0.007
MLA ≤4mm2
Cystatin Ca 0.97 (0.72-1.32) 0.88 0.92 (0.67-1.25) 0.59
NGALb 1.03 (0.77-1.37) 0.84 1.07 (0.79-1.45) 0.67
eGFRCr 30-89 mL/min/1.73 m2
VH-TCFA
Cystatin Ca 1.14 (0.89-1.45) 0.30 1.09 (0.83-1.42) 0.55
NGALb 1.01 (0.78-1.29) 0.97 0.96 (0.74-1.24) 0.74
Plaque burden ≥70%
Cystatin Ca 1.06 (0.80-1.40) 0.68 0.95 (0.69-1.30) 0.75
NGALb 1.20 (0.88-1.63) 0.25 1.21 (0.87-1.67) 0.25
MLA ≤4mm2
Cystatin Ca 0.84 (0.64-1.10) 0.19 0.73 (0.53-0.99) 0.042
NGALb 0.98 (0.74-1.29) 0.90 1.05 (0.78-1.41) 0.75
a Odds ratio (OR) per standard deviation increase in ln-transformed cystatin C with 95% confidence interval (CI). bOdds ratio (OR) 
per standard deviation increase in NGAL with 95% confidence interval (CI). cMultivariable model: adjusted for age, gender, diabetes 
mellitus, hypertension, indication for angiography, C-reactive protein.
Overall, no differences could be demonstrated between CysC and NGAL in either 
plaque burden or normalized plaque volume of the entirely imaged segment (Table 3 and 
Supplementary Table 2). Nevertheless, CysC showed a tendency towards lower normalized 
segment plaque volume (per SD increase in ln-transformed CysC: β (95% CI): -0.43 (-1.02-
0.16), p=0.16) in patients with normal kidney function; whereas no differences were observed 
in patients with mild-to-moderate kidney dysfunction.
  There was no heterogeneity between ACS and SAP patients regarding the differences in 
IVUS grayscale parameters according to CysC or NGAL levels.
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Table 3. Plasma cystatin C, NGAL and segment characteristics (degree of atherosclerosis: plaque volume and 
plaque burden; composition of coronary atherosclerosis: 4 components) as determined by VH-IVUS stratified 
according to kidney function (eGFRCr).
Cystatin Cb P NGAL
c
P
β (95% CI) β (95% CI)
eGFRCr ≥ 90 mL/min/1.73 m2
Plaque burdena -0.02 (-0.16-0.12) 0.77 -0.05 (-0.18-0.09) 0.50
Plaque volumea -0.43 (-1.02-0.16) 0.16 -0.19 (-0.77-0.38) 0.51
Fibrous, % 0.52 (-1.11-2.15) 0.53 0.60 (-0.98-2.19) 0.45
Fibro-fatty, %a 0.03 (-1.10-0.17) 0.65 0.12 (-0.02-0.25) 0.09
Necrotic core, % -0.65 (-1.84-0.53) 0.28 -0.85 (-2.00-0.30) 0.15
Dense calcium, %a 0.00 (-0.17-0.17) 0.99 -0.12 (-0.28-0.04) 0.15
eGFRCr 30-89 mL/min/1.73 m2
Plaque burdena 0.00 (-0.11-0.12) 0.94 -0.03 (-0.15-0.09) 0.66
Plaque volumea 0.16 (-0.37-0.68) 0.55 -0.04 (-0.59-0.51) 0.89
Fibrous, % -1.04 (-2.45-0.37) 0.15 0.60 (-0.89-2.09) 0.42
Fibro-fatty, %a -0.02 (-0.13-0.10) 0.76 -0.01 (-0.12-0.11 0.92
Necrotic core, % 0.44 (-0.47-1.35) 0.34 -0.27 (-1.23-0.68) 0.57
Dense calcium, %a 0.11 (-0.04-0.25) 0.15 -0.06 (-0.21-0.09) 0.44
aSquare root transformed. bUnadjusted b coefficient per standard deviation increase in ln-transformed cystatin C with 95% confidence 
interval (CI). cUnadjusted b coefficient per standard deviation increase in NGAL with 95% confidence interval (CI).
Cystatin C, NGAL and composition of atherosclerosis on radiofrequency VH-IVUS
Numbers of thin-cap fibroatheroma lesions (VH-TCFAs) according to categories of kidney 
function are depicted in Supplementary Figure 3. Significant interactions were found between 
CysC and eGFRCr in crude (p=0.002) and multivariable (p=0.003) models predicting VH-
TCFAs. In patients with normal kidney function, those with higher CysC levels had lower risk 
of VH-TCFA lesions (per SD increase in ln-transformed CysC: OR (95% CI): 0.63 (0.46-0.85), 
p=0.002) (Table 2, Figure 1B, 1D, Supplementary Figure 1). After multivariable adjustment 
including CRP levels, risk remained significantly lower (adjusted OR (95% CI): 0.59 (0.44-
0.83), p=0.002). CysC of 678.5 ng/mL was the optimal cut-off value to identify patients 
without VH-TCFA lesions (CysC ≥678.5 ng/mL) (Supplementary Figure 6). Conversely, in 
patients with mild-to-moderate kidney dysfunction, risk did not differ significantly according 
to CysC levels (adjusted OR (95% CI): 1.09 (0.83-1.42), p=0.55). The interaction between 
NGAL and eGFRCr was not statistically significant. A tendency towards lower risk of VH-
TCFA lesions was observed for higher NGAL, but only in patients with normal kidney 
function (Table 2). There was no heterogeneity between ACS and SAP patients regarding the 
difference in VH-TCFA lesions (CysC, p=0.29, NGAL, p=0.57) (Supplementary Table 1). 
- 152 -
7
PART I
At the level of the entire segment, no differences were present in radiofrequency VH-tissue 
types between CysC or NGAL (Table 3 and Supplementary Table 2).
Cystatin C, NGAL and 1-year MACE
Vital status was acquired for 569 (99.8%) patients. During the 1-year follow-up, 56 patients 
experienced the primary endpoint (MACE; Supplementary Figure 3), and 30 patients endured 
the secondary composite endpoint of all-cause mortality or ACS. In the full cohort, patients 
with higher CysC had higher risk of MACE (per SD increase in ln-transformed CysC: HR 
(95% CI):1.41 (1.10-1.79), p=0.006) (Figure 2, Supplementary Figure 2). After multivariable 
adjustment, the risk estimate lost statistical significance. For NGAL, significant differences 
in risk of MACE were not found (Figure 2, Supplementary Figure 2).
Figure 2. Plasma cystatin C, NGAL and occurrence of the 1-year MACE.
MACE=major adverse coronary event. Hazard ratio (HR) per standard deviation increase in ln-transformed cystatin C and per 
standard deviation increase in NGAL with 95% confidence interval (CI). aUnadjusted model. bAdjusted for age, gender, indication for 
angiography. cAdjusted for age, gender, indication for angiography, diabetes mellitus, hypertension, C-reactive protein; multivariable 
adjustment was constrained by the limited number of clinical endpoints.
In patients with normal kidney function, those with higher CysC levels did not have higher 
risk of MACE. (Figure 2, Supplementary Figure 2). In patients with mild-to-moderate 
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kidney dysfunction, those with higher CysC levels had higher risk of MACE in univariable 
analysis (HR (95% CI): 1.40 (1.03-1.92), p=0.03) (Figure 2, Supplementary Figure 2). In 
multivariable analysis, the HR lost statistical significance, but did not materially change (HR 
(95% CI): 1.31 (0.92-1.87), p=0.12). 
  Both in the total population and in patients with mild-to-moderate kidney dysfunction, 
a CysC of 849.0 ng/mL was the optimal cut-off value to identify patients who developed 
MACE (CysC ≥849.0 ng/mL) (Supplementary Figure 7). 
  Patterns of risk of the secondary endpoint (all-cause mortality and ACS) according to 
CysC and NGAL levels were similar to those of MACE (Supplementary Table 3).
  Finally, stratification on the indication for angiography confirmed the risk patterns 
which were found in the full cohort (Supplementary Table 4).
Discussion
We found that in patients with normal kidney function, those with higher CysC levels had 
fewer high-risk coronary lesions (VH-TCFA and lesions with PB ≥70%), while risk of MACE 
was not different. Conversely, when kidney function was mildly-to-moderately impaired, no 
differences in high-risk lesions were observed, but those with higher CysC levels had higher 
risk of MACE. Therefore, with regard to prediction of cardiovascular risk, CysC appears to 
carry potential only when eGFRCr is below 90 mL/min/1.73m2. Furthermore, patients with 
higher NGAL levels had fewer lesions with PB ≥70%, but only when they had normal kidney 
function. No differences in MACE were found for NGAL, and thus its use for cardiovascular 
risk prediction could not be substantiated. Altogether, our results on CysC suggest novel 
pathophysiological insights, because they offer an explanation for the difference in findings 
observed in experimental and epidemiologic studies so far, and imply that the association 
between CysC and cardiovascular disease may not be solely explained through its correlation 
with GFR.
  Higher CysC levels have been associated with occurrence of cardiovascular events 
in various epidemiological studies [25]. Conversely, animal experiments suggest that higher 
CysC may be favourable. Atherosclerotic mice deficient in CysC display increased plaque 
size and macrophage content, increased elastic lamina degradation and accumulation of 
smooth muscle cells [26,6]. Studies in humans have also found reduced CysC in atherosclerotic 
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and aneurysmatic aortic lesions [7]. Xu et al. have demonstrated that immune cells (CD8þ 
dendritic cells (DC) and macrophages), which are involved in atherosclerotic processes, are 
major contributors to the circulating CysC pool [27,28]. However, besides a correlation with 
GFR, the mechanisms that may explain the link between CysC and cardiovascular disease 
are still unclear. Our study provides additional insights. We found that in patients with normal 
kidney function, those with higher CysC levels had fewer high-risk coronary lesions, and 
did not have higher risk of MACE. This is in accordance with a potential ‘atheroprotective’ 
effect.
  Conversely, in patients with mild-to-moderate kidney dysfunction, differences in high-
risk lesions according to CysC level were not present. This could possibly be explained 
by the changes in CysC physiology that occur in impaired kidneys. When kidney function 
deteriorates, circulating plasma CysC increases and oxidative stress advances, both of 
which stimulate Cys to form homodimers [28,29]. When CysC forms homodimers, it cannot 
inhibit cysteine proteases, because the inhibitory region is hidden within the dimer interface. 
Thus, it may no longer be able to exhibit ‘athero-protective’ properties [30]. Although these 
hypotheses are compelling, additional clinical and experimental studies are necessary to 
further substantiate the effect modification by kidney function that we observed.
  Our findings suggest that NGAL may act on coronary artery disease through a different 
mechanism than currently investigated. A potential lack of predictive precision due to 
a limited number of MACE may explain the difference between the current results and 
previous studies [15,31]. On the other hand, a recent meta-analysis that investigated NGAL as a 
predictor of cardiovascular disease concluded that strong evidence for independent predictive 
value of NGAL is still lacking [32]. Notably, we found higher plasma NGAL levels in ACS 
patients compared to SAP patients, independently of kidney function. This could possibly be 
explained by neutrophilia as a consequence of more severe cardiac damage in ACS patients 
compared to SAP patients [33]. However, no heterogeneity between ACS and SAP patients was 
observed in the relationship between NGAL and IVUS-features of coronary atherosclerosis.
Some limitations of this study merit consideration. This study is currently the largest 
cohort in which the associations between IVUS plaque characteristics, CysC and NGAL 
were investigated. Yet, we cannot exclude the possibility of a chance finding with regard 
to effect modification by kidney function. However, both the cut-off value (based on K/
DOQI guidelines) and the study population (no kidney failure/eGFR<30) were chosen a 
priori. Still, our findings should be considered hypothesis-generating and warrant external 
- 155 -
7
PART I
validation. Second, kidney function was determined by the creatinine-based CKD-EPI 
formula, without direct measurement of GFR. Although the CKD-EPI formula has displayed 
better performance than the Modification of Diet in Renal Disease (MDRD) equation [17], it 
is still possible that a few patients are misclassified. Third, VH-IVUS imaging was limited 
to a pre-specified target segment of a non-culprit coronary artery. This study design was 
chosen based on the hypothesis that such a non-stenotic segment reflects coronary wall 
pathophysiology of the larger coronary tree [34,35]. This hypothesis, on its part, was based on 
ex-vivo, as well as in-vivo studies using IVUS in patients with myocardial infarction. These 
studies have demonstrated the presence of TCFAs in places other than the culprit lesion 
or even culprit artery [16,36]. In fact, we were subsequently able to confirm this hypothesis, 
by demonstrating that imaging characteristics of the non-culprit artery are associated with 
increased risk of MACE within the current study population [34]. Therefore, this study design 
allows us to investigate whether the patient’s burden and vulnerability of atherosclerotic 
disease e as reflected by the phenotype of a non-culprit artery segment e is associated with 
blood biomarkers [16]. Finally, although the spatial resolution of IVUS-VH is formally too 
low to detect thin caps, we have demonstrated that VH-IVUS derived TCFA lesions strongly 
and independently predict the occurrence of MACE within the current study population [34].
In conclusion, this study provides new insights into the role of plasma CysC and NGAL 
in coronary atherosclerosis. Most importantly, it shows that in patients with normal kidney 
function, those with higher CysC levels have fewer high-risk coronary lesions, while in 
patients with impaired kidneys, those with higher CysC have higher risk of MACE. Thus, this 
study implies that mild-to-moderate kidney dysfunction modifies the relationship between 
plasma CysC and coronary artery disease. This has not been established before, and it offers 
an explanation for the difference in findings observed in experimental and epidemiologic 
studies. With regard to cardiovascular risk prediction, CysC showed predictive capacities 
when eGFRCr was below 90 mL/min/1.73m2, whereas NGAL levels were not predictive of 
MACE.
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Supplementary files
Supplementary Table 1. Plasma cystatin C, NGAL and presence of thin-cap fibroatheroma (VH-TCFA) 
lesions, lesions with plaque burden (PB)≥70%, and lesions with minimal luminal area (MLA) ≤4 mm2.
Unadjusted model P Multivariable model
c
POR (95% CI) OR (95% CI)
Total population
VH-TCFA
Cystatin Ca 0.93 (0.78-1.10) 0.38 0.89 (0.74-1.08) 0.25
NGALb 0.92 (0.76-1.10) 0.36 0.88 (0.72-1.07) 0.19
Plaque burden ≥70%
Cystatin Ca 0.93 (0.76-1.14) 0.50 0.75 (0.59-0.95) 0.018
NGALb 0.95 (0.74-1.21) 0.67 0.92 (0.71-1.19) 0.51
MLA ≤4mm2
Cystatin Ca 0.90 (0.75 - 1.08) 0.27 0.79 (0.65-0.98) 0.028
NGALb 1.00 (0.82 - 1.21) 0.95 1.01 (0.82-1.24) 0.90
ACS patients
VH-TCFA
Cystatin Ca 0.86 (0.69-1.07) 0.18 0.80 (0.62-1.03) 0.085
NGALb 0.86 (0.67-1.09) 0.21 0.85 (0.66-1.08) 0.18
Plaque burden ≥70%
Cystatin Ca 0.81 (0.61-1.09) 0.17 0.57 (0.40-0.81) 0.002
NGALb 0.87 (0.62-1.24) 0.45 0.81 (0.56-1.17) 0.26
MLA ≤4mm2
Cystatin Ca 1.04 (0.79-1.28) 0.97 0.86 (0.65-1.14) 0.30
NGALb 1.11 (0.85-1.44) 0.44 1.10 (0.84-1.44) 0.50
SAP patients
VH-TCFA
Cystatin Ca 1.05 (0.81-1.37) 0.70 1.06 (0.79-1.42) 0.70
NGALb 0.96 (0.70-1.30) 0.78 0.95 (0.69-1.31) 0.75
Plaque burden ≥70%
Cystatin Ca 1.04 (0.78-1.40) 0.77 1.00 (0.72-1.38) 0.97
NGALb 1.01 (0.77-1.58) 0.60 1.05 (0.73-1.52) 0.79
MLA ≤4mm2
Cystatin Ca 0.77 (0.58-1.02) 0.071 0.73 (0.53-0.99) 0.044
NGALb 0.91 (0.67-1.24) 0.55 0.90 (0.65-1.24) 0.51
ACS=acute coronary syndrome; SAP=stable angina pectoris. Multivariable model:  adjusted for age, gender, diabetes mellitus, 
hypertension, indications for angiography, C-reactive protein. aOdds ratio (OR) per standard deviation increase ln-transformed 
cystatin C with 95% confidence interval (CI). bOdds ratio (OR) per standard deviation increase in NGAL with 95% confidence 
interval (CI). 
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Supplementary Table 2. Plasma cystatin C, NGAL and segment plaque volume, burden and VH-tissue types 
as determined by VH-IVUS, in the total population and stratified by indication for angiography. 
Cystatin Ca P NGAL
b
P
β (95% CI) β (95% CI)
Total population
Plaque burdenc 0.03 (-0.05 – 0.11) 0.44 -0.02 (-0.11 – 0.07) 0.67
Plaque volumec 0.04 (-0.31 – 0.39) 0.83 -0.05 (-0.44 – 0.34) 0.79
Fibrous, % -0.46 (-1.42 – 0.50) 0.35 0.52 (-0.54 – 1.58) 0.33
Fibro-fatty, %c 0.01 (-0.07 – 0.09) 0.86 0.05 (-0.04 – 0.13) 0.29
Necrotic core, % -0.17 (-0.83 – 0.50) 0.62 -0.56 (-1.29 – 0.17) 0.13
Dense calcium, %c 0.09 (-0.01 – 1.19) 0.072 -0.07 (-0.18 – 0.04) 0.22
ACS patients
Plaque burdena 0.01 (-0.10 – 0.12) 0.89 -0.05 (-0.16 – 0.07) 0.43
Plaque volumea -0.22 (-0.68 – 0.24) 0.35 -0.27 (-0.77 – 0.23) 0.29
Fibrous, % -0.20 (-1.50 – 1.10) 0.76 0.54 (-0.87 – 1.95) 0.45
Fibro-fatty, %a -0.05 (-0.16 – 0.06) 0.39 0.08 (-0.04 – 0.20) 0.18
Necrotic core, % -0.19 (-1.12 – 0.74) 0.69 -0.98 (-1.98 – 0.02) 0.055
Dense calcium, %a 0.12 (-0.01 – 0.24) 0.079 -0.06 (-0.20 – 0.08) 0.39
SAP patients
Plaque burdenc 0.05 (-0.07 – 0.16) 0.41 0.07 (-0.06 – 0.21) 0.29
Plaque volumec 0.35 (-0.20 – 0.90) 0.21 0.39 (-0.25 – 1.02) 0.23
Fibrous, % -0.66 (-2.09 – 0.76) 0.36 0.03 (-1.61 – 1.67) 0.97
Fibro-fatty, %c 0.71 (-0.04 – 0.18) 0.22 0.03 (-0.10 – 0.16) 0.64
Necrotic core, % -0.08 (-1.03 – 0.86) 0.86 -0.09 (-1.18 – 1.00) 0.87
Dense calcium, %c 0.04 (-0.12 – 0.19) 0.64 -0.02 (-0.20 – 0.16) 0.85
ACS=acute coronary syndrome; SAP=stable angina pectoris. aUnadjusted β per standard deviation increase in ln-transformed 
cystatin C with 95% confidence interval (CI). bUnadjusted β per standard deviation increase in NGAL with 95% confidence interval 
(CI). cSquare root transformed.
Supplementary Table 3. Plasma cystatin C, NGAL and composite endpoint of all-cause mortality/acute 
coronary syndrome (ACS) in the total population and stratified by kidney function (eGFRCr).
All-cause mortality 
/ ACS
Unadjusted P Model 1 P Model 2 PHR (95% CI) HR (95% CI) HR (95% CI)
Total population
Cystatin Ca 1.67 (1.24 - 2.27) <0.001 1.51 (1.08 - 2.10) 0.015 1.24 (0.88 - 1.77) 0.19
NGALb 1.20 (0.85 - 1.71) 0.30 1.17 (0.81 - 1.70) 0.40 1.11 (0.77 - 1.61) 0.56
eGFRCr ≥ 90 mL/min/1.73 m2
Cystatin Ca 1.39 (0.72 - 2.65) 0.32 1.33 (0.72 - 2.48) 0.36 1.11 (0.54 - 2.25) 0.78
NGALb 1.04 (0.57 - 1.89) 0.89 1.12 (0.63 - 1.98) 0.69 1.08 (0.56 - 2.11) 0.81
eGFRCr 30-89 mL/min/1.73 m2
Cystatin Ca 1.81 (1.23 - 2.66) 0.003 1.73 (1.17 - 2.55) 0.006 1.59 (1.01 - 2.50) 0.04
NGALb 1.26 (0.80 - 1.98) 0.31 1.22 (0.77 - 1.94) 0.39 1.18 (0.74 - 1.87) 0.48
Model 1: adjusted for the age, gender, indication for angiography; Model 2: model 1 + diabetes mellitus, hypertension, C-reactive 
protein. Multivariable adjustment was constrained by the limited number of clinical endpoints. aHazard ratio (HR) per standard 
deviation increase in ln-transformed cystatin C with 95% confidence interval (CI). bHazard ratio (HR) per standard deviation increase 
in NGAL with 95% confidence interval (CI). 
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Supplementary Table 4. Plasma cystatin C, NGAL and major adverse coronary events (MACE) and the 
composite of all-cause mortality / acute coronary syndrome (ACS), stratified by indication for angiography.
Unadjusted P Model 1 P Model 2 PHR (95% CI) HR (95% CI) HR (95% CI)
ACS patients
MACE
Cystatin Ca 1.41 (1.01 - 1.98) 0.047 1.24 (0.85 - 1.81) 0.27 1.10 (0.73 - 1.65) 0.66
NGALb 1.17 (0.80 - 1.70) 0.43 1.17 (0.80 - 1.72) 0.42 1.14 (0.76 - 1.69) 0.53
All-cause mortality / ACS
Cystatin Ca 1.61 (1.15 - 2.40) 0.007 1.47 (0.98 - 2.20) 0.06 1.23 (0.79 - 1.91) 0.37
NGALb 1.33 (0.89 - 1.98) 0.16 1.35 (0.89 - 2.03) 0.15 1.33 (0.86 - 2.06) 0.20
SAP patients
MACE
Cystatin Ca 1.39 (0.98 - 1.97) 0.07 1.35 (0.92 - 1.98) 0.12 1.25 (0.85 - 1.84) 0.26
NGALb 1.18 (0.77 - 1.80) 0.44 1.10 (0.72 - 1.69) 0.66 1.08 (0.70 - 1.64) 0.73
All-cause mortality / ACS
Cystatin Ca 1.71 (1.02 - 2.88) 0.042 1.61 (0.90 - 2.87) 0.11 1.40 (0.76 - 2.59) 0.28
NGALb 0.84 (0.42 - 1.70) 0.64 0.79 (0.39 - 1.61) 0.52 0.78 (0.38 - 1.58) 0.49
ACS=acute coronary syndrome; SAP=stable angina pectoris. Model 1: adjusted for the age, gender; Model 2: model 1 + diabetes 
mellitus, hypertension, C-reactive protein. aHazard ratio (HR) per standard deviation increase in ln-transformed cystatin C with 95% 
confidence interval (CI). bHazard ratio (HR) per standard deviation increase in NGAL with 95% confidence interval (CI). 
Supplementary Figure 1. Relative number of thin-cap fibroatheroma (VH-TCFA) lesions and lesions with 
plaque burden (PB)≥70% per strata of kidney function (eGFRCr) and plasma cystatin C (CysC) levels above 
and below median. 
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Supplementary Figure 2A. Cumulative incidence (1-year) of major adverse coronary events (MACE) per 
strata of kidney function (eGFRCr) and plasma cystatin C (CysC) levels above and below median.
Supplementary Figure 2B. Cumulative incidence (1-year) of major adverse coronary events (MACE) per 
strata of kidney function (eGFRCr) and plasma NGAL levels above and below median.
Supplementary Figure 3. Absolute numbers of thin-cap fibroatheroma (VH-TCFA) lesions, lesions with 
plaque burden (PB) ≥70%, lesions with minimal luminal area (MLA) ≤4 mm2 and 1-year major adverse 
coronary events (MACE) per strata of kidney function (eGFRCr).
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Supplementary Figure 4. Receiver operator characteristic (ROC) curve of plasma cystatin C (CysC) for the 
prediction of absence of lesion with plaque burden (PB) ≥70% in patients with eGFRCr ≥90 ml/min/1.73m
2. 
CysC of 773.0 ng/ml is optimal cut-off value, based on Youden index (highest sum of sensitivity and specificity -1), discriminating 
between patients who did not have lesion with PB ≥70% (CysC ≥773.0 ng/ml), and those who had (CysC <773.0 ng/ml). AUC 
(95%CI), area under the ROC curve with corresponding 95% confidence interval.
Supplementary Figure 5. Receiver operator characteristic (ROC) curve of plasma NGAL for the prediction of 
absence of lesion with plaque burden (PB)≥70% in patients with eGFRCr ≥90 ml/min/1.73m
2.
NGAL of 180.0 ng/ml is optimal cut-off value, based on Youden index (highest sum of sensitivity and specificity -1), discriminating 
between patients who did not have lesion with PB≥70% (NGAL ≥180.0 ng/ml) and those who had (NGAL <180.0 ng/ml). AUC 
(95%CI), area under the ROC curve with corresponding 95% confidence interval.
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Supplementary Figure 6. Receiver operator characteristic (ROC) curve of plasma cystatin C (CysC) for 
the prediction of absence of thin-cap fibroatheroma (VH-TCFA) lesion in patients with eGFRCr ≥90 ml/
min/1.73m2.
CysC of 678.5 ng/ml is optimal cut-off value, based on Youden index (highest sum of sensitivity and specificity -1), discriminating 
between patients who did not have VH-TCFA lesion (CysC ≥678.5 ng/ml), and those who had (CysC <678.5 ng/ml). AUC (95%CI), 
area under the ROC curve with corresponding 95% confidence interval.
 
     
Supplementary Figure 7. Receiver operator characteristic (ROC) curve for plasma cystatin C (CysC) for the 
prediction of the occurrence of major adverse coronary events (MACE) in total population and in patients 
with eGFRCr 30-89 ml/min/1.73m2. 
CysC of 849.0 ng/ml is optimal cut-off value, based on Youden index (highest sum of sensitivity and specificity -1), discriminating 
between patients who developed MACE (CysC ≥849.0 ng/ml) and those who did not (CysC <849.0 ng/ml). AUC (95% CI), area 
under the ROC curve with corresponding 95% confidence interval.
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Temporal blood biomarker 
patterns
PART II

Temporal pattern of Growth 
Differentiation Factor-15 
(GDF-15) protein after acute 
coronary syndrome (from 
the BIOMArCS study).8
Abstract
Rationale: Growth differentiation factor-15 (GDF-15) has appeared as a promising biomarker 
with strong predictive abilities in acute coronary syndrome (ACS). However, studies are 
solely based on single measurements in the acute phase of an ACS event. The way GDF-15 
patterns in post ACS patients behave on the long term is largely unknown. 
Methods & Results: We conducted a nested case-control study within our multicenter, 
prospective, observational biomarker study (BIOMArCS) of 844 ACS patients. Following 
an index ACS event, high-frequency blood sampling was performed during 1-year of follow-
up. GDF-15 was determined batchwise by electrochemiluminescence immunoessays in 37 
cases with a recurrent event during 1-year follow-up, and in 74 event-free controls. Cases and 
controls had a mean ± standard deviation age of 66.9 ± 11.3 years and 81% were men. From 
30 days onwards, patients showed stable levels, which were on average 333 (95% confidence 
interval 68-647) pg/mL higher in cases than controls (1704 vs. 1371 pg/mL; p-value 0.013). 
Additionally, in the post 30-day period, GDF-15 showed low within-individual variability in 
Buljubasic N, Vroegindewey MM, Oemrawsingh RM, Asselbergs FW, Cramer 
E, Liem A, van der Harst P,  Maas A, Ronner E, Schotborgh C, Wardeh AJ, Akkerhuis 
KM, Boersma E.
Am J Cardiol 2019; 124(1): 8-13. doi: 10.1016/j.amjcard.2019.03.049. 
Temporal pattern of Growth 
Differentiation Factor-15 
(GDF-15) protein after acute 
coronary syndrome (from 
the BIOMArCS study).
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both cases and controls. 
Conclusions: In conclusion, post ACS patients experiencing a recurrent event had stable 
and systematically higher GDF-15 levels during 30-day to 1-year follow-up than their event-
free counterparts with otherwise similar clinical characteristics. Thus, post-discharge blood 
sampling might be used throughout the course of 1 year to improve prognostication, whereas, 
in view of the low within-individual variation, the number of repeated sampling moments 
might be limited.
Introduction
In recent years, circulating growth differentiation factor-15 (GDF-15), a stress-induced 
cytokine, has emerged as a biomarker of interest due to its potential prognostic value in 
patients with cardiovascular disease [1]. In particular, elevated levels of GDF-15 are 
associated with an impaired prognosis after acute coronary syndromes (ACS) [2-6]. However, 
the prognostic value of GDF-15 in ACS patients thus far, has been mainly based on single 
measurements in the early, acute phase of an acute ischemic event. Therefore, the optimal 
time point in the stabilized post ACS phase for GDF-15 blood sampling to make prognostic 
implications remains not fully elucidated yet. We used our ‘BIOMarker study to identify the 
Acute risk of a Coronary Syndrome’ (BIOMArCS) with high-frequency blood sampling in 
post ACS patients as a platform to describe the temporal evolution of GDF-15 during 1-year 
follow-up, to evaluate differences between patients with and without a recurrent event, and 
to study the individual variability of GDF-15.
Methods
We performed a nested case-control analysis within the main BIOMArCS study that was 
approved by the medical ethics committees of all participating hospitals. The rationale and 
design of BIOMArCS are described in detail elsewhere [7]. In brief, BIOMArCS is a prospective, 
multicenter, observational study conducted in 18 participating hospitals in the Netherlands. 
A total of 844 patients, admitted for an ACS, including unstable angina pectoris, non-ST-
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elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI) 
and with at least one additional cardiovascular risk factor, were enrolled between 2008 and 
2015. Patients underwent regular blood sampling after the initial admission for ACS according 
to a strict schedule to describe the temporal evolution of blood biomarkers in the post ACS 
phase, and to reveal deviations in temporal biomarker patterns prior to a recurrent coronary 
event. Venipuncture was performed at admission, at hospital discharge and subsequently every 
fortnight during the first half year, followed by monthly blood sample collection until 1 year. 
Follow-up blood sampling was terminated permanently after coronary artery bypass grafting, 
hospital admission for heart failure, or a detoriation of renal function leading to a glomerular 
filtration rate of < 30 mL/min/1.73m2, since these conditions influence circulating biomarker 
concentrations. Ultimately, patients had 17 (median) repeated blood samples within 1 year. The 
study was performed in accordance with the criteria described in the declaration of Helsinki and 
all patients provided written informed consent for their participation. 
  The primary study endpoint was a composite of cardiac death, non-fatal myocardial 
infarction, or unstable angina pectoris, requiring urgent coronary revascularization within 
1-year follow-up. Study endpoints were adjudicated by a clinical event committee, blinded 
for any biomarker data, after the study was completed in 2015. In 2014, Roche Diagnostics 
GmbH offered the opportunity to determine GDF-15 with their pre-commercial assay in a 
limited number of BIOMArCS patients. Since no commercial GDF-15 assay would have 
been available within the foreseeable future, we decided to accept this one-time offer. We 
analyzed the blood samples of all patients with an investigator-reported endpoint event at 
that time, as well as 2 matched endpoint-free controls for each such event. Matching was 
based on admission hospital, age (± 5 year range), gender, diabetes mellitus, peripheral artery 
disease and history of coronary artery disease (CAD). We kept the results unanalyzed until 
study completion and event-adjudication. After study completion, it appeared that 37 of the 
investigator-reported events were confirmed as study endpoint. In the current analysis, these 
events were included as cases, together with their corresponding 74 matched controls. 
  Blood samples were initially handled and securely stored on-site. Aliquots were frozen at 
-80 degrees Celsius within two hours after withdrawal. Long-term storage and batchwise GDF-
15 analysis took place at the department of Clinical Chemistry of the Erasmus MC, Rotterdam 
(the Netherlands). Laboratory personnel were blinded for any clinical data, including endpoint 
data. The plasma GDF-15 concentrations were measured using the quantitative sandwich 
electrochemiluminescence immunoassay “ECLIA” (Roche Diagnostics, Mannheim, Germany) 
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on a Cobas e601 immunoassay analyzer. The lowest detection limit of GDF-15 analyte 
concentration was 400 pg/mL. No interference was found using in vitro tests to determine 
interference between 51 commonly used cardiovascular pharmaceuticals and the assay. 
  It is important to discern a fixed amount of individual biomarker variability from 
clinically relevant changes over time. Therefore, certain parameters have been described 
to define individual variability, which are needed to interpret the relevance of changes of 
repeated measurements. The coefficient of variation (CV) of a series of measurements is 
defined as 100% times the standard deviation (sd) of the measurements divided by their mean 
value ( ): 
According to the methods by Fraser and Harris [8], the total variation of a series of repeated 
measurements in individual subjects can be split in 3 components, which represent the 
variation due to the imprecision of the analytical process (CVa), the intra-individual or within-
subject variation (CVi), and the inter-individual or between-subject variation (CVg). CVa of 
GDF-15 in our laboratory appeared to be 1.75% and 1.88% for high and low concentrations, 
respectively. Subsequently, CVi was defined as the median value of the CVs of the repeated 
measurements in individual subjects (CVsubject), adjusted for the analytical variation:
Finally, CVg was determined as 100% times the standard deviation ( ) of the mean 
values of the repeated measurements in individual subjects ( ) by the (unweighted) 
mean of these means ( ):
The Index of Individuality (II) is the ratio of the combined within-subject and analytical 
variation relative to the between-subject variation:
Since a high II (>1.4) indicates a relatively high within-subject variation and low between-
subject variation, it is more likely that an unusual biomarker value will lie outside the borders 
of most overlapping values and therefore population-based reference intervals are sufficient. 
Conversely, when the II is low (<0.6), it is agreed that subjects should have their own reference 
values, based on previous samples. The Reference Change Value (RCV) reflects the limit of 
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(relative) change in biomarker values in individual subjects that can be explained by the 
combined within-subject and analytical variation. For biomarkers with a skewed distribution 
a log-normal approach has been described, and the RCV limits can be determined as follows:
We used α = 0.05 (for 95% confidence), thus Z0.025 = 1.96.
  Since GDF-15 is known to be initially elevated post ACS, all aforementioned variability 
parameters are based on >30 day blood samples. Although the exact pathophysiological 
substrate for an initial elevation of GDF-15 in the acute phase of ACS is unknown [9], a 
possible ‘washout’ effect due to an acute phase reaction is thereby hampered. After that 
period, biochemical as well as clinical stabilization are expected to be reached for adequately 
determining GDF-15 variability. Thereafter, only patients with at least three available 
measurements in that time window are included, leaving 20 cases and 46 controls for 
variability analysis. 
  Categorical data are presented as numbers and percentages. Continuous variables are 
presented as mean±standard deviation (SD) or as median and interquartile range (IQR), 
depending on their distribution. Normality of continuous variables was examined by visual 
inspection of the histogram and by normal Q-Q plots. The examined biomarker GDF-15 
(outcome) showed a skewed distribution and was therefore 2log-transformed for further analyses. 
GDF-15 biomarker trajectories were examined across different follow-up time intervals after 
the ACS index event during one year of follow-up. Within the first 7 days from admission, each 
patient’s maximum biomarker value was determined. The median values of the patient-level 
maximum were compared between the cases and controls by linear mixed effect (LME) models. 
Then, the patient-average biomarker trajectories between 7 and 30 days from admission and 
from 30 days onwards were compared between cases and controls by LME models with nested 
random effects. Time from index ACS event until each blood sample measurement and a group 
variable (case / control) were entered as fixed effects in the model, paired individuals as random 
effects and serial GDF-15 measurements as the dependent variable (model 1). Subsequently, 
we fitted multivariable LME models with adjustment for age and gender (model 2), and with 
additional adjustment for admission diagnosis, diabetes mellitus, smoking, hypertension, 
hypercholesterolemia, BMI, history of revascularization, history of myocardial infarction and 
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serum creatinine value (which was measured at each sampling moment) (model 3). Values 
were eventually backtransformed to present mean differences (95% confidence intervals (CI)) 
between cases and controls on the linear scale. All data were analyzed with SPSS (version 
21) and R statistical software (version 3.5.1). All statistical tests were two-tailed and p-values 
<0.050 were considered statistically significant.
Results
Baseline clinical characteristics are presented in Table 1. 
Table 1. Baseline clinical characteristics (n = 111). 
Variable Cases (n = 37) Controls (n = 74) P-value
Age (years) 67.9±11.7 66.3±11.2 0.79
Men 30 (81%) 60 (81%) 0.95
ST-segment elevation myocardial infarction 13 (35%) 42 (57%) <0.001
Non-ST-segment elevation myocardial infarction 18 (49%) 27 (37%) 0.17
Unstable angina pectoris 6 (16%) 5 (7%) 0.78
Smoker
Current 13 (35%) 25 (34%) 0.91
Former 11 (30%) 23 (31%) 0.97
Never 13 (35%) 26 (35%) 0.95
Diabetes mellitus 12 (32%) 26 (35%) 0.52
Hypertension 19 (51%) 40 (54%) 0.77
Hypercholesterolemia 17 (46%) 30 (41%) 0.81
Prior myocardial infarction 12 (32%) 23 (30%) 0.93
Prior percutaneous coronary intervention 11 (30%) 20 (27%) 0.88
Prior coronary artery bypass grafting 9 (24%) 10 (14%) 0.64
Prior stroke 8 (22%) 7 (10%) 0.78
Prior peripheral vascular disease 10 (27%) 13 (18%) 0.73
Values are mean±standard deviation or n (%). P-values were obtained by the linear mixed model (continuous variable) or generalized 
linear mixed model (categorical variable), whichever was appropriate.
The matching procedure appeared successful, as there were no relevant differences between 
cases and controls, except for admission diagnosis of STEMI (p-value <0.001). During the 
first 7 days after the index ACS, GDF-15 levels reached maximum values (median [IQR]) of 
2436 [2286 – 4236] pg/mL in cases and 1804 [1207 – 3749] pg/mL in the controls (p-value 
0.22). These levels slightly decreased within the first 30 days, and the mean value within the 
7 to 30 day period was 1908 pg/mL and 1590 pg/mL in cases and controls, respectively. This 
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mean difference of 318 (95% CI ranging from -215 to 1058) pg/mL was statistically non-
significant (p-value 0.26). From 30 days after the index ACS onwards until 1-year follow-
up, cases had systematically higher GDF-15 levels than controls (Table 2, Figure 1). This 
difference remained significant after correction for age, gender and multiple cardiovascular 
risk factors (p-value 0.013). These findings are confirmed in strata according to gender, 
diabetes mellitus, smoking, serum creatinine value and admission diagnosis (Supplementary 
Tables 1 - 5). No differences were observed in GDF-15 levels across the various subgroups 
(all p-values for heterogeneity were >0.05).
Table 2. Mean GDF-15 (pg/mL) values in cases and controls in the 30 days to 1 year period after ACS 
admission. 
Cases Controls Mean difference (95% CI) P-value
Model 1a 1780 1414 366 (26 - 788) 0.034
Model 2b 1744 1415 329 (2 - 732) 0.049
Model 3c 1704 1371 333 (68 - 647) 0.013
CI=confidence interval. aUnadjusted for patient characteristics. bAdjusted for age and gender. cAdjusted for age, gender, admission 
diagnosis, diabetes mellitus, smoking, hypertension, hypercholesterolemia, BMI, history of revascularization, history of myocardial 
infarction and serum creatinine value (measured at each time-point).   
 Unadjusted p-value = 0.034
Adjusted p-value = 0.013
Figure 1. Serial measurements and temporal evolvement of GDF-15 (pg/mL) in cases (red) and controls (black). 
The left graph shows the evolvement of GDF-15 since the index event (t=0) until 1-year follow-up. The right graph shows the 
evolvement of GDF-15 before the study endpoint (t=0 in cases), or until the last blood sample moment (t=0 in controls). The points 
represent measurements in individual patients. The lines represent the group average values (bold lines) and the 95% confidence 
intervals (dashed lines), using linear mixed models with nested random effects.
An overview of the different variability parameters, calculated for a selected amount of 
cases and controls, is presented in Table 3. With a CVa of 2%, both groups displayed limited 
within-subject variability (CVi of 16.3 for the cases and 11.5 for the controls), whereas the 
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between-subject variability showed larger variation (CVg of 73.1 for the cases and 62.0 for 
the controls). This is also shown by a plot (Figure 2), which illustrates low within-subject 
variability (CVi / (CVi + CVg) = 16-18%) and large between-subject variability (CVg / (CVi 
+ CVg) 82-84%) with a minimum of 579 pg/mL and a maximum of 9748 pg/mL. As could 
be expected from low within-subject variability and high between-subject variability in both 
groups, the II was low (below the threshold value of 0.6), and thus individual reference values 
are preferred. Thereby we found that the limits of change between subsequent measurements 
(RCV) are allowed to range from -36% to 57% in cases and from -28% to 38% in controls.
Table 3. Parameters describing the biological variability of GDF-15 serial measurements 30 days after the 
acute coronary syndrome index event in both cases and controls.
Cases (n = 20) Controls (n = 46)
Average biomarker level (pg/mL), median [IQR] 1423 [1122 - 2594] 1317 [966 - 1705]
Analytical coefficient of variation (CVa) 2% 2%
Intra-individual coefficient of variation (CVi) 16.3 11.5
Inter-individual coefficient of variation (CVg) 73.1 62.0
Index of individuality (II) 0.2 0.2
Reference change value (RCV) 45% 32%
Reference change value, upper limit 57% 38%
Reference change value, lower limit -36% -28%
Parameters describing the biological variability of GDF-15, as calculated by formulas presented in the method section. 
Patients ranked according to their mean value during follow-up  
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Variationwithin: 18% (cases) and 16% (controls)
Variationbetween: 82% (cases) and 84% (controls) 
Figure 2. Graphical illustration of GDF-15 variability by displaying the distribution of GDF-15 measurements 
per patient 30 days after the ACS index event.
The data points represent measurements in individual patients (cases in red; controls in black), ranked according to their mean value 
during post 30 days follow-up in order to display within- and between-individual variation. 
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Discussion
This is the first study to describe GDF-15 patterns in post ACS patients in great detail, utilizing 
a high-frequency blood sampling design during 1 year. Four key lessons were learned from 
our analysis. First, in individual patients, after reaching a peak value in the first week after 
admission, GDF-15 concentrations levelled off to levels that remain stable throughout 1-year 
follow-up. Second, importantly, there was no steady or sudden change in GDF-15 level prior 
to a recurrent event. Thus, no significant changes in GDF-15 values occurred after the initial 
post ACS phase. Third, patients who experienced a recurrent event had on average 26% 
higher GDF-15 levels than those who remained event-free. Although the prognostic value of 
GDF-15 has already been demonstrated by previous studies with one baseline measurement, 
we additionally proved that repeated post-discharge blood sampling of GDF-15 during 1 year 
might help improve accurate prognostication. Fourth, within-patient variability was much 
smaller than between-patient variability, meaning that the number of repeated blood samples 
to obtain a patient-specific stable GDF-15 level can be limited. 
  Considering the natural course of GDF-15 post ACS in our analysis, peak values are 
present in the first 7 days after an ACS, whereafter it seems that GDF-15 subtly reaches a 
stabilized phase without significant changes, especially prior to a recurrent event. By the 
use of frequent serial measurements, the stability of the marker in individual patients on the 
long term was established. This finding is supported by previous data in post ACS patients, 
demonstrating that GDF-15 concentrations show small alterations through the first 72 
hours of hospitalization and potentially several months thereafter [3,4]. The fact that GDF-15 
concentration levels remain significantly higher in patients who experience a recurrent event 
than in event-free patients over the course of a year in our study without any level changes 
around the event, suggests that GDF-15 is not merely a reflection of extent of myocardial 
damage or infarct size, but rather reflects severity of (chronic) atherosclerotic disease burden 
at any time point. This proposition is further supported by findings with cardiovascular 
magnetic resonance, demonstrating that GDF-15 is unrelated to infarct size and myocardial 
area at risk 2-4 days after the index event [9]. Furthermore, GDF-15 concentrations on 
admission seemed to be similar between NSTEMI and STEMI patients, of whom more 
severe myocardial damage can be expected [2,3]. Thus, in support of our hypothesis, previous 
studies do not indicate that GDF-15 solely mirrors tissue damage.      
  With regard to prognostication, GDF-15 has been thoroughly investigated in clinical 
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studies and shown to be an independent prognostic marker of mortality and cardiovascular 
events in both healthy individuals and CAD patients, which is in accordance with our results 
[4-6, 9-11]. Specifically, a recent meta-analysis focused on ACS patients, including 8 studies 
and 8903 participants, showed a significant hazard ratio (95% confidence interval) of 1.66 
(1.47 – 1.87) on the association between GDF-15 and mortality or recurrent MI [6]. However, 
most studies performed blood sampling only on admission at the onset of an ACS or at 
discharge during the recovery phase of an ACS. As we have demonstrated, initial GDF-15 
peak values were largely present in the first 7 days after the index ACS, which is likely the 
expression of an acute phase reaction. Therefore, single blood samples timed in the early 
phase during the course of an ACS event may represent a peak level, which does not clarify 
its prognostic implications on long term post ACS. To our knowledge, only two clinical 
studies have performed a limited number of serial GDF-15 measurements in post NSTEMI 
patients [3,4]. Wollert et al [3] collected blood samples on admission and at 24, 48 and 72 hours 
in a subgroup of 399 patients, whereas Eggers et al [4] measured GDF-15 at baseline and after 
clinical stabilization at 6 weeks, 3 months, 6 months in 950 patients. Both studies found 
significant associations with respectively 1-year and 5-year mortality at each time point. 
Along with our data with highly frequent blood sampling, we have additionally demonstrated 
that obtained blood samples within a course of 1 year post ACS will provide comparable 
prognostic information.         
  The biological variability of GDF-15 in ACS patients has not been described so far. We 
found low within-subject variability and high between-subject variability, which corresponds 
with findings from a study on the biovariability of GDF-15 conducted in 41 patients with 
stable chronic systolic dysfunction [12]. In this study, GDF-15 was measured at four blood 
sampling time points up until 3 months and showed very little biological (within-)variation, 
while there was an elevated between-individual variation (reflected by a low II). Altogether, 
describing biomarker variability is warranted to provide insight into the significance and 
interpretation of a biomarker in clinical practice. Our results indicate that changes in serial 
measurements of GDF-15 in an individual who experienced an ACS, independently of disease 
status (case or control), might be more useful than population derived reference values.
  The unique design and character of this study enabled us to provide novel data on the 
temporal evolution and variability of GDF-15 post ACS. Nevertheless, some limitations 
warrant to be acknowledged. Due to the study design and its observational character, this 
substudy is unable to demonstrate causal inference. Whether GDF-15 merely reflects CAD 
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pathways, or directly contributes to coronary pathophysiology remains unknown. Also, 
as opposed to previous studies with large cohorts, we could not demonstrate significant 
differences in GDF-15 levels between cases and controls within the first 30 days. This is 
probably due to a lack of power with a limited number of measurements <30 days within a 
relatively small cohort. In line with this, we are aware of the fact that our study comprises 
a relatively small number of study patients and events. Further, by acknowledging previous 
studies that investigated the prognostic value of GDF-15 in large study populations, our study 
encompassing an exceptional blood sampling frequency method should rather be seen as 
hypothesis-testing with an extension to existing knowledge. 
  In conclusion, with detailed analysis of the longitudinal GDF-15 pattern post ACS, we 
have demonstrated that GDF-15 concentrations remain stable during follow-up with limited 
within-individual variation. In patients who eventually experience a recurrent event, GDF-
15 is systematically elevated, independently of clinical risk factors and serum creatinine. 
Thus, to enable risk stratification with GDF-15 in post ACS patients, blood sampling might 
be used throughout the course of 1 year for prognostication, whereas the number of repeated 
sampling moments might be limited. Further exploration of the exact role of GDF-15 in 
risk stratifying post ACS patients and deciding on clear cut off points is warranted in future 
studies in order to make accurate prognostications. 
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Supplementary files
Supplementary Table 1. GDF-15 (pg/mL) values of cases and controls in strata according to gender in the 30 
days to 1 year period after index ACS.  
Men Women P for 
heterogeneityCases Controls Mean difference (95% CI) Cases Controls
Mean difference 
(95% CI)
Model 1a 1822 1446 377 (-10 - 867) 1512 1185 326 (-251 - 1262) 0.97
Model 2b 1806 1452 354 (-15 - 817) 1505 1227 279 (-281 - 1170) 0.96
Model 3c 1773 1329 444 (142 - 809) 1506 1619 -113 (-596 - 598) 0.10
CI=confidence interval. Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 
as the dependent variable, and with gender, time from index ACS event to the blood sample measurement and group variable (case 
/ control) as the main independent variables. To obtain the p-value for heterogeneity, an interaction term (group variable * gender) 
was added to the model. aUnadjusted for patient characteristics. bAdjusted for age. cAdjusted for age, admission diagnosis, diabetes 
mellitus, smoking, hypertension, hypercholesterolemia, body mass index, history of revascularization, history of myocardial infarct 
and serum creatinine value (measured at each time-point). 
Supplementary Table 2. GDF-15 (pg/mL) values of cases and controls in strata according to diabetes mellitus 
in the 30 days to 1 year period after index ACS. 
Diabetes Non-diabetes
P for heterogeneityCases Controls Mean difference (95% CI) Cases Controls
Mean difference 
(95% CI)
Model 1a 2131 1816 315 (-324 - 1228) 1605 1208 397 (37 - 860) 0.57
Model 2b 2038 1772 266 (-324 - 1096) 1607 1236 371 (22 - 815) 0.56
Model 3c 2175 1760 415 (-169 - 1213) 1508 1215 293 (9 - 643) 0.98
CI=confidence interval. Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 
as the dependent variable, and with presence of diabetes mellitus, time from index ACS event to the blood sample measurement 
and group variable (case / control) as the independent variables. To obtain the p-value for heterogeneity, an interaction term (group 
variable * diabetes mellitus) was added to the model. aUnadjusted for patient characteristics. bAdjusted for age and gender. cAdjusted 
for age, gender, admission diagnosis, smoking, hypertension, hypercholesterolemia, body mass index, history of revascularization, 
history of myocardial infarct and serum creatinine value (measured at each time-point). 
Supplementary Table 3. GDF-15 (pg/mL) values of cases and controls in strata according to smoking in the 
30 days to 1 year period after index ACS. 
Smoking Non-smoking
P for heterogeneityCases Controls Mean difference (95% CI) Cases Controls
Mean difference 
(95% CI)
Model 1a 1410 1265 145 (-294 - 784) 1997 1458 539 (65 - 1158) 0.38
Model 2b 1518 1392 126 (-326 - 771) 1889 1411 478 (50 - 1411) 0.36
Model 3c 1832 1552 280 (-226 - 978) 1646 1317 330 (-31 - 791) 0.78
CI=confidence interval. Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as 
the dependent variable, and with smoking status, time from index ACS event to the blood sample measurement and group variable 
(case / control) as the independent variables. To obtain the p-value for heterogeneity, an interaction term (group variable * smoking 
status) was added to the model. aUnadjusted for patient characteristics. bAdjusted for age and gender. cAdjusted for age, gender, 
admission diagnosis, diabetes mellitus, hypertension, hypercholesterolemia, body mass index, history of revascularization, history of 
myocardial infarct and serum creatinine value (measured at each time-point).
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Supplementary Table 4. GDF-15 (pg/mL) values of cases and controls in strata according to creatinine levels 
(μmol/L) in the 30 days to 1 year period after index ACS.
Creatinine ≥ 85 Creatinine < 85
P for heterogeneityCases Controls Mean difference (95% CI) Cases Controls
Mean difference 
(95% CI)
Model 1a 1952 1532 420 (-79 - 1091) 1490 1288 203 (-220 - 794) 0.68
Model 2b 1640 1518 122 (-92 - 977) 1545 1319 226 (-193 - 800) 0.78
Model 3c 1817 1460 357 (-25 - 841) 1553 1336 217 (-151 - 698) 0.71
CI=confidence interval. Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as 
the dependent variable, and with serum creatinine level (dichotomized into equal or above the median and below the median), time 
from index ACS event to the blood sample measurement and group variable (case / control) as the independent variables. To obtain 
the p-value for heterogeneity, an interaction term (group variable * (dichotomous) serum creatinine level) was added to the model. 
aUnadjusted for patient characteristics. bAdjusted for age and gender. cAdjusted for age, gender, admission diagnosis, smoking, diabetes 
mellitus, hypertension, hypercholesterolemia, body mass index, history of revascularization and history of myocardial infarction. 
Supplementary Table 5. GDF-15 (pg/mL) values of cases and controls in strata according to admission 
diagnosis in the 30 days to 1 year period after index ACS.
STEMI NSTEMI
P for heterogeneityCases Controls Mean difference (95% CI) Cases Controls
Mean difference 
(95% CI)
Model 1a 1535 1223 312 (-119 - 911) 1758 1792 -34 (-502 - 604) 0.29
Model 2b 1573 1275 299 (-123 - 876) 1746 1725 20 (-428 - 624) 0.36
Model 3c 1670 1337 333 (-68 - 862) 1748 1485 264 (-140 - 789) 0.76
CI=confidence interval; STEMI=ST-elevation myocardial infarction; NSTEMI=non-ST-elevation myocardial infarction. Mean 
GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as the dependent variable, and 
with admission diagnosis, time from index ACS event to the blood sample measurement and group variable (case / control) as the 
independent variables. To obtain the p-value for heterogeneity, an interaction term (group variable * admission diagnosis) was added 
to the model. aUnadjusted for patient characteristics. bAdjusted for age and gender. c Adjusted for age, gender, smoking, diabetes 
mellitus, hypertension, hypercholesterolemia, body mass index, history of revascularization, history of myocardial infarct and serum 
creatinine value (measured at each time-point). 
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Abstract  
Rationale: The intracellular mitogen-activated protein kinase (MAPK) cascade regulates 
intracellular processes that modulate cardiovascular disease progression. We explored the 
time-course of serum biomarkers that stimulate the MAPK-cascade in post-acute coronary 
syndrome (ACS) patients, prior to a recurrent coronary event.
Methods & Results: BIOMArCS is a high-frequent repeated blood sampling study in 
post-ACS patients. We performed a nested case-control study selecting the 45 patients 
who experienced a recurrent event (cases) and 2 matched event-free controls per case 
during 1-year follow-up. Olink Proteomics ’immunoassay was used to measure 25 serum 
biomarkers. Results are expressed in the arbitrary Normalized Protein eXpression (NPX) 
unit on the 2logscale. Linear mixed-effects models were applied to examine time-courses 
and differences between cases and controls. Mean age was 66 ± 12 years and 80% were 
men, with no differences between cases and controls. Early cases had significantly higher 
levels of ANG-1 (difference 0.95 NPX (95% CI 0.36-1.54), PAR-1 (difference 0.50 NPX 
- 206 -
10
(95% CI 0.22-0.77) and BMP-6 (difference 0.55 NPX (95% CI 0.21-0.90) than controls. No 
differences in biomarker levels were observed between late cases and matching controls. In 
particular, in cases, no increase was observed prior to the moment of the recurrent event.
Conclusions: Patients with an early recurrent coronary event after an index-ACS had higher 
levels of ANG-1, PAR-1 and BMP-6 than patients who remained event-free. 
Introduction
Although outcome for patients with cardiovascular disease (CVD) has improved over the last 
decades, hospitalization rates are still increasing [1-3]. This increase can partly be explained by 
the increasing population of patients who survived an acute coronary syndrome (ACS) and 
who are at risk of experiencing a recurrent coronary event [2]. As CVD is dynamic and shows 
considerable interpatient variation, to improve secondary prevention, insight in the course of 
CVD in individual subjects is required. Since biomarker profiles may serve as a proxy for 
CVD status and development, the exploration of (established and) evolving markers covering 
relevant pathophysiological processes is warranted.
  The mitogen-activated protein kinase (MAPK) cascade, is an intracellular cascade of 
proteins that enables extracellular stimuli - blood biomarkers - to modulate several intracellular 
processes i.e., cell growth, differentiation, proliferation, and apoptosis [4]. Basic research has 
shown that the MAPK-cascade plays a pivotal role in cellular processes that advance CVD 
progression [5]. First, the MAPK-cascade promotes atherosclerotic lesion formation, i.e., by 
inducing inflammation and cell apoptosis. Secondly, it may activate pathological cardiac 
remodeling after myocardial infarction by constraining myocyte mitosis and promoting fibrosis. 
Thirdly, the cascade might be directly involved in the development of in-stent restenosis [5].
  In view of the pivotal role of the MAPK-cascade in the development and progression 
of CVD, blood biomarkers that regulate the cascade may be useful for the identification of 
patients with CVD who are at higher risk of developing a (recurrent) coronary event. However, 
translational research relating the MAPK-cascade to clinical CVD progression is scarce [5].
  We aimed to explore the course of protein blood biomarkers that stimulate the 
intracellular MAPK-cascade in post-ACS patients prior to the development of a recurrent 
coronary event during one year of follow-up.
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Methods
Study population
We performed a case-control study that is embedded in The ‘BIOMarker study to identify 
the Acute risk of a Coronary Syndrome’ (BIOMArCS) [6]. BIOMArCS is a multicenter 
observational study with a unique high-frequency sampling design, to study the course of 
blood biomarkers in patients following an ACS in anticipation of a recurrent event. The 
design of BIOMArCS has been described in detail elsewhere [6]. In brief, BIOMArCS enrolled 
844 patients with ACS, aged ≥ 40 years and who had at least 1 pre-specified cardiovascular 
risk factor. After enrolment, venipuncture was performed at admission, discharge, and 
subsequently every two weeks during the first half-year and every month during the second 
half-year. A median number of 17 repeated blood samples per patient were obtained.
  BIOMArCS was approved by the Institutional Review Boards of all enrolling hospitals, 
and all participating patients provided written informed consent. BIOMArCS is registered in 
The Netherlands Trial Register NTR1698 and NTR1106.
Case-control design
The current analysis is based on a case-control approach. A total of 45 patients (cases) in 
BIOMArCS reached the composite study endpoint of cardiac death, non-fatal myocardial 
infarction (MI), or unstable angina (UA) requiring urgent coronary revascularization during 
one year of follow-up after the index-ACS. These cases were with two controls that are 
selected from BIOMArCS event-free patients. Cases and controls were matched on age, sex 
and admitted hospital. For reasons of efficiency, for each case, the blood sample at hospital 
admission and the last and second last samples prior to the recurrent coronary event have 
been analyzed. In controls, we selected the blood sample at hospital admission and the blood 
sample that corresponds in time with the recurrent event of the matched case.
  As a pragmatic choice, separate analyses were performed for cases (and their matching 
controls) that experienced their event in the first 30 days after the index-ACS, and for cases 
(and their matching controls) that experienced their event thereafter. Hence, we were able 
to differentiate between the behavior of biomarkers during the acute and post-stabilization 
phase after the index-ACS.
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Biomarker measurements
Targeted protein biomarker measurements were performed by the Proximity Extension Assay 
(PEA) Technique using Olink Proteomics’ CVD II panel (Olink Proteomics AB, Uppsala, 
Sweden). Details concerning PEA and the CVD II panel are described on the website 
of Olink Proteomics (www.olink.com). In brief, the PEA technique consists of a pair of 
oligonucleotide-labelled antibody probes that pairwise bind to a targeted protein biomarker 
in a blood sample. This binding induces amplification of the protein biomarker by real-time 
PCR (Fluidigm® BioMark™ HD System).
  The PEA technique enables simultaneous analysis of all protein biomarkers of the CVD 
II panel in one blood sample. Olink proteomics’ CVD II panel provides measurements of 25 
protein blood biomarkers that are related to the intracellular MAPK-cascade (overview of 
proteins in Table 1). Every measured protein blood biomarker is expressed in an arbitrary unit 
on the log2-scale called Normalized Protein eXpression (NPX). Accordingly, an increase or 
decrease of one NPX corresponds with a doubling or halving of a biomarker serum level. 
NPX values cannot be compared across different proteins. For each protein biomarker, 
general calibrator curves to calculate approximate concentrations are available on the website 
of Olink Proteomics.
Table 1. Overview of the assessed protein biomarker.
Abbreviation Full name Synonyms Molecular function
NEMO NF-kappa-B essential modulator IKBKG, FIP3 Binding protein
HB-EGF Proheparin-binding EGF-like growth 
factor
DTR, DTS, HEGFL Growth factor/receptor
SCF Stem cell factor KITLG,MGF Cytokine/growth factor
PDGF subunit B Platelet-derived growth factor subunit B PDGFB,PDGF2, SIS Developmental protein/
growth factor
GDF-2 Growth/differentiation factor 2 BMP9 Cytokine/growth factor
ANG-1 Angiopoietin-1 ANGPT1 Developmental protein
CCL3 C-C motif chemokine 3 MIP1A, SCYA3, G0S19-1 Chemokine
TIE2 Angiopoietin-1 receptor TEK, VMCM, VMCM1 Receptor
PAR-1 Proteinase-activated receptor 1 F2R, CF2R, TR Receptor
LEP Leptin OB, OBS Hormone/growth factor
REN Renin Hydrolase
TNFRSF11A Tumor necrosis factor receptor 
superfamily member 11A
RANK, ODFR, CD265, 
NFKB activator
Receptor
THPO Thrombopoietin / megakaryocyte 
colony-stimulating factor
MGDF Cytokine/hormone
FGF-21 Fibroblast growth factor 21 Growth factor
GAL-9 Galectin-9 LGALS9 Binding protein
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Table 1 continued.
Abbreviation Full name Synonyms Molecular function
SRC Proto-oncogene tyrosine-protein kinase 
SRC
SRC1,  C-SRC Kinase
GH Growth hormone GH1, somatotropin Hormone
XCL1 X-C motif chemokine ligand 1 Lymphotactin, LTN, 
SCYC1, ATAC, SCM-1
Chemokine
FGF-23 Fibroblast growth factor 23 HYPF Growth factor
CCL17 C-C motif chemokine 17 SCYA17, TARC Chemokine
IL-18 Interleukin-18 IGIF, IL1F4 Cytokine
BMP-6 Bone morphogenetic protein 6 VGR1, VGR Cytokine/developmental 
protein/growth factor
IL-6 Interleukin-6 IFNB2, BSF2, CDF, HGF Cytokine/growth factor
AMBP Alpha-1-microglobulin/bikunin 
precursor
HCP, ITIL, ITI, Bikunin, 
EDC1, Trypstatin
Protease inhibitor
CD40-L CD40 ligand CD40LG, TNFSF5, TRAP, 
HIGM1, CD154
Cytokine
Statistical analysis
Continuous variables are presented as medians with interquartile range (IQR) and categorical 
variables as numbers with percentages. Differences between cases and controls were 
compared with Mann-Whitney U and Pearson Chi-square tests, respectively.
  As indicated, all biomarkers were analyzed on a log2-transformed scale. We fitted a 
linear mixed-effects model for every biomarker to describe patient-specific longitudinal 
biomarker trajectories as a function of time. Likelihood ratio tests and F-tests were used for 
hypothesis testing, whereas residuals were used to examine the model assumptions.
  We considered 25 biomarkers. To adjust for inflation of the type I error with multiple 
testing, statistical significance was stated at p=0.003 (two-tailed test), based on the matrix 
spectral decomposition method [7]. R statistical software (version 3.4.0) was used for analyses, 
in particular the package nlme (https://cran.r-project.org/web/packages/nlme/index.html).
Results
Baseline characteristics
Mean age of all patients was 66.0 ± 11.9 years and 80.2% were men. Cases and controls did 
not show any significant differences in presentation, initial treatment, cardiovascular risk 
factors and medication at first blood sample, indicating successful matching (Table 2).
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Table 2. Baseline clinical characteristics.
Cases Controls P-value(n = 44) (n = 87)
Presentation and initial treatment
Age, years 67.5 (57.3-77.5) 66.7 (57.4-75.5) 0.83
Male gender, n (%) 35 (79.5) 70 (80.5) 0.90
Admission diagnosis, n (%) 0.38
STEMI 16 (36.4) 42 (48.3)
NSTEMI 22 (50.0) 33 (37.9)
UAP 6 (13.6) 12 (13.8)
CAG performed, n (%) 39 (88.6) 82 (94.3) 0.25
PCI performed, n (%) 33 (86.8) 67 (81.7) 0.48
CKmax, U/L 418 [195-1142] 513 [169-1332] 0.94
Cardiovascular risk factors
Smoking, n (%) 0.81
Current 17 (38.6) 35 (40.2)
Former 12 (27.3) 27 (31.0)
Never 15 (34.1) 25 (28.7)
Diabetes mellitus 16 (36.4) 32 (36.8) 0.96
Hypertension, n (%) 21 (47.7) 44 (50.6) 0.76
Hypercholesterolemia, n (%) 19 (43.2) 46 (52.9) 0.30
Creatinine, µmol/L 88 (73-93) 81 (67-97) 0.15
Cardiovascular history
Peripheral arterial disease, n (%) 10 (22.7) 7 (8.0) 0.018
Myocardial infarction, n (%) 14 (31.8) 33 (37.9) 0.49
Percutaneous coronary intervention, n (%) 14 (31.8) 29 (33.3) 0.86
Coronary artery bypass grafting, n (%) 10 (22.7) 17 (19.5) 0.67
Stroke, n (%) 9 (20.5) 5 (5.7) 0.010
Valvular heart disease, n (%) 4 (9.1) 3 (3.4) 0.18
Heart failure, n (%) 4(9.1) 1 (1.1) 0.025
Medication at first blood sample moment >7 days after the index ACSa
Aspirin, n (%) 35 (92.1) 76 (92.7) 0.91
P2Y12 inhibitor, n (%) 36 (94.7) 74 (90.2) 0.41
Vitamin K antagonist, n (%) 7 (18.4) 8 (9.8) 0.18
Statin, n (%) 35 (92.1) 79 (96.3) 0.32
Beta-blocker, n (%) 36 (94.7) 69 (84.1) 0.10
ACE-inhibitor or ARB, n (%) 34 (89.5) 65 (79.3) 0.17
ACE=angiotensin converting enzyme; ARB=angiotensin II receptor blocker; CKmax=maximum creatine kinase during the index 
admission; NSTEMI=non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; UAP: unstable angina 
pectoris.aThe first blood sample >7 days was taken at a median (25th-75th percentile) of 24 (16-34) days after the index ACS. 
Continuous variables are presented as median [25th-75th percentile]. Categorical variables are presented as number (percentage).
Biomarker trajectories in the first 30 days after the index ACS
Fifteen cases reached the study endpoint within 30 days after the index ACS. They had higher 
serum levels of ANG-1 (difference of 0.95 NPX, 95% confidence interval (CI) 0.36-1.54), 
PAR-1 (difference of 0.50 NPX, 95% CI 0.22-0.77) and BMP-6 (difference of 0.55 NPX, 
95% CI 0.21-0.90) than the matched controls (Table 3, Figure 1 left hand panel). 
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Table 3. Difference in biomarker serum level between cases and controls ≤ 30 days. 
Biomarker (NPX) Coefficient 95% CI P-value
NEMO 1.16 (0.36 - 1.95) 0.005
HB-EGF 0.61 (0.11 - 1.12) 0.018
SCF -0.13 (-0.59 - 0.32) 0.55
PDGF subunit B 0.92 (0.31 - 1.54) 0.004
GDF-2 -0.063 (-0.35 - 0.23) 0.66
ANG-1 0.95 (0.36 - 1.54) 0.002
CCL3 0.29 (-0.12 - 0.71) 0.16
TIE2 0.12 (-0.048 - 0.29) 0.16
PAR-1 0.50 (0.22 - 0.77) <0.001
LEP 0.35 (-0.31 - 1.00) 0.29
REN 0.45 (-0.18 - 1.08) 0.16
TNFRSF11A 0.41 (0.003 - 0.82) 0.048
THPO 0.22 (-0.018 - 0.45) 0.069
FGF-21 0.55 (-0.39 - 1.49) 0.24
GAL-9 0.16 (-0.083 - 0.41) 0.19
SRC 0.29 (-0.18 - 0.76) 0.22
GH 0.71 (-0.61 - 2.02) 0.29
XCL1 0.34 (0.018 - 0.66) 0.039
FGF-23 0.90 (0.16 - 1.63) 0.018
CCL17 0.77 (0.089 - 1.46) 0.028
IL-18 0.19 (-0.15 - 0.52) 0.27
BMP-6 0.55 (0.21 - 0.90) 0.002
IL-6 0.95 (0.074 - 1.82) 0.034
AMBP 0.11 (-0.033 - 0.25) 0.13
CD40-L 1.32 (0.41 - 2.22) 0.006
ACS=acute coronary syndrome, CI=confidence interval, NPX=Normalized Protein eXpression. For every biomarker, the difference 
in biomarker serum level between cases and controls is expressed in a relative arbitrary unit on the log 2 scale. Thus, an increase or 
decrease of one NPX corresponds with a doubling or a halving of the protein biomarker serum level. 
Biomarker trajectories after 30 days
Thirty cases had the study endpoint in >30 days after the index ACS. Interestingly, in these 
late cases, the biomarker levels during the first 30 days after the index ACS tended to be 
lower than in the early cases (Table 4). In the post-30 day time window, cases and matched 
controls appeared to have similar levels of biomarkers (Table 5). Importantly, we found no 
steady or sudden increase in biomarkers in the days or weeks prior to the recurrent event.
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Figure 1. Timecourse of PAR-1, BMP-6 and ANG-1.
NPX=Normalized Protein eXpression.
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Table 4. Biomarker serum levels in the first 30 days for cases only.
Biomarker (NPX) Early casesa Late casesa P-value
NEMO 6.61±1.08 5.80±1.25 0.062
HB-EGF 5.62±0.89 5.03±0.73 0.049
SCF 8.31±0.87 8.08±0.60 0.40
PDGF subunit B 10.47±0.84 9.49±1.16 0.012
GDF-2 3.16±0.55 2.94±0.37 0.19
ANG-1 9.31±0.91 8.38±1.21 0.022
CCL3 4.04±0.59 3.59±0.36 0.013
TIE2 7.02±0.19 6.86±0.39 0.16
PAR-1 8.66±0.35 8.26±0.48 0.012
LEP 5.26±0.93 4.94±0.51 0.23
REN 8.36±1.34 8.31±1.06 0.91
TNFRSF11A 5.55±0.68 5.15±0.61 0.084
THPO 2.99±0.33 2.87±0.80 0.60
FGF-21 7.01±1.51 6.72±1.12 0.54
Gal-9 7.93±0.39 7.79±0.39 0.34
SRC 7.20±0.37 7.06±0.55 0.40
GH 8.02±2.14 7.27±1.96 0.31
XCL1 4.77±0.52 4.79±0.49 0.92
FGF-23 4.02±1.77 2.84±0.63 0.025
CCL17 8.74±1.14 8.57±1.26 0.70
IL-18 8.59±0.58 8.36±0.46 0.21
BMP-6 5.23±0.60 4.80±0.77 0.091
IL-6 6.00±1.86 4.89±1.37 0.062
AMBP 6.00±0.22 5.90±0.23 0.26
CD40-L 7.28±1.41 6.28±1.44 0.058
NPX: Normalized Protein eXpression. aPatient-level mean value±standard deviation. Blood samples ≤30 days after the index ACS 
were available for 15 ≤30 days cases and 17 >30 days cases.
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Discussion
Serum levels of ANG-1, PAR-1 and BMP-6 were significantly higher in patients who 
developed a recurrent coronary event within the first 30 days following an ACS than in their 
matching controls. In the time period >30 days after the index-ACS until 1 year follow-
up, patients with and without a recurrent coronary event had similar patterns of MAPK 
stimulating biomarkers. 
  Our study results suggest that during the first 30 days post-ACS, the initial ACS induces 
numerous stimuli that activate the intracellular MAPK-cascade, which, in turn, may induce 
a pro-inflammatory and thrombogenic state, leading to a recurrent event. Potentially, other 
processes play a more important role in the initiation of a new coronary event following 
stabilization after the first 30 days post-ACS.
  PAR-1 is a receptor expressed by cardiomyocytes, fibroblasts, smooth muscle cells and 
vascular endothelial wall cells [8]. Basic scientific research showed that PAR-1 may stimulate 
pathological remodeling after cardiac ischemia/reperfusion injury [8,9]. Moreover, PAR-1 
is involved in hemostasis and thrombosis [8,10,11]. PAR-1 modulates thrombin signaling and 
is expressed on platelets, and may activate platelet secretion and aggregation. Local tissue 
injury of the vascular endothelial wall might induce endothelial responses via PAR-1, like 
recruitment of leukocytes and platelets, to manage infection or damage [11]. Accordingly, 
higher PAR-1 serum levels during the first 30 days following an ACS, might play a role 
in pathological remodeling after an ACS, and may lead to the development of (platelet-
dependent) arterial thrombosis, and thus the recurrence of a coronary event.
  BMP-6 is part of the transforming growth factor β family of cytokines. BMP-6 is 
involved in activation of osteogenic markers in mesenchymal stem cells, and may modulate 
ectopic cartilage and bone matrix formation [12]. Bone matrix formation is one of the key 
processes responsible for vascular calcification [13]. Since BMPs are overexpressed in 
(vulnerable) atherosclerotic lesions, it is suggested that BMPs modulate vascular calcification 
[14]. Furthermore, it is observed that BMPs contribute to vascular inflammation [14-16]. Lastly, 
previous research has indicated that oxidative stress may induce BMP-6 expression and 
thereby vascular inflammation and calcification [12]. Thus, it could be hypothesized that post-
ACS oxidative stress may induce higher BMP-6 serum levels, which - in turn - might induce 
vascular inflammation and a recurrent coronary event. 
  ANG-1 is a widely expressed biomarker and is involved in multiple cellular processes 
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that occur following an ACS [17-19]. ANG-1 modulates endothelial cell survival, proliferation, 
migration and reorganization. Furthermore, it promotes angiogenesis and vascular quiescence. 
However, in the absence of vascular endothelial growth factor (VEGF) exposure, ANG-1 
may promote vessel regression [18].
  To the contrast of our study, previous research indicated that ANG-1 positively 
modulates cardiovascular disease, and promotes cardiomyocyte survival and reduces infarct 
size [20-22]. Furthermore, one study showed that a lower serum level of ANG-1 on admission 
date, significantly predicted the development of one-year major cardiovascular events in 
post-ACS patients [21].
  Despite the complexity of the process, it is of interest to study blood biomarkers that 
stimulate the intracellular MAPK-cascade, since they may serve as novel biomarkers for 
aggravation of CVD. Because of the exploratory character of this study, our study results are 
limited to the examination of divergent biomarker patterns and thus, primarily, are valuable 
for exploration and identification of (novel) protein blood biomarkers. Further research is 
needed to establish whether the studied protein blood biomarkers may actually be used to 
identify post-ACS patients who are at higher risk of developing a recurrent
coronary event.
Limitations
Since we chose to use Olinks’ Proteomics PEA high throughput analysis to efficiently analyze 
our samples for potential discovery of novel protein blood biomarkers, our study results 
lack generalizability because of the use of arbitrary units. In addition, although Olinks’ 
Proteomics PEA is an assay that gives highly reproducible results [23]. PEA technique still 
needs improvements to assure complete reproducibility. Lastly, because of the small number 
of events in our study, differences between cases and controls may have been masked.
Conclusion
In conclusion, the serum levels of ANG-1, PAR-1 and BMP-6, all biomarkers that stimulate 
the MAPK-cascade, were significantly elevated in patients with ACS who developed an early 
recurrent coronary event. These signaling proteins warrant further study on their potential use 
as novel biomarkers to identify high risk post-ACS patients.
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Abstract
Rationale: Conflicting results exist regarding the association between a common Haptoglobin 
(Hp) polymorphism and risk of coronary artery disease. We investigated the association of 
three functionally different anti-oxidant and anti-inflammatory Hp phenotypes (Hp1-1, Hp2-
1, Hp2-2) with invasively measured degree and composition of coronary atherosclerosis as 
determined by intravascular ultrasound(-virtual histology) (IVUS(-VH)) as well as near-
infrared spectroscopy (NIRS).         
Methods & Results: Non-culprit coronary artery segments of 581 patients with acute 
coronary syndrome (ACS) or stable angina pectoris were imaged with IVUS(-VH). In 203 
patients, the segments were also imaged with NIRS. Pre-procedural blood samples were 
drawn for Hp phenotyping. Degree (segment plaque volume, segment plaque burden (PB); 
presence of lesions with PB≥70%) and composition (segment fractions of fibrous, fibro-fatty, 
dense calcium, and necrotic core tissue; presence of IVUS-VH derived thin-cap fibroatheroma 
lesions) of coronary atherosclerosis were measured. No differences were present between 
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the three Hp phenotypes with regard to degree and composition of coronary atherosclerosis 
in the full cohort. However, ACS patients with a Hp2-1 or Hp2-2 phenotype had a higher 
segment PB percentage (β (95% CI): 3.88 (0.31 – 7.44), p=0.033), increased prevalence of 
lesions with PB≥70% (OR (95% CI): 3.61 (1.06 – 12.30), p=0.040), and a tendency towards 
a higher segment plaque volume (β (95% CI): 1.29 (-0.04 – 2.62), p=0.056) in multivariable 
analyses. 
Conclusions: Although in the full cohort no associations could be demonstrated between 
Hp phenotypes and plaque characteristics, a significant association was present between 
phenotypes resulting from a genotype containing a Hp2 allele (Hp2-1 or Hp2-2) and a higher 
degree of atherosclerosis in patients with ACS. 
Introduction
Circulating haptoglobin (Hp) is hypothesized to influence atherosclerosis through its anti-
oxidant and immunomodulatory properties. Specifically, it prevents hemoglobin-driven 
oxidative reactions in response to intraplaque hemorrhage, and stimulates a variety of pro- 
and anti-inflammatory cytokines [1, 2]. The Hp gene carries a common polymorphism with two 
alleles (Hp1 and Hp2), resulting in three functionally-different phenotypes, each characterized 
by a unique protein structure: Hp1-1 (wildtype genotype; dimer), Hp2-1 (heterozygous variant; 
linear polymer) and Hp2-2 (homozygous variant; cyclic polymer) [2]. The homozygous variant 
Hp2-2 produces a dysfunctional protein with the lowest anti-oxidant and anti-inflammatory 
properties as compared to the proteins encoded by Hp2-1 or Hp1-1 [1, 2]. 
  Although the molecular functions of these proteins in the vascular wall have been 
well investigated and seem to be clear, clinical studies on the association of Hp phenotypes 
with coronary events have rendered conflicting results [3, 4]. In order to further increase 
understanding of the pathophysiological relation between Hp phenotypes and coronary 
atherosclerosis, imaging studies using coronary angiography and CT angiography have been 
performed. However, these have not been able to further elucidate potential mechanisms 
[5, 6]. The imaging techniques used in these studies only enable evaluation of the lumen of 
the coronary artery. Conversely, radiofrequency intravascular ultrasound (IVUS) and near-
infrared spectroscopy (NIRS) enable evaluation and quantification of the arterial wall itself. 
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However, studies on Hp phenotype and invasively-measured coronary atherosclerotic plaque 
characteristics by IVUS or NIRS are currently lacking. 
  In the current study, we investigated the relation between Hp phenotype and in-vivo 
measurements of degree and composition of coronary atherosclerosis by IVUS and NIRS 
in 581 patients undergoing coronary angiography. Herewith, we aimed to provide additional 
insights into the pathophysiology concerning Hp and coronary atherosclerosis.
Methods
The rationale and design of the ATHEROREMO-IVUS study and its ATHEROREMO-
NIRS substudy have been described in detail elsewhere [7-9]. These studies were approved 
by the medical ethics committee of the Erasmus MC and performed in accordance with the 
declaration of Helsinki. All included patients provided written informed consent. 
  In brief, 581 patients with an indication for coronary angiography due to stable angina 
pectoris (SAP) or acute coronary syndrome (ACS) underwent IVUS imaging of a non-
stenotic segment of at least 40mm in length in a predefined non-culprit coronary artery 
with the Volcano™ s5/s5i Imaging System (Volcano Corp., San Diego, USA), using the 
Volcano™ Eagle Eye Gold IVUS catheter (20MHz) [7]. The order of preference for selection 
of the non-culprit coronary artery segment was: 1. Left anterior descending artery; 2. Right 
coronary artery; 3. Left circumflex artery. An automatic pullback system was used with a 
standard pull back speed of 0.5mm per second. Both IVUS grayscale and virtual histology 
(IVUS-VH) analyses were performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, 
USA) software. The external elastic membrane and luminal borders were contoured for 
each frame (median interslice distance, 0.40mm). The degree and composition of each 
atherosclerotic plaque were assessed. Plaque volume (mm3) was defined as the total volume 
of the external elastic membrane occupied by atheroma and normalized for the length of the 
imaged segment. Plaque burden (%) was defined as plaque and media cross-sectional area 
divided by external elastic membrane cross-sectional area and is presented as a percentage. 
Atherosclerotic plaque composition was characterized into fibrous (FI), fibro-fatty (FF), 
dense calcium (DC) and necrotic core (NC) tissue and expressed as percentages of total 
plaque volume. Three types of high-risk lesions were identified: 1. Virtual Histology-IVUS 
derived thin-cap fibroatheroma (VH-TCFA) lesions (presence of >10% confluent necrotic 
- 276 -
PART III
core in direct contact with the lumen); 2. Lesions with plaque burden ≥70%; 3. Lesions with 
a minimal luminal area ≤4.0 mm2. Hp phenotypes were successfully determined in 574 of 
the patients who underwent IVUS(-VH) imaging (Figure 1). NIRS (InfraReDx, Burlington, 
Massachusetts, USA) of the same segment was performed in a subset of 191 patients, as well 
as 12 additional patients that only underwent NIRS, not IVUS [7, 9] (Figure 1). The U.S. Food 
and Drug Administration-approved NIRS system, as used in this study, consisted of a 3.2-F 
rapid exchange catheter, a pullback and rotation device. Image acquisition was performed by 
a motorized catheter pullback at a speed of 0.5mm per second and 240 rotations per minute. 
The Lipid Core Burden Index (LCBI) score was measured and represents the amount of lipid 
core in the imaged segment on a 0-to-1000 scale, as described previously [9]. Both IVUS 
and NIRS images were analyzed off-line by an independent core laboratory (Cardialysis 
BV, Rotterdam, the Netherlands), by personnel blinded for baseline patient characteristics 
and Hp phenotypes. Two-hundred of the 203 patients who underwent NIRS imaging, were 
successfully phenotyped, resulting in a total of 585 successfully phenotyped and imaged 
patients for the current investigation (Figure 1). 
  EDTA plasma samples were drawn from the arterial sheath prior to coronary angiography 
and transported to the clinical laboratory of the Erasmus MC for further processing and 
storage at a temperature of -80°C within two hours after blood collection. After completion of 
the cohort, all frozen EDTA-plasma samples were transported under controlled conditions (at 
a temperature of -80°C) to the Laboratory of Experimental Cardiology, University Medical 
Center Utrecht, Utrecht, The Netherlands, where Hp phenotypes were differentiated through 
western blotting. 
  The primary endpoint consisted of major adverse cardiovascular events (MACE), and was 
defined as a composite of all-cause mortality, ACS, and unplanned coronary revascularization. 
The secondary endpoint consisted of the composite of all-cause mortality and ACS.  ACS 
was defined as the clinical diagnosis of (non-)ST-segment elevation myocardial infarction 
or unstable angina pectoris [10, 11]. Unplanned coronary revascularization was defined as any 
repeat PCI or coronary artery bypass grafting that was not foreseen at the index procedure. 
Follow-up data were collected during 1 year. Vital status was obtained from municipal 
civil registries and questionnaires were sent focusing on the occurrence of MACE to all 
living patients (response rate of 92.3%). Upon patients’ approval, additional information 
was obtained from hospital discharge letters and treating physicians whenever necessary. 
Endpoints were adjudicated based on original source data by a clinical events committee. 
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Figure 1. Flowchart patient inclusion in the ATHEROREMO-IVUS study, ATHEROREMO-NIRS substudy 
and ATHEROREMO Haptoglobin phenotype substudy.
ACS=acute coronary syndrome; Hp=Haptoglobin; IVUS(-VH)=intravascular ultrasound(-virtual histology); NIRS=near-infrared 
spectroscopy.
Variables with a non-normal distribution were transformed by using either the natural 
logarithm (ln) or square root for further analyses. Univariate analyses were performed by 
ANOVA or Student’s t-test for continuous variables and Chi-squared test for categorical 
variables, comparing the phenotypes. Multivariate linear and logistic regression analyses 
were performed with Hp phenotype as the independent variable and with adjustment for the 
potential confounders age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia 
and previous myocardial infarction. Interaction terms were used to test for effect modification 
by indication for angiography (ACS versus SAP). Subsequently, analyses were stratified on 
indication. Since ACS subgroup analysis showed (VH-)IVUS values of similar magnitude 
in the Hp2-1 and Hp2-2 groups, a post-hoc analysis was performed comparing ACS patients 
with wildtype Hp1-1 versus a pooled group with the variant phenotypes Hp2-1 and Hp2-2. 
Furthermore, a subgroup analysis was performed in diabetic patients (n=99). Finally, the 
association between Hp phenotype and clinical endpoints after 1 year of follow-up was 
examined with Cox proportional hazard regression analyses. 
  All data were analyzed with SPSS software (IBM SPSS Statistics for Windows, 
Version 23, Armonk, NY, USA). All statistical tests were two-tailed and p-values <0.05 were 
considered statistically significant.
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Results
Baseline characteristics
Baseline clinical and procedural characteristics of the 3 phenotype groups are presented 
in Table 1. Prevalence of phenotype Hp1-1, Hp2-1 and Hp2-2 was 16.1% (n=94), 45.5% 
(n=266), and 38.5% (n=225), respectively, and this distribution was in Hardy-Weinberg 
equilibrium (p=0.67). Mean age±standard deviation was 61.9±12.6, 62.4±10.7 and 
60.0±11.4 years, respectively (p=0.07). Except for history of myocardial infarction, there 
were no differences in clinical or procedural characteristics across the various phenotypes. 
As expected, circulating plasma haptoglobin concentration was lowest for Hp1-1 and highest 
for Hp2-2 (p=<0.001, Table 1). 
Table 1. Baseline clinical and procedural characteristics of the Haptoglobin phenotype groups in the full 
cohort (n = 585).
Haptoglobin 1-1
(n = 94)
Haptoglobin 1-2
(n = 266)
Haptoglobin 2-2
(n = 225) P-value
a
Clinical characteristics
Age, years 61.9 ± 12.6 62.4 ± 10.7 60.0 ± 11.4 0.07
Male gender, n (%) 69 (73.4) 200 (75.2) 173 (76.9) 0.79
Diabetes mellitus, n (%) 11 (11.7) 46 (17.3) 43 (19.1) 0.28
Hypertension, n (%) 48 (51.1) 138 (51.9) 118 (52.7) 0.96
Dyslipidemia, n (%) 45 (47.9) 154 (57.9) 126 (56.3) 0.24
Smoking, n (%) 25 (26.6) 83 (31.2) 63 (28.0) 0.61
Positive family history, n (%) 58 (61.7) 139 (52.3) 110 (49.1) 0.12
Peripheral artery disease, n (%) 4 (4.3) 18 (6.8) 14 (6.2) 0.68
Previous myocardial infarction, n (%) 24 (25.5) 98 (36.8) 64 (28.4) 0.050
Previous PCI, n (%) 26 (27.7) 91 (34.2) 73 (32.4) 0.51
Previous CABG, n (%) 3 (3.2) 9 (3.4) 7 (3.1) 0.99
Previous stroke, n(%) 3 (3.2) 12 (4.5) 10 (4.4) 0.85
History of renal insufficiency, n (%) 4 (4.3) 21 (7.9) 8 (3.6) 0.10
Haptoglobin level, mg/ml 0.79 [0.58 – 0.99] 1.53 [1.10 – 2.20] 1.60 [1.10 – 2.30] <0.001
Procedural characteristics
Indication for coronary angiography
Acute coronary syndrome, n (%) 49 (52.1) 144 (54.1) 127 (56.4) 0.76
Stable angina pectoris, n (%) 45 (47.9) 122 (45.9) 98 (43.6) 0.76
Coronary artery disease
No significant stenosis, n (%) 4 (4.3) 17 (6.4) 22 (9.8) 0.16
1-vessel disease, n (%) 57 (60.6) 138 (51.9) 117 (52.0) 0.30
2-vessel disease, n (%) 26 (27.7) 82 (30.8) 60 (26.7) 0.58
3-vessel disease, n (%) 7 (7.4) 29 (10.9) 26 (11.6) 0.54
PCI performed 86 (91.5) 233 (87.6) 195 (86.7) 0.48
PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft surgery. Continuous variables are presented as 
mean ± SD or median [interquartile range], depending on their distribution. Categorical variables are presented as n (%). aP-values 
obtained by ANOVA for the continuous variables and Chi-squared test for the categorical variables.
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Degree and composition of coronary atherosclerosis
No differences could be demonstrated between the different phenotypes with regard to the 
degree and composition of atherosclerosis as assessed by IVUS-VH or NIRS (Table 2). The 
same could be concluded for the subgroup analysis of diabetic patients (n=99, data not shown). 
Table 2. NIRS and (VH-)IVUS segment and lesion characteristics of the Haptoglobin phenotype groups in 
the full cohort (n = 585). 
Haptoglobin 1-1
(n = 94)
Haptoglobin 2-1
(n = 266)
Haptoglobin 2-2
(n = 225) P-value
c
Segment plaque characteristicsa
Degree of atherosclerosis
Plaque volume, mm3 240.7 [118.5 – 313.4] 235.1 [150.8 – 332.9] 216.0 [147.6 – 323.3] 0.94
Plaque burden, % 37.4 ± 12.1 38.3 ± 11.6 38.4 ± 11.1 0.80
Plaque composition 
Fibrous percentage 57.6 ± 12.0 57.4 ± 11.4 58.2 ± 11.7 0.74
Fibro-fatty percentage 9.1 [5.9 – 12.4] 9.2 [5.9 – 13.3] 8.4 [5.3 – 11.9] 0.19
Necrotic core percentage 21.7 ± 8.1 21.0 ± 8.3 21.8 ± 7.7 0.57
Dense calcium percentage 9.5 [5.3 – 14.4] 9.5 [5.4 – 15.3] 9.1 [4.9 – 15.1] 0.92
Lipid Core Burden Index (LCBI)b 47.5 [9.0 – 93.5] 40.5 [16.0 – 85.8] 40.0 [13.3 – 80.8] 0.82
Lesion plaque characteristicsa
Degree of atherosclerosis
≥1 Lesion with PB ≥70%, n (%) 18 (20.2) 54 (20.5) 51 (23.2) 0.74
≥1 Lesion with MLA ≤4.0mm2, n (%) 29 (32.6) 83 (31.7) 68 (30.9) 0.96
Plaque composition
≥1 TCFA, n (%) 43 (48.3) 106 (40.3) 91 (41.2) 0.40
PB=plaque burden; MLA=minimal lumen area; TCFA=thin-cap fibroatheroma. Continuous variables are presented as mean ± SD 
or median [interquartile range], depending on their distribution. Categorical variables are presented as n (%). aIVUS-VH imaging 
was performed in 574 patients. bNIRS imaging was performed in a subset of 200 patients. cP-values obtained by ANOVA for the 
continuous variables and Chi-squared test for the categorical variables.
Significant interactions were present between Hp phenotype and indication for angiography 
(ACS versus SAP) for the association with plaque volume, plaque burden, FI tissue percentage 
and lesions with PB≥70% (p-values for interaction all <0.05 in uni- and multivariate analysis). 
In line with this, in ACS patients, phenotypes resulting from a genotype containing a Hp2 
allele (Hp2-1 or Hp2-2) were significantly associated with a higher plaque volume (p=0.031) 
in univariate analysis and tended to be associated with a higher plaque volume in multivariate 
analysis (β (95% CI): 1.29 (-0.04 – 2.62) mm3 increase in (square root transformed) plaque 
volume for having Hp2-1 or Hp2-2 as compared to Hp1-1, p=0.056) (Table 3, Figure 2). 
Moreover, in ACS patients these phenotypes were independently associated with a larger 
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plaque burden (β (95% CI): 3.88 (0.31 – 7.44) % increase in PB for having Hp2-1 or Hp2-2 
as compared to Hp1-1, p=0.033) (Table 3, Figure 3), as well as an increased prevalence of 
lesions with PB≥70% (OR (95%CI): 3.61 (1.06 – 12.30), p=0.040) (Table 3, Figure 4). With 
respect to atherosclerotic plaque composition, no associations were present with the various 
VH-tissue types, LCBI or VH-TCFA lesions in ACS patients (Table 3). 
Table 3. NIRS and (VH)-IVUS segment and lesion characteristics of the Haptoglobin phenotype groups in 
patients with ACS (n = 320). 
Haptoglobin 1-1
(n = 49)
Haptoglobin 2-1 
or 2-2
(n = 271)
P-valuec β (95% CI) P-valued
Haptoglobin level, mg/ml 0.84 [0.63 – 1.10] 1.60 [1.10 – 2.50] <0.001 0.65 (0.45 – 0.85) <0.001
Segment plaque characteristicsa
Degree of atherosclerosis
Plaque volume, mm3 173.5 [107.3 – 303.1] 215.5 [141.2 – 304.2] 0.031 1.29 (-0.04 – 2.62) 0.056
Plaque burden, % 32.9 ± 10.6 37.6 ± 11.8 0.014 3.88 (0.31 – 7.44) 0.033
Plaque composition 
Fibrous percentage 61.4 ± 11.2 58.5 ± 12.0 0.13 -2.99 (-6.80 – 0.83) 0.12
Fibro-fatty percentage 8.6 [4.6 – 12.0] 8.6 [5.5 – 12.0] 0.35 0.18 (-0.14 – 0.51) 0.26
Necrotic core percentage 21.2 ± 8.3 21.8 ± 8.6 0.68 0.43 (-2.37 – 3.22) 0.76
Dense calcium percentage 6.7 [4.9 – 11.3] 8.3 [4.9 – 13.8] 0.28 0.21 (-0.17 – 0.58) 0.28
Lipid Core Burden Index (LCBI)b 48.0 [6.0 – 91.0] 44.5 [16.0 – 88.0] 0.53 0.03 (-0.71 – 0.77) 0.93
Lesion plaque characteristicsa P-valuec OR (95% CI) P-valued
Degree of atherosclerosis
≥1 Lesion with PB≥70%, n (%) 3 (6.7) 56 (21.0) 0.023 3.61 (1.06 – 12.30) 0.040
≥1 Lesion with MLA ≤4.0mm2, n (%) 11 (24.4) 80 (30.1) 0.44 1.30 (0.61 – 2.70) 0.51
Plaque composition
≥1 TCFA, n (%) 22 (48.9) 119 (44.6) 0.59 0.78 (0.41 – 1.51) 0.46
Continuous variables are presented as mean ± SD or median [interquartile range], depending on the distribution. Categorical variables 
are presented as n (%).  Beta (β) indicates the increase or decrease (minus sign) in each (transformed) imaging segment parameter 
for the Haptoglobin 2-1 or 2-2 ACS patients as compared to Haptoglobin 1-1 ACS patients. Odds ratio (OR) increase in each lesion 
parameter for the Haptoglobin 2-1 or 2-2 ACS patients as compared to Haptoglobin 1-1 ACS patients. aIVUS-VH imaging was 
performed in 313 ACS patients. bNIRS imaging was performed in a subset of 93 ACS patients. cP-values (univariate) obtained 
by the independent Student’s two-sample t-test for the continuous variables and Chi-squared test for the categorical variables. dP-
values (multivariate) obtained by linear regression analyses for continuous variables and logistic regression analyses for categorical 
variables with Haptoglobin 1-1 as the reference category. Models adjusted for age, gender, smoking, diabetes mellitus, hypertension, 
dyslipidemia and previous myocardial infarction.
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Figure 2. Segment plaque volume in the Haptoglobin phenotypes within the full cohort and within the ACS 
subgroup. 
ACS=acute coronary syndrome; Hp=Haptoglobin.
* P-value for difference in segment plaque volume between Hp2-1 or Hp2-2 as compared to Hp1-1 within the ACS subgroup. 
Adjusted for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial infarction.
Figure 3. Segment plaque burden in the Haptoglobin phenotypes within the full cohort and ACS subgroup.
ACS=acute coronary syndrome; Hp=Haptoglobin.
* P-value for difference in segment plaque burden between Hp2-1 or Hp2-2 as compared to Hp1-1 within the ACS subgroup. 
Adjusted for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial infarction.
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Figure 4. Presence of large lesions in the Haptoglobin phenotypes within the full cohort and ACS subgroup.
ACS=acute coronary syndrome; Hp=Haptoglobin.
* P-value for difference in presence of large lesions between Hp2-1 or Hp2-2 as compared to Hp1-1
within the ACS subgroup. Adjusted for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial 
infarction.
 
Clinical endpoints 
With regard to clinical outcome, associations between Hp phenotype and 1-year cardiovascular 
outcome could not be demonstrated, both in the full cohort and in the ACS and diabetes 
subgroups. In particular, the Hp phenotypes were not associated with the occurrence of 
MACE (primary composite endpoint) on multivariate analysis: HR (95% CI) 0.88 (0.52 – 
1.49) for Hp2-1 and 0.97 (0.57 – 1.67) for Hp2-2 in the full cohort; HR (95% CI) 0.77 (0.38 
– 1.56) for Hp2-1 and 0.70 (0.33 – 1.49) for Hp2-2 in the ACS subgroup; HR (95% CI) 0.91 
(0.30 – 2.82) for Hp2-1 and 0.94 (0.30 – 3.02) for Hp2-2 in the diabetic subgroup.
- 283 -
13
PART III
13
Discussion
To our knowledge, this is the first study that investigated the relation between Hp phenotypes 
and coronary plaque characteristics as assessed with IVUS-VH and NIRS in patients with 
CAD. Although no associations could be demonstrated between Hp phenotypes and coronary 
plaque characteristics in the full cohort, in ACS patients phenotypes Hp2-1 and Hp2-2 were 
significantly associated with a higher degree of coronary atherosclerosis as expressed by 
higher segment plaque burden and higher prevalence of lesions with PB≥70%, as compared 
to Hp1-1. 
  Existing imaging studies on Hp phenotype and atherosclerosis as assessed with either 
coronary angiography or CT angiography are limited in number and were mainly performed 
in specifically defined study populations, such as patients with diabetes mellitus [5, 6, 12, 13]. 
Overall, these studies did not find any associations between Hp phenotype and coronary 
atherosclerosis [5, 6, 12, 13]. The interaction between Hp phenotype and acute versus stable 
clinical presentation of CAD has not been investigated earlier. A potential, biologically 
plausible explanation for this interaction could be that patients who ultimately experience 
ACS represent a subgroup that exhibits an increased  pro-inflammatory [14] and oxidative 
state [15-17] as compared to SAP patients. In these patients, elevated oxidative stress may not 
only be present systemically [15, 16] but also locally at the level of the atherosclerotic plaque, 
as part of the pathogenesis and evolution towards an ACS. The latter results, among others, 
from intraplaque hemorrhage, which occurs more often in ACS than in SAP patients, and 
gives rise to a local release of hemoglobin (iron) into the atherosclerotic plaque [18]. Such 
a state leads, among several other reactions, to local generation of reactive oxygen species 
and consequently lipid peroxidation [15], which eventually may contribute to accelerated 
atherosclerotic plaque growth [15, 19] in these patients. This process may be further enhanced in 
Hp2 phenotypes (Hp2-1 and Hp2-2) due to their reduced anti-oxidant and anti-inflammatory 
properties as compared to Hp1-1 [1, 2]. A previous study in mice supports this hypothesis by 
demonstrating increased iron, lipid peroxidation and macrophage accumulation in Hp2-2 
atherosclerotic plaques as compared with Hp1-1 plaques [20]. This was confirmed in humans 
by autopsy studies that have demonstrated more advanced atherosclerotic plaques in Hp2-
2 compared to Hp1-1 individuals [21]. In contrast to Hp1-1 proteins, the Hp2-1 and Hp 2-2 
proteins have low affinity for both hemoglobin and the macrophage CD163 scavenger 
receptor in order to clear hemoglobin (iron) from the atherosclerotic plaque and prevent its 
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harmful intraplaque oxidative reactions [2, 22]. Altogether, these studies indicate that oxidative 
stress might strongly be implicated in the atherosclerotic process with a critical role for Hp 
proteins in its further development. 
  In a previous study within the same cohort, we could not demonstrate an association 
between plasma Hp concentration and (VH-)IVUS plaque characteristics or clinical events 
[8]. Although the biological function of Hp in the vascular wall might not directly depend on 
its plasma concentrations, but rather on its protein structure, there is a direct correlation of Hp 
phenotype with Hp plasma concentrations. Specifically, Hp concentration is higher in Hp2-2 
than in Hp1-1 individuals, because of the weaker binding of Hp2-2 proteins to hemoglobin 
and the macrophage CD163 receptor [22]. Thus, since Hp concentrations may at least in part 
be phenotype-dependent, these negative results seem consistent with our current findings.
  Epidemiologic studies investigating the association between Hp phenotype and incidence 
of CAD in the general population are limited in number and have yielded contradicting results. 
While De Baquer et al found that Hp1-1 individuals were at higher risk of CAD mortality as 
compared to the other Hp phenotypes [3], the Framingham Heart Offspring Study (n=3273) 
could not demonstrate any relationship between Hp phenotype and CAD prevalence in the 
overall study population [4]. 
  The majority of clinical studies concerning Hp phenotypes has focused on diabetic 
individuals, since strong evidence exists that Hp phenotype and diabetic state significantly 
interact with regard to prevalence of CAD. It has been demonstrated that Hp2-2 individuals 
with diabetes have a higher risk of adverse cardiovascular outcomes as compared to the other 
phenotypes [4, 23-27], which is thought to be caused by the decreased anti-oxidant capabilities 
of the Hp2-2 protein in conjunction with an exceptionally high level of oxidative stress in 
diabetes [28, 29]. However, some other studies could not confirm these findings [30], or even 
rendered contradictory results [4]. We also could not demonstrate any associations with in-
vivo coronary plaque characteristics or 1-year clinical outcome in diabetic patients. Our 
findings are in agreement with a study in type 2 diabetic patients, that could not demonstrate 
an association between Hp genotype and coronary artery calcification (CAC) as a reflection 
of total coronary atherosclerotic burden [5]. On the other hand, a larger case-control study on 
type 1 diabetic patients found that the Hp2-2 genotype was a predictor of CAC progression. 
The limited number of diabetic participants (n=99) in our cohort may have contributed to the 
lack of such an association in our study.
  Our study has several limitations that warrant acknowledgement. Firstly, our findings in 
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the ACS subgroup should be considered as hypothesis-generating, because the comparison 
of Hp2-2 and Hp2-1 on the one hand with Hp1-1 on the other hand in the ACS patients was a 
post-hoc analysis. Nevertheless, the interaction terms between Hp phenotypes and indication 
for catheterization were highly significant in multivariate analyses. Secondly, IVUS(-VH) 
imaging took place of a non-culprit coronary artery segment only. However, this approach 
was developed under the hypothesis that such a non-culprit target segment adequately 
reflects coronary wall pathophysiology of the larger coronary tree, and this hypothesis has 
been confirmed by several studies [31, 32]. Finally, this study was not primarily designed to 
investigate the association between Hp phenotypes and atherosclerosis and clinical outcome 
in diabetic patients. A small number of diabetic patients in this study may have contributed 
to the lack of significant associations between Hp phenotypes and degree and composition of 
atherosclerosis in this subgroup. 
  In conclusion, in patients undergoing coronary angiography, no associations were 
present between Hp phenotypes and invasively-measured coronary atherosclerotic plaque 
characteristics by IVUS and NIRS. However, patients with Hp2-1 or Hp2-2 presenting 
with ACS had a significantly higher degree of coronary atherosclerosis as compared to 
Hp1-1. Thus, genetic differences in the endogenous anti-oxidant status, as reflected by the 
haptoglobin phenotype, may be of considerable importance in patients suffering from CAD. 
Our hypothesis-generating findings should be confirmed by other, large studies in order to 
identify patient groups that might benefit from risk stratification by Hp phenotyping in the 
future.  
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Discussion and Summary
PART IV

General discussion 
and summary14
Recurrent adverse cardiovascular events still occur in a substantial proportion of coronary 
artery disease (CAD) patients, despite enhanced technology and augmented treatment 
options. The need for improved risk prediction in patients with CAD has therefore been the 
main drive for this thesis. By expanding our knowledge on blood biomarkers and genetic 
polymorphisms that may play a part in the pathophysiology of CAD, a road to the future of 
optimal risk stratification in patients with established CAD is created. In the present chapter, 
the main findings of this thesis are summarized and placed into a broader context.       
1. Better understanding of human coronary atherosclerosis by linking blood biomarkers 
to intracoronary imaging. 
In the first part of this thesis, biological processes that might be linked to atherosclerosis 
are studied in relation to coronary atherosclerosis by means of intracoronary imaging 
within the European Collaborative Project on Inflammation and Vascular Wall Remodeling 
in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study. The 
characteristics of each atherosclerotic plaque in a non-culprit artery were studied in 581 
patients with stable angina pectoris (SAP) or acute coronary syndrome (ACS), who were 
admitted for coronary angiography. By using virtual-histology intravascular ultrasound 
(VH-IVUS) the extensiveness, composition and vulnerability of coronary plaques were 
assessed of either a segment or lesion. The extent / degree of coronary atherosclerosis was 
determined by measuring plaque burden, plaque volume, minimal luminal area in segments 
and the occurrence of lesions with ≥70% plaque burden or ≤4.0mm2 minimal lumen area. 
The composition / phenotype of the atherosclerotic plaque was assessed by identifying 
plaque components as dense calcium, necrotic core, fibro-fatty and fibrous tissue. The 
vulnerability was characterized by the presence of VH-IVUS derived thin-cap fibroatheroma 
(TCFA) lesions. Additionally, patients’ clinical information was collected and pre-procedural 
blood samples were drawn for biomarker determination. By collecting these data from 
various sources we aim to improve our understanding on the role of external influences and 
circulating biomarkers in the development of (vulnerable) coronary atherosclerotic plaques. 
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Furthermore, clinical follow-up of these patients from inclusion until 1 year was performed 
to explore the prognostic value of (novel) circulating biomarkers in predicting recurrent 
adverse events.     
  In Chapter 2 the relationship between cigarette smoking and coronary atherosclerosis 
is described. With regard to degree of atherosclerosis, current smokers had slightly higher 
coronary plaque burden than never smokers, especially in patients presenting with ACS. With 
respect to plaque composition, fibro-fatty tissue was the prevailing compound in the coronary 
arteries of cigarette smokers. Lastly, cigarette smoking was not associated with coronary 
plaque vulnerability. Lack of such an association may in part be explained by the possibility 
that rather plaque erosion than vulnerable plaque rupture is the underlying mechanism for 
coronary events in smoking CAD patients, as suggested by earlier, histopathological studies. 
Although sufficient evidence is available demonstrating that smoking directly impacts 
multiple aspects in atherosclerosis, less is currently known about the associations of smoking 
and the in-vivo plaque structure within the coronary artery itself. Altogether, these findings 
modestly contribute towards a better understanding of the complex pathophysiologic 
relationship between cigarette smoke exposure and CAD.            
  Chapter 3 highlights fibrinogen as a biomarker of interest in coronary atherosclerosis 
to provide additional insight into the nature of relationship with CAD. The association of 
plasma fibrinogen with extent, composition and vulnerability of coronary atherosclerosis, as 
well as with 1-year cardiovascular outcome, was investigated. Higher circulating fibrinogen 
levels were associated - not independently of C-reactive protein (CRP) - with higher degree 
of coronary atherosclerotic plaque burden, particularly in patients presenting with ACS. 
Substantial associations of fibrinogen with coronary plaque composition, vulnerability and 
1-year cardiovascular outcome were absent. Overall, these results point towards involvement 
of fibrinogen in progression of coronary atherosclerotic plaque formation, especially in ACS 
patients, rather than in plaque vulnerability or clinical events directly.         
  In Chapter 4 the association between adiponectin and VH-IVUS coronary plaque 
characteristics, as well as 1-year cardiovascular outcome, was studied to further elucidate the 
pathophysiology of adiponectin in patients with established CAD. Adiponectin levels were 
associated with 1-year mortality, mainly in patients presenting with SAP. In SAP patients, 
adiponectin was associated with features of plaque vulnerability. The exact mechanism 
behind the positive association between adiponectin and coronary plaque (in)stability 
warrants further investigation specifically in SAP patients.        
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  Chapter 5 evaluates four circulating chemokines in relation to coronary atherosclerosis, 
as well as 1-year clinical outcome. Circulating regulated upon activation normal T-cell 
expressed and secreted (RANTES) was demonstrated to be a promising biomarker, that 
correlated with coronary plaque burden, vulnerability and cardiovascular outcome (in 
particular death and re-occurrence of ACS). 
  Chapter 6 describes the relationship between eight different circulating cytokines and 
coronary plaque characteristics assessed with VH-IVUS. Higher circulating tumor necrosis 
factor alpha (TNF-α, pro-inflammatory cytokine) was associated with higher coronary plaque 
burden and with plaque vulnerability in SAP patients; and lower circulating interleukin-10 
(IL-10, anti-inflammatory cytokine) in SAP and ACS patients. Furthermore, the relationship 
between the investigated cytokines and 1-year cardiovascular outcome has been investigated 
as well. However, none showed prognostic value for clinical outcome. Taken together, these 
results imply that the potential effect of TNF-α and IL-10 on coronary atherosclerosis cannot 
automatically be extrapolated to clinical outcome.  
  Chapter 7 focuses on two renal biomarkers in relation to coronary atherosclerosis and 
occurrence of 1-year recurrent clinical events. In patients with a normal renal function, plasma 
cystatin C (a glomerular marker) and plasma neutrophil gelatinase-associated lipocalin (a 
tubular marker) showed an inverse relationship with high-risk coronary lesions such as TCFA 
plaques and lesions with large plaque burden (>70%). However, in patients with an impaired 
renal function, these ‘protective’ effects were absent, leading to novel (pathophysiological) 
insights. Furthermore, only higher cystatin C levels in exclusively patients with renal 
dysfunction predicted 1-year adverse clinical events. In other words, cystatin C appears to 
carry most potential of the two renal biomarkers with regard to cardiovascular risk prediction, 
but only in patients with deteriorated kidney function.     
  In conclusion, the study of circulating biomarkers in relation to VH-IVUS derived coronary 
plaque characteristics resulted in distinct findings, which led to new pathophysiological 
insights and hypotheses. Also, the exploration of the biomarkers’ capability in predicting 
recurrent events showed that adiponectin, RANTES and cystatin C are promising in the 
road towards improving secondary cardiovascular risk prediction. Lastly, we have learned 
the importance of stratifying patients on treatment indication (ACS versus SAP) within the 
spectrum of CAD to account for their different pathophysiological entities.  
  When investigating the association between the aforementioned biomarkers and 
coronary plaque characteristics, it must be acknowledged that the ATHEROREMO-IVUS 
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study design does not permit causal inference. In this cross-sectional design both coronary 
plaque characteristics were measured and blood samples were drawn simultaneously. The 
possibility that the biomarkers may be the result of clinical presentation rather than its cause, 
cannot be excluded. Nevertheless, this study provides novel data on biomarkers in relation 
to in-vivo assessment of the coronary arterial wall (i.e. more accurate measures of coronary 
atherosclerosis) and have herewith resulted in new hypotheses complementary to existing 
studies investigating these associations. Thus, although causal inference is debatable, the 
generated data by this unique study may still be informative, since they provide additional 
insights into the complex pathophysiological relation between biomarkers and CAD.      
  Furthermore, in general it can be stated that the association between the biomarkers and 
1-year cardiovascular outcome was not substantial. This may have, in part, been caused by a 
limited number of clinical events, leading to a lack of statistical power to demonstrate strong 
associations. Another possible explanation may include the fact that the magnitude of effect 
of the investigated biomarkers separately is small in the context of this multifactorial disease. 
2. Towards enhanced risk stratification in established CAD by studying blood 
biomarker patterns in detail. 
In the second part of this thesis, the behavioral temporal pattern after an acute coronary 
syndrome admission of novel and established cardiovascular biomarkers is described during 
1-year follow-up. This has been performed within the BIOMarker study to identify Acute 
risk of a Coronary Syndrome (BIOMArCS) consisting of 844 patients, of whom frequently 
repeated blood sample measurements were drawn shortly after ACS admission until 1 year. 
Utilizing a high-frequency blood sampling design enables a unique insight in the value of 
these biomarkers for purposes of long-term secondary cardiovascular risk prediction.        
  Chapter 8 concentrates on growth differentiation factor-15 (GDF-15) patterns and 
individual variability in 111 ACS patients. Differences in temporal changes between patients 
with (cases) and without (controls) a recurrent event (composite of cardiovascular mortality, 
myocardial infarction or unstable angina pectoris requiring urgent coronary revascularization) 
during follow-up were of particular interest. It appeared that post ACS patients experiencing 
a recurrent event had systematically higher GDF-15 levels during 1-year follow-up than their 
event-free counterparts with otherwise similar clinical characteristics. Additionally, GDF-15 
showed low within-individual variability. Altogether, postdischarge blood sampling of GDF-
15 might be used throughout the course of 1 year to improve prognostication, whereas, in 
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view of the low within-individual variation, the number of repeated measurements might be 
limited.      
  In Chapter 9 the temporal evolution of established cardiovascular biomarkers (high-
density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, total cholesterol, 
cardiac Troponin T (TnT), NT-proBNP and CRP) in diabetic post ACS patients is studied 
with their respect to inter-ethnic differences. Thus far, most cardiovascular biomarkers have 
been merely validated in Caucasians, and little is known about their generalizability to other 
ethnic groups. Especially in Asia, where CAD now is an upcoming epidemic, the need for 
biomarker validation is warranted. Therefore, the 1-year trajectories following the index ACS 
event were displayed for each biomarker and compared between 48 Caucasian (Dutch) and 
48 clinically matched Chinese patients. The observational findings revealed that Caucasian 
patients persistently possessed higher levels of LDL, total cholesterol, triglycerides, TnT and 
CRP than Chinese patients. No differences in HDL and NT-proBNP were observed between 
the two cohorts. This exploratory analysis could give more insight into blood biomarker 
related differences among ethnic groups and underscores the fact that it may not be convenient 
to solely apply findings from most Western cohorts to Chinese individuals.  
  Chapter 10 examines the short- (<30 days) and long-term (30 days – 1 year) time 
course of protein blood biomarkers that stimulate the intracellular mitogen-activated protein 
kinase (MAPK) cascade in 135 post ACS patients. Temporal differences between patients 
with (cases) and without (controls) a recurrent event (composite of cardiovascular mortality, 
myocardial infarction or unstable angina pectoris requiring urgent coronary revascularization) 
were particularly investigated. Serum levels of angiopoietin-1 (ANG-1), protease-activated 
receptor-1 (PAR-1) and bone morphogenetic protein-6 (BMP-6) were significantly higher 
in patients developing a recurrent event than their matching controls, but only in the first 30 
days following ACS. Hence, prognostic abilities of these signaling proteins - that may serve 
as novel biomarkers in the field of CAD - should be further evaluated in the acute phase after 
ACS.              
 Concluding, the exploration of novel blood biomarkers reflecting relevant 
pathophysiological processes in CAD may lead to identification of markers that might be 
useful for risk prediction and even be of interest as therapeutic targets. In this respect, our 
investigation led to promising findings of GDF-15, ANG-1, PAR-1 and BMP-6 as the result 
of studying their detailed patterns over time. Also, relevant and sustainable differences have 
been discovered between Caucasian and Chinese patients for established cardiovascular 
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biomarkers, which emphasizes the need for an ethnicity-specific approach.         
  Temporal biomarker patterns have been compared between cases and controls according 
to a case-cohort design within BIOMArCS. For reasons of efficiency, biomarkers were 
determined in all cases who reached the study endpoint, but in a limited number of event-free 
patients. This analysis approach allows to reveal clinically relevant differences with sufficient 
statistical power in an efficient way. The strength of the BIOMArCS study lies in the fact 
that serial measurements have been obtained directly after an ACS (index event) and before 
an ACS (recurrent event), which enables accurate observations of alterations in biomarker 
patterns prior to an event. This is in contrast to previous studies with single measurements 
of blood biomarkers, often obtained in the early, acute phase of an acute ischemic event. 
Moreover, the collection of multiple measurements represents a more stable state during a 
longer period, less affected by accidental factors than single measurements.     
  It is important to emphasize the observational character of BIOMArCS and its substudies, 
implying that causal inference cannot be demonstrated. Whether the investigated blood 
biomarkers merely reflect pathways of disease in CAD, or directly contribute to coronary 
pathophysiological cascades as mediators, remains to be unravelled. Also, it must be noted 
that genetic, environmental and specific clinical information of the study participants, 
possibly influencing circulating blood biomarkers, such as diet or infarct size, was lacking. 
These possible confounders were - as far as possible - addressed by matching patients on 
clinical characteristics and admission diagnosis. Lastly, by specifically studying post ACS 
patients, it is not known whether these findings can be extrapolated to other CAD patients or 
applied to the general population in primary prevention.  
3. Towards enhanced risk stratification and improved treatment benefit in established 
CAD by genetic polymorphisms.
In the third part of this thesis, the relationship between genetic polymorphisms and 
cardiovascular outcome has been studied in order to investigate its usefulness in cardiovascular 
risk stratification. Furthermore, the value of some genetic variants for targeting therapy in 
patients who would benefit most from ACE-inhibitors has been assessed as well. These 
associations have been investigated in the PERindopril GENEtic Associations (PERGENE) 
study, a substudy of the EURopean trial On reduction of cardiac events with Perindopril in 
stable coronary Artery disease (EUROPA). The EUROPA trial was a randomized, double-
blind, placebo-controlled clinical trial designed to assess the effect of the ACE-inhibitor 
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perindopril on adverse cardiovascular outcome in 12218 patients with stable CAD. PERGENE 
was a cardiovascular pharmacogenetic substudy investigating polymorphisms that might 
modify the treatment benefit of the ACE-inhibitor perindopril on adverse cardiovascular 
outcome. The latter chapter (chapter 13) in this part describes the association between genetic 
polymorphisms and coronary plaque characteristics, as part of the previously mentioned 
ATHEROREMO-IVUS study. 
  Chapter 11 encompasses a comprehensive analysis of seven functional variants in the 
vascular endothelial growth factor (VEGF) and kinase insert domain-containing receptor 
(KDR) genes in relation to cardiovascular outcome as well as treatment benefit entailed 
by the ACE-inhibitor perindopril. In a total of 8711 investigated stable CAD patients, no 
associations were found between VEGF/KDR polymorphisms or their haplotypes with 
4-year cardiovascular outcome. On the other hand, multiple VEGF/KDR polymorphisms, 
especially when combined into one pharmacogenetic score, modified the treatment effect 
of perindopril on adverse cardiovascular outcome. Altogether, these findings do not support 
that VEGF/KDR variants are useful for risk assessment in stable CAD, but might rather be 
used to increase treatment benefit of the ACE-inhibitor perindopril with regard to prevention 
of adverse cardiovascular outcome. A possible interaction between VEGF/KDR variants and 
ACE-inhibitor therapy has never been investigated before in clinical studies and therefore 
revealed novel information on this matter. 
  Chapter 12 focuses on two α-adducin (ADD1) polymorphisms (rs4961 and rs4962) 
in relation to cardiovascular outcome, treatment effect by the ACE-inhibitor perindopril and 
hypertension. In a total of 9327 patients with stable CAD, ADD1 polymorphisms were not 
associated with 4-year cardiovascular outcome. Nor did they modify treatment benefit of 
perindopril in terms of blood pressure reduction or cardiovascular risk reduction. With regard 
to hypertension, only minor allele carriers of the rs4963 polymorphism had a significanly 
lower prevalence of hypertension than their wild type homozygote counterparts. It can be 
stated – based on these findings – that ADD1 polymorphisms do not provide a window of 
opportunity for possible future cardiovascular risk prediction, nor for individualized tailoring 
of ACE-inhibitor therapy in patients with stable CAD.         
  In Chapter 13 a common haptoglobin (Hp) polymorphism has been studied by assessing 
its protein phenotypes (Hp 1-1, Hp 2-1, Hp 2-2) in a total of 585 patients undergoing coronary 
angiography for SAP or ACS. The degree and composition of coronary atherosclerosis in these 
patients has been determined by IVUS-VH and near-infrared spectroscopy (NIRS), enabling 
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to investigate the relationship between Hp phenotype and invasively-measured coronary 
plaque characteristics. There was a positive association between Hp 2 phenotypes (Hp 2-1 
and Hp 2-2) and the degree of atherosclerosis in ACS patients, meaning that ACS patients 
possessing a Hp 2 phenotype are at higher risk for more advanced coronary atherosclerosis 
than ACS patients with a Hp 1 phenotype. Thus, genetic differences in the endogenous anti-
oxidant status, as reflected by the Hp phenotype, may be of importance in risk stratification 
of patients suffering from CAD.            
  Overall, by examining specific genetic variants within the range of CAD, two main 
objectives have been addressed in this part of the thesis. First, the specified polymorphisms 
were valued on their potential capability in cardiovascular risk prediction. While VEGF/KDR 
and ADD1 polymorphisms did not seem promising in this field, haptoglobin polymorphisms 
may have shown to be useful in coronary risk stratification. Second, the role of the investigated 
polymorphisms in optimizing treatment benefit of ACE-inhibitors in stable CAD patients 
was evaluated. In this respect, an interaction was found between treatment effect of the ACE-
inhibitor perindopril on cardiovascular outcome and VEGF/KDR polymorphisms, but not 
ADD1 polymorphisms. This knowledge might be useful information towards the road of 
targeting pharmacological treatment at an individual level.          
  It must be noted that the VEGF/KDR and ADD1 polymorphisms have been analyzed 
within a well-designed placebo-controlled double-blinded randomized controlled trial 
with a large sample size and relatively long follow-up. However, some aspects warrant 
consideration. The lack of association between the separately analyzed polymorphisms 
and 4-year cardiovascular outcome might be explained by the fact that it is likely that the 
contribution of a single single-nucleotide polymorphism (SNP) to prognosis is minimal; an 
individual SNP might not be able to carry prognostic information alone. Therefore, specific 
combinations of several SNPs were reconstructed into haplotypes in order to gain more 
power. Still, there was no significant association present between any of the haplotypes and 
cardiovascular outcome. It must also be mentioned that the generalizability of the results has 
limitations regarding the type of patients and type of agent, meaning that these findings may 
not be directly extrapolated to all CAD patients and all ACE-inhibitors. The PERGENE study 
population consisted of predominantly male Caucasian patients with stable CAD, receiving 
perindopril. Therefore, these results must be carefully interpreted with regard to women, 
other ethnicities, other CAD types and different ACE-inhibitors.      
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Main conclusions15
A couple of lessons can be learned from this thesis and may be summarized as follows:
PART 1: 
•	 Recurrent adverse cardiovascular events still commonly occur in patients with established 
coronary artery disease, demanding an ongoing gain in knowledge, improved risk 
stratification / prediction tools and enhanced treatment strategies.  
•	 By linking external influences and circulating blood biomarkers to invasively measured 
coronary plaque characteristics, additional pathophysiological insights may be provided. 
•	 Cigarette smoking and circulating fibrinogen rather contribute to the degree of coronary 
atherosclerotic burden than coronary plaque vulnerability, especially in ACS patients. 
•	 Conversely, circulating adiponectin has involvement in coronary plaque vulnerability 
specifically in SAP patients. 
•	 Several chemokines (MCP-1, MIP-1α, RANTES) and cytokines (TNF-α, IL-10) are 
associated with various aspects of degree, composition and vulnerability of coronary 
atherosclerosis. 
•	 Higher circulating levels of renal biomarkers (cystatin C and NGAL) are related to less 
high-risk coronary lesions, but not in CAD patients with an impaired renal function.  
•	 Adiponectin, RANTES and cystatin C carry predictive value for 1-year adverse clinical 
events in established CAD. Thus, these circulating biomarkers are potential candidates 
whose incremental value should be further evaluated in prediction models of recurrent 
events in CAD patients. 
•	 Stratifying patients on CAD type (ACS versus SAP) is essential to account for their 
different pathophysiological way of acting. 
PART 2: 
•	 Exploring novel blood biomarkers reflecting relevant pathophysiological processes in 
CAD may lead to identification of markers that might be useful for risk prediction and 
even be of interest as therapeutic targets. 
•	 Previous blood biomarker studies within the field of CAD mainly focus on single 
measurements in the early, acute phase of an acute ischemic event.  
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•	 Learning about the temporal evolution of blood biomarkers after ACS by means of high-
frequency blood sampling can be useful in 4 ways: 
 - Observing the behavior and stability of the marker in the acute phase and on the 
long term after an event. 
 - Observing its behavioral pattern before a recurrent event.
 - Comparing biomarker patterns between patients with and without a recurrent event. 
 - Determining within- and between-patient variability of the marker.   
•	 Post ACS patients experiencing a recurrent event have stable and systematically higher 
GDF-15 levels during 1-year follow-up than their matching controls. Therefore, blood 
sampling of GDF-15 might be used throughout the course of 1 year post ACS to improve 
prognostication with a limited number of necessary repeated measurements.
•	 On the other hand, blood biomarkers stimulating intracellular mitogen-activated protein 
kinase (ANG-1, PAR-1, BMP-6) only have predictive value in the acute phase for post 
ACS patients experiencing a recurrent event.    
•	 Relevant and sustainable differences exist in long-term temporal patterns of established 
cardiovascular biomarkers (LDL, total cholesterol, triglycerides, troponin T and CRP) 
between Caucasian and Chinese post ACS patients, emphasizing the need for an 
ethnicity-specific approach.  
PART 3:
•	 Studying the relationship between genetic polymorphisms and cardiovascular outcome is 
useful to determine the utility of genetics in secondary cardiovascular risk stratification. 
•	 Variants in the vascular endothelial growth factor (VEGF), kinase insert domain-
containing receptor (KDR) and α-adducin (ADD1) genes do not carry prognostic 
information on 4-year adverse cardiovascular outcome in stable CAD patients. 
•	 Genetic differences in the endogenous anti-oxidant status, as reflected by the haptoglobin 
phenotype, may be of importance in determining a higher risk for more advanced 
coronary atherosclerosis in ACS patients.
•	 Genetic variants can be utilized to target pharmacological treatment in those who would 
benefit most and to herewith contribute to personalized medicine. 
•	 Multiple VEGF/KDR polymorphisms modified the treatment effect of perindopril on 
adverse cardiovascular outcome in patients with stable CAD.     
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Clinical perspectives 
and future directions16
Ongoing research in coronary pathophysiology over the past decennia has led to crucial 
discoveries, responsible for a ‘paradigm shift’ in the conceptualization of underlying 
mechanisms in CAD. The investigation of blood biomarkers has been essential in this 
respect. Our current view on CAD has shifted from a chronic, steady and progressive 
metabolic process towards a more multifactorial, dynamic disease. Further improvement 
in our understanding of coronary pathophysiology could be established by continuing to 
investigate the value of established biomarkers and persist in searching for novel biomarkers. 
Eventually, this ongoing conceptual development could lead to new potential targets for 
therapeutic interventions.      
  Bearing this theory in mind, blood biomarkers could also contribute towards a 
disease management transition, in which CAD patients are no longer considered to be a 
homogeneous group requiring similar long-term pharmacotherapeutic treatment. Instead, 
CAD patients should be regarded as a heterogeneous group with a more individual approach, 
considering their different composition of constantly dynamic underlying pathophysiological 
components. In this respect, blood biomarkers could potentially fulfill a key role, since they 
possess the ability to quite specifically reflect the pathophysiological alterations through 
varying circulating levels over time. Ultimately and ideally, the assessment of blood 
biomarkers in clinical practice would be an easy and fast application tool to non-invasively 
gain information on the individual coronary risk of the patient. Hereby it could serve for risk 
stratification to identify ‘high risk’ patients in order to take early preventive measures before 
the actual occurrence of a recurrent event. Also, genetic variants could be a valuable addition 
to individually decide who benefits most from certain pharmacotherapeutic interventions. 
With current available tools for risk stratification, it is not possible to predict recurrent events 
in a specific and short future timeframe or to guide therapy towards good responders. It must 
be acknowledged that the observational, exploratory and hypothesis-generating findings of 
this thesis do not aim a direct implementation in clinical practice. They rather provide new 
pathophysiological insights and lessons to be learned for setting up future studies, that aim 
for directly applicable results in medical practice. 
Clinical perspectives 
and future directions
16
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Concluding, an optimal risk stratification score for daily practice in established CAD 
would ideally be an individual approach and consist of clinical characteristics combined 
with intracoronary imaging, genetics and (repeated) measurements of multiple biomarkers 
carrying the most prognostic information. By identifying ‘high risk’ patients who would most 
likely benefit from (targeted) therapy in advance, adverse cardiac event reduction may be 
established. The exploratory findings of this thesis need to be combined in large, prospective 
clinical studies and further explored on their potential additional value in cardiovascular risk 
prediction over established clinical covariates. Thus, much progress remains to be made on 
this field in the future era of ‘personalized medicine’. 
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Dutch summary (Nederlandse samenvatting) 
Herhaaldelijke ongunstige cardiovasculaire events komen nog altijd voor in een aanzienlijk 
deel van patiënten met coronaire hartziekte, ondanks verbeterde technologieën en een 
toegenomen aantal behandelopties. De behoefte aan een betere risicovoorspelling bij 
patiënten met coronairlijden is daarom de grootste ‘drive’ geweest voor dit proefschrift. Door 
onze kennis te vergroten op het gebied van bloedbiomarkers en genetische polymorfismen, 
die een rol lijken te spelen in de pathofysiologie van coronairlijden, wordt gestreefd naar een 
optimale risicostratificatie in patiënten met verworven coronaire hartziekte. In dit hoofdstuk 
worden de hoofdresultaten van dit proefschrift samengevat en in een bredere context geplaatst. 
1. Een beter begrip over coronair atherosclerose in mensen creëren door bloedbiomarkers 
te linken aan intracoronaire beeldvorming.   
In het eerste deel van dit proefschrift worden biologische processen - met een mogelijke 
betrokkenheid bij atherosclerose - bestudeerd in relatie tot coronair atherosclerose door 
middel van intracoronaire beeldvorming binnen de European Collaborative Project on 
Inflammation and Vascular Wall Remodeling in Atherosclerosis – Intravascular Ultrasound 
(ATHEROREMO-IVUS) study. De karakteristieken van elke atherosclerotische plaque in een 
‘non-culprit’ (niet ziek) coronairvat zijn in 581 patiënten bestudeerd, die verwezen waren voor 
coronairangiografie omwille van stabiele angina pectoris (SAP) of acuut coronairsyndroom 
(ACS). Door gebruik te maken van ‘virtual-histology intravascular ultrasound’ (VH-IVUS) 
werd de uitgebreidheid, compositie (samenstelling) en kwetsbaarheid van de plaques bepaald 
in een segment of lesie van een coronairvat. De uitgebreidheid / omvang van coronair 
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atherosclerose werd vastgesteld door het meten van ‘plaque burden’, ‘plaque volume’, 
‘minimal lumen area’ in segmenten en de aanwezigheid van het aantal lesies met ≥70% 
‘plaque burden’ of ≤4.0mm2 ‘minimal lumen area’. De compositie (het fenotype) van de 
atherosclerotische plaque werd vastgesteld door de bepaling van verschillende plaque 
componenten zoals ‘dense calcium’, ‘necrotic core’, ‘fibro-fatty’ en ‘fibrous’ weefsel. De 
‘vulnerability’ (kwetsbaarheid) van een plaque werd gekarakteriseerd door de aanwezigheid 
van VH-IVUS bepaalde ‘thin-cap fibroatheroma’ (TCFA) lesies. Daarnaast werd klinische 
informatie over de patiënten verzameld en werden voor de procedure bloedbuizen 
afgenomen ten behoeve van biomarkerbepalingen. Het doel van het verzamelen van al deze 
informatie is om een beter begrip te creëren over de rol van externe invloeden en circulerende 
bloedbiomarkers in de ontwikkeling van (kwetsbare) coronair atherosclerotische plaques. 
Bovendien werd een klinische follow-up van de patiënten uitgevoerd vanaf inclusie tot 1 jaar 
om de prognostische waarde van (nieuwe) circulerende bloedbiomarkers te onderzoeken in 
het voorspellen van herhaaldelijke ongunstige events.                     
  In Hoofdstuk 2 wordt de relatie tussen roken en coronair atherosclerose beschreven. 
Met betrekking tot de omvang van de atherosclerose, bleken huidige rokers iets meer coronair 
‘plaque burden’ te hebben dan nooit-rokers, vooral in patiënten die zich presenteerden met 
ACS. Ten aanzien van de plaque compositie, bleek ‘fibro-fatty’ weefsel het overheersende 
type bestanddeel te zijn in de coronairen van huidige rokers. Tot slot werd geen associatie 
gevonden tussen roken en ‘vulnerability’ van de coronaire plaque. Het ontbreken van een 
dergelijke associatie zou deels verklaard kunnen worden door de mogelijkheid dat plaque 
erosie - en niet zozeer plaqueruptuur - het onderliggende mechanisme zou kunnen zijn voor 
coronaire events in rokende patiënten met coronairlijden, zoals al eerder werd gesuggereerd 
door histopathologische studies. Alhoewel voldoende bewijs voorhanden is dat roken op 
allerlei vlakken invloed uitoefent op het proces van atherosclerose, is er momenteel minder 
bekend over associaties tussen roken en de ‘in vivo’ plaquestructuur binnen het coronairvat 
zelf. Alles tezamen leveren deze bevindingen een geringe bijdrage aan een beter begrip over 
de complexe pathofysiologische verhouding tussen roken en coronairlijden.           
  Hoofdstuk 3 accentueert fibrinogeen als mogelijke interessante bloedbiomarker in 
coronair atherosclerose om aanvullend inzicht te creëren in de relatie tot coronairlijden. 
De associatie tussen fibrinogeen met uitgebreidheid, compositie en kwetsbaarheid van 
coronair atherosclerose, alsmede met cardiovasculaire uitkomsten binnen 1 jaar, werd 
onderzocht. Hieruit bleek dat hoe hoger de circulerende fibrinogeenwaarden waren, hoe 
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groter de uitgebreidheid van coronair atherosclerose was, vooral bij patiënten met ACS. 
Deze relatie was echter niet onafhankelijk van ‘C-reactive protein’ (CRP). Er werden geen 
beduidende associaties gevonden tussen fibrinogeen en coronaire plaque compositie, plaque 
‘vulnerability’ of cardiovasculaire uitkomsten binnen 1 jaar. Al met al duiden deze resultaten 
erop dat fibrinogeen eerder een rol speelt in coronaire atherosclerotische plaque progressie, 
met name in ACS patiënten, dan in de ‘vulnerability’ van de plaque of een directe invloed 
heeft op coronaire events.          
  In Hoofdstuk 4 is de associatie bestudeerd tussen adiponectine met zowel VH-IVUS 
afgeleide coronaire plaque karakteristieken als 1-jaar cardiovasculaire uitkomsten, om de 
pathofysiologische rol van adiponectine in patiënten met coronaire hartziekte verder te 
verduidelijken. Adiponectine levels bleken geassocieerd te zijn met 1-jaars mortaliteit in alle 
patiënten met coronairlijden, maar vooral gedreven door patiënten die zich presenteerden 
met SAP. Ook bleek alleen in SAP patiënten adiponectine geassocieerd te zijn met plaque 
karakteristieken omtrent ‘vulnerability’. Het exacte onderliggende mechanisme wat betreft 
de associatie tussen adiponectine en coronaire plaque (in)stabiliteit dient nader te worden 
onderzocht in met name SAP patiënten.  
  Hoofdstuk 5 beschrijft vier circulerende chemokines in relatie tot coronair atherosclerose 
en klinische uitkomsten binnen 1 jaar. Circulerende ‘regulated upon activation normal T-cell 
expressed and secreted’ (RANTES) kwam uit de resultaten als een veelbelovende biomarker, 
welke correleerde met coronaire ‘plaque burden’, ‘plaque vulnerability’ en cardiovasculaire 
uitkomsten (met name mortaliteit en herhaaldelijk voorkomen van ACS).  
  Hoofdstuk 6 beschrijft de relatie tussen acht verschillende circulerende cytokines 
and coronaire plaque karakteristieken, zoals bepaald met VH-IVUS. Hogere circulerende 
waarden van ‘tumor necrosis factor alpha’ (TNF-α, pro-inflammatoire cytokine) bleken 
geassocieerd te zijn met meer coronaire ‘plaque burden’ en ‘plaque vulnerability’ in alleen 
SAP patiënten; en lagere circulerende waarden van interleukine-10 (IL-10, anti-inflammatoire 
cytokine) in alle patiënten met coronairlijden. Daarnaast is de relatie van de onderzochte 
cytokines bekeken met 1-jaar cardiovasculaire uitkomsten. Echter, geen van allen toonde 
enige prognostische waarde voor klinische uitkomst. Alles bij elkaar genomen, wijzen deze 
resultaten erop dat een potentieel effect van TNF-α en IL-10 op coronair atherosclerose niet 
direct geëxtrapoleerd kan worden naar klinische uitkomst.   
  Hoofdstuk 7 focust op twee renale biomarkers in relatie tot coronair atherosclerose 
en voorkomen van herhaaldelijke ongunstige klinische events binnen 1 jaar. In patiënten 
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met een normale nierfunctie, bleken plasma ‘cystatine C’ (een glomerulaire marker) en 
plasma ‘neutrophil gelatinase-associated lipocalin’ (een tubulaire marker) een omgekeerde 
relatie te hebben met hoog-risico coronaire laesies zoals ‘TCFA’ plaques en laesies met 
veel ‘plaque burden’ (>70%). Echter, bij patiënten met een verslechterde nierfunctie, 
konden deze ‘beschermende’ effecten niet aangetoond worden, wat heeft geleid tot nieuwe 
(pathofysiologische) inzichten. Bovendien bleek alleen bij patiënten met een slechte 
nierfunctie hogere cystatine C levels van voorspellende waarde te zijn voor een ongunstige 
klinische uitkomst binnen 1 jaar. Met andere woorden, cystatine C blijkt van de twee renale 
biomarkers de meeste potentie te hebben met betrekking tot cardiovasculaire risicopredictie, 
maar alleen in patiënten met een verslechterde nierfunctie.     
  Concluderend heeft het bestuderen van circulerende biomarkers in relatie tot VH-
IVUS afgeleide coronaire plaque karakteristieken geresulteerd in verschillende bevindingen, 
die tot nieuwe pathofysiologische inzichten en hypothesen heeft geleid. Tevens heeft het 
onderzoek naar het vermogen van de biomarkers in het voorspellen van herhaaldelijke events 
laten zien dat adiponectine, RANTES en cystatine C veelbelovend zijn in de weg naar het 
verbeteren van secundaire cardiovasculaire risicopredictie. Tot slot hebben we van onze 
resultaten geleerd dat het van belang is om patiënten op behandelindicatie (ACS versus SAP) 
te stratificeren binnen het spectrum van coronaire hartziekten om rekening te houden met 
diens verschillende pathofysiologische entiteiten.   
  In het onderzoek naar de associatie tussen de eerder genoemde biomarkers en coronaire 
plaque karakteristieken, moet erkend worden dat de opzet van de ATHEROREMO-IVUS studie 
niet in staat stelt om causale inferentie aan te tonen. In deze cross-sectionele studieopzet zijn 
tegelijkertijd coronaire plaque karakteristieken middels VH-IVUS bepaald en bloedbuizen 
afgenomen. De mogelijkheid dat de biomarkers eerder het gevolg zijn van de klinische 
presentatie dan de oorzaak, kan daarom niet worden uitgesloten. Desalniettemin levert dit 
onderzoek nieuwe data aan over biomarkers in relatie tot een in-vivo beoordeling van de 
coronaire arteriële wand (oftewel een nauwkeurigere meting van coronair atherosclerose) en 
heeft daarbij geresulteerd in nieuwe hypotheses aanvullend op reeds bestaande studies, die 
deze associaties op andere wijzen hebben onderzocht. Alhoewel causale inferentie betwist kan 
worden, zijn de tot stand gekomen data uit dit onderzoek toch uniek en informatief, aangezien 
ze nieuwe inzichten hebben verschaft in de complexe pathofysiologische verbanden tussen 
biomarkers en coronaire hartziekten.        
  Daarnaast kan over het algemeen gesteld worden dat de associatie tussen de biomarkers 
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en cardiovasculaire uitkomsten binnen 1 jaar niet substantieel was. Dit kan deels te maken 
hebben gehad met een beperkt aantal klinische events in deze studie, wat heeft geleid tot 
een gebrek aan statistische power om sterke associaties aan te kunnen tonen. Een andere 
mogelijke verklaring is het feit dat het aandeel van iedere biomarker afzonderlijk relatief 
klein is in de context van een multifactoriële aandoening.    
2. Een betere risicostratificatie bij verworven coronaire hartziekten door patronen in 
bloedbiomarkers te bestuderen. 
In het tweede deel van dit proefschrift wordt het gedragspatroon beschreven van nieuwe en 
reeds bestaande cardiovasculaire biomarkers gedurende 1 jaar na het doormaken van een 
ACS event. Dit is uitgevoerd binnen de BIOMarker study to identify Acute risk of a Coronary 
Syndrome (BIOMArCS), bestaande uit 844 patiënten, in wie frequente herhaaldelijke 
bloedafnames hebben plaatsgevonden direct na een ACS tot aan 1 jaar. Door gebruik te maken 
van een schema met hoog-frequente bloedafnames kan op een unieke wijze inzicht worden 
verkregen in de waarde van de onderzochte biomarkers voor secundaire cardiovasculaire 
risicopredictie op de langere termijn.     
  Hoofdstuk 8 concentreert zich op growth differentiation factor-15 (GDF-15) patronen 
en diens individuele variabiliteit in 111 ACS patiënten. Er is met name gekeken naar 
patroonverschillen tussen patiënten met (cases) en zonder (controls) een herhaaldelijk event 
(een samengesteld eindpunt bestaande uit cardiovasculaire mortaliteit, myocardinfarct of 
instabiele angina pectoris waarvoor een urgente coronaire revascularisatie benodigd was) 
gedurende de follow-up. Uit de resultaten bleek dat post-ACS patiënten met een herhaaldelijk 
event stabiele en systematisch hogere GDF-15 waarden hadden gedurende de 1-jaars follow-
up dan klinisch vergelijkbare post-ACS patiënten zonder een herhaaldelijk event. Daarnaast 
kwam naar voren dat GDF-15 een lage intra-individuele variabiliteit had. Al met al kan 
hieruit geconcludeerd worden dat het herhaaldelijk afnemen van GDF-15 tot 1 jaar na het 
doormaken van een ACS nut heeft om prognosebepalingen te verbeteren, waarbij - in het 
kader van lage intra-individuele variabiliteit – het aantal herhaalde metingen beperkt kan 
blijven.              
  In Hoofdstuk 9 worden interetnische verschillen bestudeerd van reeds bestaande 
cardiovasculaire biomarkers in het beloop over de tijd (high-density lipoprotein (HDL), low-
density lipoprotein (LDL), triglyceriden, totaal cholesterol, Troponine T (TnT), NT-proBNP 
en CRP) in post-ACS patiënten met diabetes mellitus. Tot nu toe zijn cardiovasculaire 
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biomarkers veelal alleen gevalideerd in Kaukasische populaties en is er weinig bekend 
over de generaliseerbaarheid van deze biomarkers in andere etnische groepen. Met name in 
Azië, waar coronaire hartziekten nu opkomend zijn, is er behoefte aan biomarkervalidatie. 
Derhalve is het beloop over de tijd 1 jaar na een primair ACS event weergegeven voor elke 
biomarker en vergeleken tussen 48 Kaukasische (Nederlandse) en 48 klinisch vergelijkbare 
Chinese patiënten. Deze observatie onthulde dat Kaukasische patiënten persisterend hogere 
LDL, totaal cholesterol, triglyceriden, TnT en CRP waarden hadden dan Chinese patiënten. 
Er werden geen verschillen gezien in HDL en NT-proBNP waarden tussen de twee cohorten. 
Deze explorerende analyse zou meer inzicht kunnen geven in bloedbiomarker-gerelateerde 
verschillen tussen etnische groepen en benadrukt het feit dat bevindingen gebaseerd op 
Westerse groepen mogelijk niet direct toepasselijk zijn op Chinese individuen.          
  Hoofdstuk 10 onderzoekt in 135 post-ACS patiënten het tijdsbeloop op de korte (< 30 
dagen) en lange (30 dagen - 1 jaar) termijn van eiwit bloedbiomarkers, die de ‘intracellular 
mitogen-activated protein kinase’ (MAPK) cascade stimuleren. Patroonverschillen over de tijd 
tussen patiënten met (cases) en zonder (controls) een herhaaldelijk event (een samengesteld 
eindpunt bestaande uit cardiovasculaire mortaliteit, myocardinfarct of instabiele angina 
pectoris waarvoor een urgente coronaire revascularisatie benodigd was) werden met name 
onderzocht. ‘Angiopoietin-1’ (ANG-1), ‘protease-activated receptor-1’ (PAR-1) en ‘bone 
morphogenetic protein-6’ (BMP-6) serumwaarden waren significant hoger in patiënten met 
een herhaaldelijk event in vergelijking met gelijkwaardige patiënten zonder doorgemaakt 
herhaaldelijk event (controls), maar alleen kort (in de eerste 30 dagen) na een ACS. Derhalve 
dienen de prognostische eigenschappen van deze signaaleiwitten - die als nieuwe biomarkers 
dienst zouden kunnen doen - verder onderzocht te worden in de acute fase van een ACS.            
Concluderend, de zoektocht naar nieuwe bloedbiomarkers, die relevante pathofysiologische 
processen in coronairlijden reflecteren, kan leiden tot het identificeren van markers die van nut 
zouden kunnen zijn voor risicopredictie en zelfs zouden kunnen fungeren als therapeutisch 
doelwit. Met het oog daarop heeft ons onderzoek geleid tot veelbelovende resultaten met 
betrekking tot GDF-15, ANG-1, PAR-1 en BMP-6 door het in detail bestuderen van diens 
patronen over de tijd. Bovendien zijn er relevante verschillen naar boven gekomen tussen 
Kaukasische en Chinese patiënten in tijdspatronen van reeds bestaande cardiovasculaire 
biomarkers, wat impliceert dat een etniciteitsspecifieke benadering nodig is.                
  Het biomarkerbeloop over de tijd is vergeleken tussen cases en controls volgens een 
‘case-cohort’ opzet binnen de BIOMArCS studie. Omwille van efficiëntie zijn uiteindelijk 
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alle cases en een beperkt aantal controls gekozen voor verdere analyse. Deze opzet maakt 
mogelijk dat klinisch relevante verschillen ontdekt kunnen worden met voldoende statistische 
power op een efficiënte wijze. De kracht van deze studie zit in het feit dat seriële metingen 
direct na een ACS (index event) en vóór een ACS (herhaaldelijk event) zijn verricht, wat 
maakt dat accurate veranderingen in biomarkerpatronen vóór de toetreding van een event 
geobserveerd kunnen worden. Dit is in tegenstelling tot eerdere studies, die vaak in de vroege, 
acute fase van een ischemisch event een éénmalige meting hebben verricht. Bovendien 
reflecteert een verzameling aan metingen beter de stabiliteit van de biomarker gedurende een 
langere periode dan een éénmalige meting, die onderworpen kan zijn aan incidentele factoren 
(bijvoorbeeld stress, voeding). 
  Het is relevant om ook het observationele karakter van de BIOMArCS studies te 
benadrukken, omdat dit impliceert dat causale verbanden niet direct aangetoond kunnen 
worden. Het moet dus nog uitgezocht worden of de bestudeerde bloedbiomarkers slechts de 
ziekteprocessen in coronairlijden reflecteren of dat ze daadwerkelijk als ‘mediators’ bijdragen 
aan de coronaire pathofysiologie. Ook moet opgemerkt worden dat het ontbrak aan informatie 
over genetische factoren, omgevingsinvloeden (zoals voeding) en specifieke klinische 
gegevens over de geïncludeerde patiënten (zoals infarctgrootte of resterende ejectiefractie), 
die mogelijk circulerende bloedbiomarkers hebben beïnvloed. Deze potentiële verstorende 
factoren (oftewel ‘confounders’) werden zoveel als mogelijk vermeden door het matchen 
van patiënten (cases en controls) op klinische factoren en diagnose bij opname. Tot slot, door 
het specifiek bestuderen van post-ACS patiënten zoals in het BIOMArCS onderzoek, kan niet 
worden achterhaald of deze bevindingen doorgetrokken kunnen worden naar patiënten met 
een andere coronaire hartziekte of toegepast kunnen worden op de algemene populatie met 
betrekking tot primaire preventie.         
3. Een betere risicostratificatie en groter behandelvoordeel bij verworven coronaire 
hartziekten door de bepaling van genetische polymorfismen.  
In het derde deel van dit proefschrift is de relatie tussen genetische polymorfismen en 
cardiovasculaire uitkomsten bestudeerd om de bruikbaarheid ervan te onderzoeken in 
cardiovasculaire risicostratificatie. Daarnaast is van een aantal genetische varianten bepaald 
of ze van toegevoegde waarde kunnen zijn in risicoreductie door specifieker ACE-inhibitors 
te richten op patiënten, die het meeste profiteren van deze middelen. Deze associaties zijn 
onderzocht in de PERindopril GENEtic Associations (PERGENE) studie, een onderdeel van 
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de EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery 
disease (EUROPA) studie. De EUROPA studie was een gerandomiseerde, dubbelblinde, 
placebogecontroleerde klinische studie, die opgezet is om het effect van de ACE-inhibitor 
perindopril te bepalen op cardiovasculaire uitkomsten in 12218 patiënten met stabiel 
coronairlijden. De cardiovasculaire farmacogenetische PERGENE studie was daarvan een 
substudie, die polymorfismen onderzocht met een mogelijke invloed op het behandelvoordeel 
van de ACE-inhibitor perindopril op cardiovasculaire uitkomsten. Het laatste hoofdstuk 
(hoofdstuk 13) van dit deel beschrijft de associatie tussen genetische polymorfismen en 
coronaire plaque karakteristieken, als onderdeel van de eerder beschreven ATHEROREMO-
IVUS studie.        
  Hoofdstuk 11 bevat een omvangrijke analyse van zeven functionele varianten in de 
‘vascular endothelial growth factor’ (VEGF) en ‘kinase insert domain-containing receptor’ 
(KDR) genen in relatie tot zowel cardiovasculaire uitkomsten als behandelvoordeel door 
de ACE-inhibitor perindopril. Er werden uiteindelijk geen associaties gevonden tussen 
VEGF/KDR polymorfismen of haplotypen met 4-jaars cardiovasculaire uitkomsten in 
8711 onderzochte patiënten met stabiel coronairlijden. Daartegenover blijken wel meerdere 
VEGF/KDR polymorfismen - met name wanneer gecombineerd in de vorm van een 
farmacogenetische score - het behandeleffect van perindopril op cardiovasculaire uitkomsten 
te modificeren. Kortom, deze bevindingen ondersteunen dat VEGF/KDR polymorfismen 
eerder gebruikt zouden kunnen worden om het behandelvoordeel van de ACE-inhibitor 
perindopril te vergroten met het oog op het reduceren van ongunstige cardiovasculaire 
uitkomsten, dan dat VEGF/KDR polymorfismen gebruikt zouden kunnen worden in de 
risicobepaling van stabiel coronairlijden. Een mogelijke interactie tussen VEGF/KDR 
varianten en ACE-inhibitor behandeling is een nieuwe bevinding, aangezien dit nog niet 
eerder onderzocht is in klinische studies.  
  Hoofdstuk 12 focust op twee ‘α-adducin’ (ADD1) polymorfismen (rs4961 en rs4962) in 
relatie tot cardiovasculaire uitkomsten, behandeleffect van de ACE-inhibitor perindopril en 
hypertensie. In een totaal aantal van 9327 patiënten met stabiel coronairlijden, waren de ADD1 
polymorfismen niet geassocieerd met cardiovasculaire uitkomsten op een termijn van 4 jaar. 
Tevens was er geen associatie tussen en de polymorfismen en het effect van perindopril op de 
bloeddruk of cardiovasculaire uitkomst. Wat betreft hypertensie, hebben alleen dragers van 
het recessieve allel van de rs4963 variant een significant lagere prevalentie van hypertensie 
dan hun dominante homozygote equivalenten. Op basis van deze bevindingen kan gesteld 
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worden dat ADD1 polymorfismen voor zowel toekomstige cardiovasculaire risicopredictie 
als geïndividualiseerde ACE-inhibitor therapie in patiënten met stabiel coronairlijden geen 
kans maken.              
  In Hoofdstuk 13 is een veelvoorkomende ‘haptoglobine’ (Hp) polymorfisme 
onderzocht door middel van de bepaling van eiwitfenotypen (Hp 1-1, Hp 2-1, Hp 2-2) in 
585 patiënten, die een coronairangiografie moesten ondergaan omwille van SAP of ACS. De 
omvang en samenstelling van de coronair atherosclerose is in deze patiënten bepaald met 
VH-IVUS en ‘near-infrared spectroscopy’ (NIRS), waarna de relatie werd onderzocht tussen 
de verschillende Hp fenotypen en deze invasief gemeten coronaire plaque karakteristieken. 
Er werd een relatie gevonden tussen de Hp 2 fenotypen (Hp 2-1 en Hp 2-2) en de omvang 
van atherosclerose in ACS patiënten, wat betekent dat ACS patiënten met een Hp 2 fenotype 
een grotere kans hebben op het ontwikkelen van meer progressieve coronair atherosclerose 
dan ACS patiënten met een Hp 1 fenotype. Oftewel, genetische verschillen in de endogene 
anti-oxidante status als weerspiegeling van het Hp fenotype, kan van belang zijn in de 
risicostratificatie van patiënten die lijden aan coronaire hartziekte. 
  Globaal genomen zijn er twee hoofdzaken aangestipt in dit deel van het proefschrift 
waarin specifieke genetische varianten binnen de coronaire hartziekten zijn onderzocht. 
Allereerst zijn de gespecificeerde polymorfismen op hun potentiële waarde onderzocht als 
cardiovasculaire risicovoorspellers. Daarin zijn VEGF/KDR en ADD1 polymorfismen niet 
veelbelovend uit de verf gekomen, maar lijken ‘haptoglobine’ polymorfismen wel bruikbaar 
binnen de coronaire risicostratificatie. Daarnaast is bekeken wat de rol is van de onderzochte 
polymorfismen in het optimaliseren van het behandelvoordeel van ACE-inhibitors bij mensen 
met stabiel coronairlijden. In dat opzicht is een interactie gevonden tussen VEGF/KDR 
polymorfismen en het behandeleffect van de ACE-inhibitor perindopril op cardiovasculaire 
uitkomsten. Deze interactie werd niet gevonden met de onderzochte ADD1 polymorfismen. 
Deze opgedane kennis kan een stukje informatie bijdragen aan de ontwikkeling van het meer 
gericht (farmacologisch) behandelen op individueel niveau.        
  Gesteld moet worden dat de VEGF/KDR en ADD1 polymorfismen zijn geanalyseerd 
binnen een goed doordachte placebogecontroleerde dubbelblinde gerandomiseerde studie met 
een grote steekproefomvang en relatief lange follow-up. Echter, sommige aspecten verdienen 
nadere aandacht. Het ontbreken van een verband tussen de afzonderlijk geanalyseerde 
polymorfismen en 4-jaars cardiovasculaire uitkomst zou kunnen worden verklaard door 
het feit dat waarschijnlijk de bijdrage aan prognose van een enkele ‘single-nucleotide 
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polymorphism’ (SNP) minimaal is; een individuele SNP kan wellicht geen prognostische 
informatie alleen dragen. Om die reden zijn specifieke combinaties van een aantal SNPs 
gemaakt en gevormd tot ‘haplotypes’ om meer power te verkrijgen. Desondanks bleef een 
significante associatie tussen de haplotypes en cardiovasculaire uitkomsten uit. Ook moet 
worden opgemerkt dat de generaliseerbaarheid van de resultaten beperkt is als het gaat om het 
type patiënt en type geneesmiddel; de gevonden resultaten kunnen naar waarschijnlijkheid 
niet direct worden doorgetrokken naar alle patiënten met coronaire hartziekten en naar alle 
soorten ACE-inhibitors. De PERGENE studiepopulatie bestond voornamelijk uit mannelijke 
Kaukasische patiënten met stabiel coronairlijden onder perindopril. Dit betekent dat 
voorzichtigheid moet worden geboden met de interpretatie van de resultaten in vrouwen, 
andere bevolkingsgroepen, andere coronaire hartziekten en diverse ACE-inhibitors.        
Er kunnen een aantal lessen worden getrokken uit dit proefschrift en als volgt worden 
samengevat: 
Deel 1:
•	 Herhaaldelijke ongunstige cardiovasculaire events komen nog altijd vaak voor in 
patiënten met verworven coronairlijden, wat vereist dat kennis op dit gebied verder 
ontwikkeld moet worden, risicostratificatie / voorspelmethoden verbeterd moet(en) 
worden en behandelstrategieën verfijnd moeten worden.     
•	 Door externe factoren en circulerende bloedbiomarkers te linken aan invasief gemeten 
coronaire plaque karakteristieken, kunnen aanvullende pathofysiologische inzichten 
worden verkregen. 
•	 Zowel roken als circulerend fibrinogeen dragen eerder bij aan de omvang / grootte van 
coronair atherosclerose dan aan de kwetsbaarheid van de coronaire atherosclerotische 
plaque, met name in patiënten gediagnosticeerd met ACS.  
•	 Daarentegen heeft circulerend adiponectine laten zien mogelijk wel invloed te hebben op 
coronaire plaque ‘vulnerability’ (kwetsbaarheid), met name in patiënten gediagnosticeerd 
met SAP. 
•	 Verscheidene chemokines (MCP-1, MIP-1α, RANTES) en cytokines (TNF-α, IL-10) 
zijn geassocieerd met diverse VH-IVUS parameters, die de omvang, compositie en 
kwetsbaarheid van coronaire atherosclerose beschrijven.  
•	 Hogere waarden van circulerende renale biomarkers (cystatine C en NGAL) zijn 
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geassocieerd met een lager voorkomen van hoog-risico coronaire laesies in patiënten 
met coronairlijden, maar niet in diegenen met een slechte nierfunctie.  
•	 Adiponectine, RANTES en cystatine C zijn voorspellend voor ongunstige klinische 
events gedurende een follow-up van 1 jaar in patiënten met verworven coronairlijden. 
Dit zijn dus potentiële circulerende biomarkers, die verder onderzocht moeten worden 
in predictiemodellen om hun toegevoegde waarde vast te stellen in het voorspellen van 
herhaaldelijke events in coronaire hartziekten. 
•	 Het stratificeren van patiënten op soort coronairlijden (ACS versus SAP) is essentieel 
om rekening te houden met de verschillen in het onderliggende pathofysiologische 
substraat.  
Deel 2: 
•	 Het zoeken naar nieuwe bloedbiomarkers, die relevante pathofysiologische processen 
in coronairlijden reflecteren, kan leiden tot het identificeren van markers die bruikbaar 
kunnen zijn ten behoeve van risicopredictie en zelfs zouden kunnen fungeren als 
therapeutisch doelwit.   
•	 Eerdere studies op het gebied van bloedbiomarkers in coronairlijden focussen 
voornamelijk op éénmalige metingen in de vroege, acute fase van een ischemisch event. 
•	 Het bestuderen van het tijdsbeloop van bloedbiomarkers na een ACS event door middel 
van zeer frequente bloedafnames kan op 4 manieren nuttige informatie opleveren:  
 - Het gedrag en de stabiliteit van de marker waarnemen in de acute fase en op lange 
termijn na een ischemisch event. 
 - Het gedragspatroon observeren vóór het optreden van een herhaaldelijk event. 
 - De vergelijking maken in biomarkerpatronen tussen patiënten met en zonder het 
optreden van een herhaaldelijk event. 
 - Het bepalen van de intra- en inter-individuele variabiliteit van de marker. 
•	 Post-ACS patiënten die een herhaaldelijk event doormaken hebben stabiele en 
systematisch verhoogde GDF-15 waarden tijdens 1-jaars follow-up in vergelijking met 
hun gelijkwaardige controls. Aldus kan herhaald afnemen van GDF-15 gedurende 1 jaar 
na een ACS de prognosebepaling verbeteren met een beperkt aantal benodigde herhaalde 
metingen.  
•	 Anderzijds zijn de bloedbiomarkers, die de ‘intracellular mitogen-activated protein 
kinase’ (MAPK) cascade stimuleren (ANG-1, PAR-1, BMP-6), alleen voorspellend in 
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de acute fase voor post-ACS patiënten die een herhaaldelijk event doormaken.   
•	 Er bestaan relevante en standvastige verschillen in tijdspatronen op de lange termijn 
van reeds bestaande cardiovasculaire biomarkers (LDL, totaal cholesterol, triglycerides, 
troponin T en CRP) tussen Kaukasische en Chinese post-ACS patiënten, wat de suggestie 
wekt dat een etniciteitsspecifieke benadering nodig is.       
Deel 3:
•	 Het bestuderen van de relatie tussen genetische polymorfismen en cardiovasculaire 
uitkomsten is zinvol om het nut van genetica in secundaire cardiovasculaire 
risicostratificatie te bepalen. 
•	 Varianten in de VEGF, KDR en ADD1 genen zijn niet prognostisch voor ongunstige 
cardiovasculaire uitkomsten gedurende 4 jaar in patiënten met stabiel coronairlijden.  
•	 Genetische verschillen in de endogene anti-oxidante status als weerspiegeling van het 
haptoglobine fenotype, kan van belang zijn in de bepaling van het dragen van een hoger 
risico op uitgebreidere coronaire atherosclerose in ACS patiënten.  
•	 Genetische varianten kunnen worden gebruikt om farmacologische behandeling 
specifieker te richten op patiënten, die daar het meest baat van zouden kunnen hebben en 
om op die manier bij te dragen aan ‘personalized medicine’. 
•	 Verscheidene VEGF/KDR polymorfismen bleken van invloed te zijn op het 
behandelresultaat van perindopril op ongustige cardiovasculaire uitkomsten in patiënten 
met stabiel coronairlijden. 
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om en met jullie lachen! Ik ga het missen nu we niet meer zo vaak kunnen afspreken. Minka, 
we begonnen als ‘ambassador’ collega’s voor de EUR, eindigden als vriendinnen en later 
zelfs als buren. De deur zal altijd voor je openstaan, ook in Denemarken. Stephanie, wie 
had ooit aan het begin van de coschappen gedacht dat jij uiteindelijk mijn belangrijkste 
koffiemaatje in dit hele promotietraject zou zijn? Veel dank aan jou en Krishna voor de leuke 
intermezzo’s tussen alle data, analyses en het schrijven door. Ik zal de babyccino’s met Faye, 
het ontbijten, lunchen, koffieleuten en cocktails drinken in de stad heel erg missen. Mounira, 
wat bewonder ik jou als persoon, dokter, echtgenote en moeder. Je bent een mooi mens. 
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Lieve Sanaz, wat bijzonder om jou als goede vriendin en paranimf aan mijn zijde te hebben. 
Met jou was het een ‘klik op het eerste gezicht’ toen we elkaar ontmoetten op de eerste dag 
van de studie geneeskunde. Je begrijpt mij als geen ander, we lachen om dezelfde stomme 
dingen en raken nooit uitgepraat. Mijn bewondering is groot voor de stappen die je aan het 
zetten bent binnen de plastische chirurgie. Ik zou het je niet na kunnen doen.   
Liefste Jasmina, mijn grote zus, vriendin voor het leven en natuurlijk ook paranimf. Wij 
kennen elkaar als geen ander: we zijn zo verschillend, maar tegelijkertijd ook zo hetzelfde. 
Ontzettend bedankt voor alle onvoorwaardelijke steun en zorgzaamheid. Je bent een 
goudeerlijke, onafhankelijke en ijzersterke vrouw. Weet dat je ook altijd op mij kunt rekenen: 
723 kilometer verandert daar niets aan. Wij zullen altijd aan elkaars zijde staan en ik kijk uit 
naar nog veel meer onvergetelijke avonturen samen!   
At the end of this journey, I moved to Denmark, where I started to learn the language with 
a fantastic group of medical professionals. We started as strangers, but soon ended up like 
a family. Thank you all so much for your interest and compassion for my PhD thesis. Dear 
Maria, teaching Danish is a work of (he)art. Thank you for inspiring and motivating us 
every day by your unique way of teaching. You have not only shown to be a passionate 
and excellent teacher, but also a kind person with a beautiful heart. Thank you for your 
understanding, support and all you have done for me so far to make a great start in Denmark. 
It’s simply amazing how you make it possible to get us start working already after 3 months. 
And please don’t kill me for writing this section in English. Elise, what a pleasure it is to 
have you as a teacher as well. With you we learn, but also laugh a lot – which makes it a joy 
to come to class. Thank you for your kindness, patience and interest. Lisa, Danmarks bedste 
sygeplejerske fra Italien! Without you, learning Danish would not be the same. Thanks for 
the daily laughs you bring to our classes, car rides and coffeedates. Dirk, who would have 
thought that having lunch, singing songs and a daily drive with two girls in your car – is not 
that bad? We couldn’t have imagined the group without you! Myriam, we both know what it 
means to move to another country for love. Your positivity and look on the future is inspiring. 
Cristina, I recognize myself so much in you. ‘Du skal tale perfekt Dansk’ – I am sure we will 
get there one day! Esther, wat was ik blij dat er een leuke, spontane, Nederlandse meid aan 
de groep werd toegevoegd. Laten we er wat van gaan maken in Denemarken!                                                     
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It’s not the place, it’s the people that make you feel like home. I want to thank the entire 
family-in-law for their warm welcome and genuine interest in everything I do. Samija & 
Muenes, od prvog dana sam osjetila vašu toplinu, pozitivnu energiju i podršku. Hvala vam 
na sve što ste učinili za mene da se osjećam kao kod kuće. Admir & Lamija, I could have not 
wished for a better brother-in-law and a sweeter sister-in-law. Together with Tarik & Amra, 
I want to thank all of you for your incredible kindness. Your understanding, support and 
interest is deeply appreciated. Looking forward to make many more new memories together. 
A special thanks to Semra & Melisa for their warm welcome in Denmark the first week in 
September and for sharing my love for sushi.      
Min kære Haris, it’s finally done. Never in a million years I could have guessed the turn my 
life would get when we met 2.5 years ago. Thank you for making me smile every day since 
then. Thank you for your positivity and inspiring look on life. Thank you for believing in me, 
even when I didn’t. Thank you for learning me to take risks and drop fears. Without your 
commitment, perseverance, tranquility, understanding and care, we would have not come this 
far. I look back to wonderful memories along this journey and let’s enjoy all that is ahead of 
us. Together we move mountains! 
Tot slot bedank ik mijn liefste ouders, moji tata i mama. Dit proefschrift is voor jullie en 
dankzij jullie. In de bloei van jullie leven, zijn jullie afgereisd naar het onbekende met 
twee kleine kinderen en slechts één koffer in de hand. Jullie hebben huis en haard verlaten 
om noodgedwongen ergens anders weer opnieuw te beginnen. Mijn dank voor wat jullie 
opgeofferd hebben om mij en Jasmina een gouden toekomst te geven, is niet in woorden 
uit te drukken. Dankzij jullie eerlijkheid, wijze adviezen, belangstelling, geborgenheid en 
bemoediging, zijn wij zo ver gekomen. Ik hoop dat ik minstens net zoveel voor jullie terug 
zal kunnen doen. 
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